

CURRICULUM VITAE



Richard Leo Wahl, M.D.

Date: January 2018

Citizenship: United States of America

Address and Telephone Numbers:

Office: Mallinckrodt Institute of Radiology
Washington University School of Medicine
510 S. Kingshighway
St. Louis, MO 63110
Tel: 314-362-7100
Fax: 314-361-5428

Home: 936 Buena Vista
St. Louis, MO 63105

Present Position: Elizabeth E. Mallinckrodt Professor of Radiology
Professor of Radiation Oncology
Director, Edward Mallinckrodt Institute of Radiology
Chair, Department of Radiology

Education:

Undergraduate: 1970-1974	Wartburg College, Waverly, IA;	B.A. (Chemistry)
Graduate: 1974-1978	Washington University School of Medicine, St. Louis, MO	M.D.
2008	Wartburg College, Waverly, IA	ScD <i>honoris causa</i>
Post Graduate: 1978-1979	Intern: Internal Medicine, University of California, San Diego, CA	

1979-1982 Resident: Diagnostic Radiology, Mallinckrodt Institute of Radiology
Washington University School of Medicine, St. Louis, MO

1982-1983 Nuclear Medicine Fellowship: Mallinckrodt Institute of Radiology
Washington University School of Medicine, St. Louis, MO

1982-1983 Immunology Research Fellow (concurrent):
Division of Allergy and Clinical Immunology, Howard
Hughes Medical Institute
Department of Internal Medicine, Washington University
School of Medicine. St. Louis, MO

Additional Training:

November 2007

“Leadership Development for Physicians in Academic Health Centers”, Harvard School of Public Health

Academic Positions/Employment:

1983-1987

Assistant Professor of Internal Medicine, Co-Director, Nuclear Imaging, University of Michigan Medical Center, Ann Arbor, MI

1987-1990

Associate Professor of Internal Medicine and Radiology; Director of General Nuclear Imaging, University of Michigan Medical Center, Ann Arbor, MI

1990-2000

Professor of Internal Medicine and Radiology; Director of General Nuclear Imaging, University of Michigan Medical Center, Ann Arbor, MI

2000-2014

Director, Division of Nuclear Medicine / PET; Vice-Chair for Technology and New Business Development; Professor, The Russell H. Morgan Department of Radiology and Radiological Science; Henry W. Wagner, Jr., M.D., Professor in Nuclear Medicine, Professor of Oncology Johns Hopkins Medical Institutions, Baltimore, MD

2014-Present

Adjunct Professor of Radiology and Radiological Science, Johns Hopkins University

2014-Present

Chair of the Department of Radiology, Washington University School of Medicine; Director of the Edward Mallinckrodt Institute of Radiology; Elizabeth E. Mallinckrodt Professor of Radiology

University and Hospital Appointments and Committees:

1983-1987

Co-Director, Nuclear Imaging, University of Michigan Medical Center

1987-2000

Director, General Nuclear Imaging, University of Michigan Medical Center

1995-2000

Director, Radiopharmaceutical Program, University of Michigan Comprehensive Cancer Center

2000-2014

Director, Division of Nuclear Medicine / PET Center; Vice-Chair for Technology and New Business Development; Professor, The Russell H. Morgan Department of Radiology and Radiological Science; Henry W. Wagner, Jr., M.D., Professor in Nuclear Medicine, Professor of Oncology Johns Hopkins Medical Institutions, Baltimore, MD

2005- 2014

Director: Imaging Response Assessment Laboratory, Sidney Kimmel Cancer Center, Johns Hopkins University

2008-2013

Senior Medical Advisor, Tawam Molecular Imaging Center, JHU International, Al-Ain, Abu Dhabi

2014-Present

Chair of the Department of Radiology, Washington University School of Medicine; Director of the Edward Mallinckrodt Institute of Radiology; Elizabeth E. Mallinckrodt Professor of Radiology

Medical Licensure and Board Certification:

1979 National Board of Medical Examiners
 1982 American Board of Radiology - Diagnostic Radiology
 1983 American Board of Radiology - Special Competency in Nuclear Radiology
 1985 American Board of Nuclear Medicine
 Licensure: Michigan, Maryland, Missouri

Honors and Awards:

1973 Alpha Chi, Wartburg College
 1973 Beta Beta Beta, Wartburg College
 1974 Summa Cum Laude, Wartburg College
 1978 Alpha Omega Alpha, Washington University School of Medicine
 1986 Marc Tetalman Memorial Award, Society of Nuclear Medicine
 1987 Jerome W. Conn Internal Medicine Research Award
 1992 Society of Computed Body Tomography and Magnetic Resonance: Hounsfield Award (with Drs. L.E. Quint and Charles Meyer) for "CT/FDG PET Fusion Imaging for Staging Lung Cancer"
 1992 Berson & Yalow Research Award, Society of Nuclear Medicine
 1992 Listed, Marquis "Who's Who in the Midwest"
 1992 Listed: "Best Doctors in America"
 1993-99 Member: American Board of Nuclear Medicine
 1993 RSNA Cum Laude award for Scientific Exhibit at 79th Scientific Assembly and Annual Meeting
 1994 J. Nuclear Medicine Basic Science Manuscript of the Year with Dr. K. Higashi
 1994 Listed, Marquis "Who's Who in America" and "Who's Who in the World"
 1995 Wartburg College "Distinguished Alumnus Award"
 1996 Listed, Marquis "Who's Who in Science and Engineering"
 1996 Listed: "Best Doctors in America - Midwest Region"
 1996 Listed, Marquis: "Who's Who in Medicine and Healthcare"
 1996 Fellow: American College Nuclear Physicians
 1998 "Alavi-Mandel Award," Society of Nuclear Medicine, best basic science paper by trainee with T. Torizuka, MD
 1999 DOE Achievement Award for "Radiopharmaceutical Therapy for the next Millennium"
 2002 "Distinguished Scientist: for 2001: Academy of Molecular Imaging, Orlando, FL
 2003 "Best of the Best" MI Industry top 10, Radiology's top performers. Medical Imaging 2005, 2006, 2007
 2005 "Most Influential Radiology Researcher", "Aunt Minnie Award"

- 2007 Endocrine Society and Pfizer Award: International Award for Excellence in Published Clinical Research in The Journal of Clinical Endocrinology and Metabolism in 2006”, with Pacini F. Ladenson PW and others.
- 2007 “Alavi-Mandel Award,” best basic science paper JNM with James Engles
- 2013 RSNA Honored Educator Award
- 2015 Elected to member in National Academy of Medicine

Editorial Responsibilities:

Editorial Boards

- 1994 - present Journal of Nuclear Medicine
- 1998 - present Clinical Positron Imaging
- 1998 - present Journal of the International Society of Tumor Targeting
- 1999 - present Cancer Biotherapy and Radiopharmaceuticals
- 1999 - present Molecular Imaging and Biology
- 2003 - present European Journal of Nuclear Medicine and Molecular Imaging
- 2005 - present Journal of the Hong Kong College of Radiologists

Journal Reviewer

Cancer; Journal of Nuclear Medicine; Radiology; Cancer Research; European Journal of Cancer & Clinical Oncology; Journal of Immunological Methods; Journal of National Cancer Institute; American Journal of Medicine; Gastroenterology; Journal of Clinical Oncology, Nature Medicine, Clinical Cancer Research, Radiology, Nature Medicine, Science, Cancer Research, New England Journal of Medicine, Clinical Lipodology.

Study Sections/Reviews

- 1986-present Ad-Hoc reviewer for Dept of Energy and Veterans Administration Merit Review
- 1987 Special reviewer for Experimental Immunology Study Section, NCI and Veterans Administration.
- 1988 Member: Special Study Section RFA-87-CA-33 "Application of Chelate Conjugated Radiolabeled Monoclonal Antibodies Specifically to Diagnostic Imaging."
- 1988 Member: Ad Hoc Study Section: NCI-CM 97570-74 "Single Photon Radiopharmaceuticals for Function, Metabolism and Tissue Localization."
- 1988 Site Visitor: National Cancer Institute Program Project Grants (x3).
- 1988 Special reviewer for Veterans Administrative merit and RAGS review. Ad Hoc Experimental Immunology Study Section member
- 1988 Special reviewer for Department of Energy
- 1989 Special reviewer for NIH and VA grants
- 1990 Site visitor, NIH Program Project Grant
- 1990-1994 Member: NIH Experimental Immunology Study Section
- 1991 Ad-Hoc NIH Radiation Study Section
- 1992 Special Reviewer: Department of Energy
- 1992 Ad-Hoc NIH Radiation Study Section
- 1993 Chairman, Institute for Clinical PET Program Committee (oncology)
- 1994 Ad-Hoc reviewer, NIH PO-1 on Radioimmunotherapy
- 1996 Ad-Hoc reviewer, AHCPR
- 1998 Special Review Panel, Department of Defense–Breast Cancer Imaging Program Reviewer, Department of Energy
- 1999 NIH Resource Center, review of Cyclotron Produced Tracers
- 1999 Review Panel Member, Biomedical Applications, U.S. Dept of Energy
- 1999 Review Panel Member, Susan Komen Foundation, NIH
- 1999 Ad-Hoc reviewer, MRC Canada
- 1999 - 2001 Advisory Board TRIUMF Life Sciences Program, Vancouver, Canada
- 1999 Ad-Hoc reviewer, NIH Experimental Immunology Study Section
- 1999 Board of Scientific Counselors: NIH Clinical Center, Ad-Hoc External Reviewer for Imaging Science Program

2000	Reviewer, VA Merit Grants
2000	Special Reviewer, Irish Voluntary Health Agency
2000	Department of Energy
2001	Ad Hoc Member, Experimental Therapeutic Study Section
2002	NIH/NCI Reviewer, PO1 grants
2012	NIH Concept Review & BQSFP Study Review Panel
2012-14	NIH U-01 reviewer, QIN (Quantitative Imaging Network)
2013	French “NIH” Program Review—PET projects
2014	NIH RO-1 review. Experimental Therapeutics
2015	NCI Special Emphasis Review Panel: Quantitative Imaging for Evaluation of Responses to Cancer Therapies

Professional Societies and Organizations:

American Board of Nuclear Medicine (Chair: Credentials Committee 1994-1997, Secretary 1997, Chairman of the Board 1998)
 American Federation for Clinical Research
 American Medical Association
 American College of Nuclear Physicians (Fellow) CANP
 American College of Radiology (Fellow) FACR
 American Association for Cancer Research
 American Roentgen Ray Society
 American Society for Clinical Investigation
 Central Chapter, Society of Nuclear Medicine
 Central Society for Clinical Research
 Institute of Clinical PET - (President 1995-1996) (International Program Chair, Board of Directors)
 Michigan Radiological Society
 Maryland Radiological Society
 Radiological Society of North America
 Society of Nuclear Medicine
 National Academy of Medicine

1984-1986	Finance Committee; Central Chapter, Society of Nuclear Medicine
1989-1990	Sub-chairman Infectious Disease/Immunology Program Subcommittee; Society of Nuclear Medicine
1989-2000	Governmental Affairs Committee; American College of Nuclear Physicians
1989-2000	Radiopharmaceutical Committee; American College of Nuclear Physicians
1990-1992	Planning Committee; Immunoscintigraphy/ Immunotherapy Program
1990-1993	Sub chairman: Monoclonal Antibody Program; Society of Nuclear Medicine Annual Meeting
1990-1995	Scientific Affairs and Research Committee; Society of Nuclear Medicine
1990-1995	Program Committee (Nuclear Medicine); Radiological Society of North America
1992-2000	Program Committee; High Country Nuclear Medicine Meeting; Society of Nuclear Medicine
1992-	Member: Correlative Imaging Council; Society of Nuclear Medicine
1992-1993	Program Committee, Institute for Clinical PET
1993-1994	Chair: PET in Oncology Educational Program; Society of Nuclear Medicine
1993-1995	Chair: Radiopharmaceutical Affairs Committee, American College of Nuclear Physicians
1993	NIH Clinical Center Review: Nuclear Medicine, PET and Radiology
1993-1996	Sub-Chairman: Oncology Non-Antibody Program: Society of Nuclear Medicine
1993-1998	Board of Directors: Institute for Clinical PET
1994-1997	Chair; Credentials Committee: American Board of Nuclear Medicine
1994-1995	Chair: Program Committee: Institute for Clinical PET (1995 annual meeting)
1994	Therapy Council, Society of Nuclear Medicine
1995-1996	President: Institute for Clinical PET
1996-1997	Secretary: American Board of Nuclear Medicine
1998-1999	Chairman: American Board of Nuclear Medicine

2000 Fellow: American College of Radiology (FACR)
 2002-2007 Medicare Coverage Advisory Committee (MCAC)
 2003 American Society of Clinical Oncology (ASCO) Setinel Node Task Force and PET Scanning Task force
 2007-present Radiological Society of North America, Quantitative Imaging Biomarker Alliance (QIBA) Steering Committee Member. Committee Co-Chair PET/Nuclear Medicine
 2014-present Chair: Nuclear Medicine Coordinating Committee (RSNA/QIBA)
 2015-present NCI Clinical Imaging Steering Committee (CISC)
 2016- Sustainability Task Force (QIBA)
 2017- NCI Working Group on Targeted Radionuclide Therapy

Organization Activities

University of Michigan

1986-2000 Member, The University of Michigan Cancer Center
 1986-2000 Clinical Research Center Advisory Committee
 1987-1989 Henry Ford Hospital Research Committee
 1988-1996 University of Michigan Cancer Research Committee
 1990-1993 Department of Internal Medicine House Officer Selection Committee
 1992-2000 University of Michigan PET Operating Committee
 1994-1997 Member, University of Michigan Faculty Senate Assembly
 1995-2000 Member, University of Michigan-Memorial-Phoenix Project (Nuclear Reactor) Executive Committee
 1995-2000 Director, Radiopharmaceuticals in Cancer Program, University of Michigan Cancer Center
 1997-1998 Member, Therapy Guidelines Committee, Anticoagulation Team: Venous Thrombosis, PE Diagnosis, University of Michigan Medical Center.
 1998-2000 Member, University of Michigan Hospitals Credentials & Privileges Committee

Johns Hopkins University

2000-Present Member, Radiology Executive Committee, Quality Control Committee, and Promotions Committee, and Practice Plan Committee, Chair: PET Operations Committee
 2001-2006 Joint Committee of Medical Education, JHU
 2002-2008 Gamma Plus, Baltimore Board of Directors
 2006-2014 Cancer Center Research Review Committee
 2009 -present JHU ICTR advisory board

Washington University

2014 – Present Member of: Executive Faculty, Academic Affairs, Research Affairs, BJH/WUSM Joint Clinical Planning Oversight Committee, Faculty Practice Plan and Siteman Cancer Center, Pediatrics Chair Search Committee, Faculty Hiring Policy Subcommittee, Center for Human Immunology and Immunotherapy Programs Member (CHiPs)
 2016 Co-Chair , Faculty Hiring and Employment Culture Workgroup

Major Invited Professorships and Lectureships:

1993 Daniel R. Biello Lecture - 7th Annual; Washington University School of Medicine
 1993 Plenary Lecture, European Association of Nuclear Medicine, Lausanne, Switzerland
 1994 Plenary Lecture, Japanese Society of Nuclear Medicine, Sapporo, Japan
 1996 E. S. Garnett Lecturer, McMaster University School of Medicine, Hamilton, Ontario
 1996 - Fellow: American College Nuclear Physicians
 1997 "James Quinn 3rd Memorial Lecture," Central Chapter Society of Nuclear Medicine
 1997 16th Annual Philip M. Johnson Memorial Lecture, Columbia University, New York, NY
 1998 "Chamberlain" Lecturer, Temple University School of Medicine, Philadelphia, PA
 1998 "Marie Curie Lecturer," Plenary Lecture, European Association of Nuclear Medicine/World Federation of Nuclear Medicine and Biology Meeting, Berlin, Germany
 1999 "E. Pendergrass New Horizons Lecturer," Radiological Society of North America
 2000 "James Quinn 6th Memorial Lecture," Central Chapter Society of Nuclear Medicine

- 2000 Plenary Lecture, Jornada Paulista Radiologia, Sao Paulo, Brazil
- 2000 Plenary Lecture, Australian New Zealand Society of Nuclear Medicine
- 2005 Plenary Lecture: Japanese Society of Nuclear Medicine
- 2005 Plenary Lecture: European Society of Nuclear Medicine
- 2006 Plenary Lecture: European Society of Nuclear Medicine
- 2007 Plenary Lecture Japanese Radiological Society
- 2008 Henry N. Wagner Plenary Lecture, Society of Nuclear Medicine, Annual Meeting, New Orleans, LA
- 2011 Plenary Lecture: Japanese Society Nuclear Medicine (Tskuba City, Japan)
- 2014 Plenary Lecture: Swiss Radiological Society (Montreux, Switzerland)
- 2014 Chaudhuri Annual Lecture in Nuclear Medicine: EVMS, Norfolk, VA
- 2015 Plenary lecture: International Symposium on Radiopharmaceutical Sciences, Columbia, MO
- 2016 SNMMI PET Center of Excellence Peter Valk Memorial Award and Lectureship
- 2016 Fuchs Plenary Session, International Congress of Radiology, Buenos Aires, Argentina

Invited Presentations:

1. "Improved Radioimaging and Tumor Localization with Monoclonal F(ab')₂." Guest lecturer, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI, January 28, 1983
2. "Monoclonal Antibody Imaging." Grand Rounds, Department of Radiology, University of Colorado, Denver, CO, February 22, 1983
3. "The Impact of Monoclonal Antibodies on Nuclear Medicine." William Beaumont Hospital, Royal Oak, MI, February 13, 1984
4. "Clinical Tomographic Imaging." Central Chapter of Society of Nuclear Medicine Technologist Review Course, William Beaumont Hospital, Department of Nuclear Medicine, Royal Oak, MI, March 28, 1984
5. "Monoclonal Antibodies in Clinical Medicine." 12th Annual Advances in Internal Medicine Course, Towsley Center, University of Michigan Medical Center, May 1984
6. "Imaging With Monoclonal Antibodies." Southeast Michigan Association of Technical Affiliates, William Beaumont Hospital, Royal Oak, MI, September, 1984
7. "Monoclonal Antibodies, A Review." Wartburg College Interdisciplinary Science Convocation, Waverly, IA, September 17, 1984
8. "Multi-Modal Imaging." Michigan Society of Radiologic Technologists Annual Meeting, Grand Rapids, MI, September 29, 1984
9. "SPECT in Nuclear Oncology: Emphasis on Monoclonal Antibodies." Tomographic Symposium, Ann Arbor, MI, October 19, 1984
10. "Monoclonal Antibodies: Impact on Clinical Nuclear Medicine." Presented to Henry Ford Hospital for Continuing Education, Department of Radiology, Detroit, MI, May 16, 1985
11. "Monoclonal Antibodies: Impact on Clinical Nuclear Medicine." Review Course, Presented to the Society of Nuclear Medicine 32nd Annual Meeting, Houston, TX, June 4, 1985
12. "Radiolabeled Monoclonal Antibodies for Diagnosis and Therapy." Central Chapter of the Society of Nuclear Medicine, Fall Meeting, Ann Arbor, MI, October 12-13, 1985
13. "Radiolabeled Monoclonal Antibodies for the Diagnosis and Therapy of Cancer." Presented to Radiology Grand Rounds, University of Texas Southwestern Medical Center, Dallas, TX, November 8, 1985
14. "Rational Use of Bone Scanning in the Era of Budget Deficits." Michigan State Medical Society, Annual Meeting, Dearborn, MI, November 13, 1985
15. "Monoclonal Antibody Imaging and Therapy - 1986." Guest Lecturer, Division of Nuclear Medicine, University of Kentucky, Lexington, KY, February 12, 1986
16. "Michigan Radiology Resident Review Course 1986." Ann Arbor, MI, April 4, 1986
17. "Monoclonal Antibodies Impact of the 'Computer Revolution.'" Central Chapter, Society of Nuclear Medicine, Milwaukee, WI, April 5, 1986

18. "Imaging with Radiolabeled Monoclonal Antibodies." Advances in Internal Medicine Course, 14th Annual Spring Update, University of Michigan Medical Center, Towsley Center, Ann Arbor, MI, May 13, 1986
19. "Update on Melanoma." Cancer Center Seminar, University of Michigan Medical Center, Oncology Grand Rounds, Ann Arbor, MI, October 3, 1986
20. "Intracarotid and Intracranial Delivery of Monoclonal Antibodies." Eighteenth Annual Edgar A. Kahn Neurosurgical Meeting, University of Michigan Medical Center, Towsley Center, Ann Arbor, MI, October 17, 1986
21. "Radiolabeled Monoclonal Antibody Therapy and Imaging." Current Issues in Clinical Oncology, University of Michigan Medical Center, Towsley Center, Ann Arbor, MI, October 25, 1986
22. "Nuclear Medicine Update." Differential Diagnosis in Radiology - 4th Annual Review Course for Residents, University of Michigan Medical Center, Ann Arbor, MI, April 4, 1987
23. "Strategies to Enhance Radioimmunodiagnosis and Radioimmunotherapy." Memorial Sloan Kettering Cancer Center, New York, NY, June 21, 1987
24. "Methods to Enhance Radioimmunodiagnosis and Therapy of Cancer." Center for Molecular Medicine and Immunology, Newark, NJ, July 17, 1987
25. "Improving Radioimmunodiagnosis and Radioimmunotherapy of Cancer." Dow Chemical, Midland, MI, August 7, 1987.
26. "Regional Antibody Delivery." NeoRx Corporation, Seattle, WA, August 27, 1987
27. "Imaging with Radiolabeled Antibodies." University of Pittsburgh, Pittsburgh, PA, September 23, 1987
28. "Immunoscintigraphy: The Promise and the Reality." International Symposium on Recent Advances in Nuclear Medicine, Udine, Italy, October 2-3, 1987
29. "Infection Detection: Nuclear Medicine Studies for the Generalist." Michigan State Medical Society, Southfield, MI, November 12, 1987
30. "Radiolabeled Antibody Imaging." Wayne State University, School of Medicine, Detroit, MI, November 19, 1987
31. "Radiolabeled Antibody Imaging." Review Course, Radiological Society of North America, Chicago, IL, December 1, 1987.
32. "Radiolabeled Antibodies for Diagnosis and their Quality Control." Michigan Clinical Ligand Society, Southfield, MI, March 18, 1988
33. "Monoclonal Antibody Lymphoscintigraphy in Melanoma." American Society of Dermatologic Surgeon, Monterey, CA, April 15, 1988
34. "Nuclear Medicine Update." Differential Diagnosis in Radiology - 5th Annual Review Course for Residents, University of Michigan Medical Center, Ann Arbor, MI, 1988
35. "Immunoscintigraphy 1988." Mallinckrodt Institute of Radiology, St. Louis, MO, May 6, 1988
36. "Monoclonal Antibodies." Ontario Association of Medical and Radiologic Technologists, Windsor, Ontario, Canada, May 14, 1988
37. "Radiolabeled Antibodies in Oncology." Michigan Cancer Foundation Seminar, Detroit, MI, May 19, 1988
38. "Potential and Pitfalls of Radiolabeled Antibodies." Presented while Visiting Professor at the University of Minnesota Medical Center, Minneapolis, MN, June 15, 1988
39. "Diagnosis and Treatment with Radiolabeled Antibodies." Medicine Grand Rounds, University of Michigan Medical Center, Ann Arbor, MI, August 5, 1988
40. "Therapy with Radiolabeled Antibodies." Royal College of Physicians of Canada Annual Meeting with Canadian Society of Nuclear Medicine & Canadian Association of Radiation Therapists, Ottawa, Canada, October 24, 1988
41. "Monoclonal Antibody Imaging." Radiology Grand Rounds, University of Pennsylvania, Philadelphia, PA, November 22, 1988
42. "Radiolabeled Antibody Imaging." Review Course, Radiological Society of North America, Chicago, IL, November 28, 1988

43. "Diagnostic Imaging with Radiolabeled Antibodies." Radiology Grand Rounds, University of Michigan Medical Center, Ann Arbor, MI, January 19, 1989
44. "Monoclonal Antibodies in Radiology." Radiology Conference, University of Miami School of Medicine, Miami, FL, January 23, 1989
45. "Monoclonal Antibodies in Ovarian Cancer." Twenty-fourth Annual San Francisco Cancer Symposium, San Francisco, CA, February 11, 1989
46. "Monoclonal Antibodies: Where Are We Today?" Central Chapter: Society of Nuclear Medicine, Chicago, IL, March 10, 1989
47. "Rational Use of Bone Scans." Pittsburgh Roentgen Society, Pittsburgh, PA, April 12, 1989
48. "Radiolabeled Monoclonal Antibodies: New Imaging and Therapeutic Agents." Pittsburgh Roentgen Society, Pittsburgh, PA, April 12, 1989
49. "Emergency Nuclear Medicine." University of Pittsburgh Department of Radiology, Pittsburgh, PA, April 13, 1989
50. "Introduction to Positron Emission Tomography (PET)." University of Pittsburgh Department of Radiology, Pittsburgh, PA, April 13, 1989
51. "Imaging and Immunity: Monoclonal Antibodies." 89th Annual American Roentgen Ray Society Meeting, New Orleans, LA, May 12, 1989
52. "Imaging of Metastatic Disease to the Liver and Bone." Regional Cancer Center Continuing Education Course, Erie, PA, September 29, 1989
53. "Radiolabeled Antibody Imaging Categorical Review Course." Radiological Society of North America, Chicago, IL, November 30, 1989
54. "Differential Diagnosis in Radiology," Nuclear Medicine Review, University of Michigan Medical Center, Ann Arbor, MI, March 10, 1990
55. "Radiolabeled Monoclonal Antibodies in the Diagnosis and Treatment of Cancer," Helsinki University Hospital, Helsinki, Finland, April 18, 1990
56. "Radioantibody Therapy of Cancer." Department of Microbiology and Immunology, Turku University, Turku, Finland, April 19, 1990
57. "Monoclonal Antibody Diagnosis and Treatment of Cancer." Academy of Finland Nuclear Medicine Review, Turku University, Turku, Finland, April 19, 1990
58. "Radioimmunotherapy of Non-Hodgkin's Lymphomas." National Institutes of Health, Bethesda, MD, May 14, 1990
59. "Experimental and Clinical Studies in Cancer Imaging and Therapy." 1990 American Society of Microbiology Conference on Biotechnology, Chicago, IL, June 8, 1990
60. "FDG PET of Breast Cancer: Imaging and Monitoring the Response to Treatment, and Intense Normal Lymph Node Uptake of FDG Following Subcutaneous Injection: A Potential Pitfall in FDG PET Tumor Imaging." European Workshop on FDG in Oncology, Heidelberg, Federal Republic of Germany, June 15-16, 1990
61. "An Update on Radioimmunotherapy." American College of Nuclear Medicine, 17th Annual Scientific Meeting, Baltimore, MD, September 14-16, 1990
62. "Radioimmunoimaging & Therapy Review." Visiting Professor, McMaster University, Hamilton, Ontario, Canada, September 19, 1990
63. "New Nuclear Medicine Techniques in Head and Neck Cancer." Third International Head & Neck Oncology Research Conference, American Society for Head & Neck Surgery, Las Vegas, NV, September 26-28, 1990.
64. "Overview: Experimental Targeting." Third Conference on Radioimmuno-detection and Radioimmuno-therapy of Cancer, American College of Radiology, Princeton, NJ, November 15, 1990
65. "Advances in Nuclear Oncology." Children's Hospital of San Francisco, San Francisco, CA, January 17, 1991
66. "Immunoscintigraphy & Immunotherapy." Northern California Chapter Annual Midwinter Meeting, The Society of Nuclear Medicine, Oakland, CA, January 17, 1991

67. "Intraperitoneal Antibody Delivery Systems: Ovarian Cancer-Biological Consideration." Current Status and Future Directions of Immunoconjugates-Monoclonal Antibody Based Imaging and Treatment-III, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Key Biscayne, FL, January 25-27, 1991
68. "Therapy of Lymphoma with Radiolabeled Monoclonal Antibodies." Current Status and Future Directions of Immunoconjugates-Monoclonal Antibody Based Imaging and Treatment-III, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Key Biscayne, FL, January 25-27, 1991
69. "Use of PET in the Diagnosis and Therapy of the Oncology Patient." PET Modern Applications in Clinical Medicine Conference, University of Arkansas for Medical Sciences, Little Rock, AR, March 23, 1991
70. "Nuclear Oncology: Monoclonal Antibodies and PET." Johns Hopkins University, Baltimore, MD, April 8, 1991
71. "PET in the Brain." St. Francis Hospital, Peoria, IL, April 26, 1991
72. "PET Applications in Cardiology and Oncology." Methodist Hospital, Peoria, IL, April 26, 1991
73. "Antibodies & PET: Their Role in Tumor Imaging & Treatment." Southeastern Michigan Associates & Technical Affiliates (SEMATA), Michigan College of Nuclear Medicine Physicians (MCNMP), Farmington Hills, MI, May 16, 1991
74. "Radiolabeled Antibodies: Overview of Imaging Applications." Society of Nuclear Medicine, Technologist Section, The Society of Nuclear Medicine 38th Annual Meeting, Cincinnati, OH, June 11-14, 1991
75. "Immunology & Tumor Targeting." American Association of Physicists in Medicine 33rd Annual Meeting, San Francisco, CA, July 24, 1991
76. "Nuclear Imaging of the Brain: Recent Advances." Western Neuroradiological Society, Laguna Nigel, CA, October 18, 1991
77. "Monitoring the Response of Breast Cancer to Chemotherapy with PET." Institute for Clinical PET, 3rd Annual Meeting, Washington, DC, October 25, 1991
78. "Positron Emission Techniques in the Assessment of Cancer." Philadelphia Chapter, Society of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, November 13, 1991
79. "Progress in Imaging & Treatment of Cancer Utilizing Nuclear Techniques." Tumor Conference, Crittenton Hospital, Rochester, MI, November 20, 1991
80. "PET Imaging in Cancer." Hybritech, Incorporated, San Diego, CA, March 3, 1992
81. "PET in Oncology." American College of Nuclear Physicians 18th Annual Meeting and Scientific Sessions, San Diego, CA, March 3, 1992
82. "Radioimmunotherapy of Cancer." American College of Nuclear Physicians 18th Annual Meeting and Scientific Sessions, San Diego, CA, March 5, 1992
83. "Monoclonal Antibodies: Experience in the Past Decade and a View Toward the Next." Central Chapter of the Society of Nuclear Medicine 33rd Annual Spring Meeting, Chicago, IL, March 13-15, 1992
84. "Imaging Cancer with PET." High Country Nuclear Medicine Symposium, Vail, CO, March 13, 1992
85. "PET Applications in Oncology." Mideastern Chapter of the Society of Nuclear Medicine, Washington, DC, April 11, 1992
86. "New Radiopharmaceuticals for Cancer Diagnosis." Eastern Great Lakes Chapter of the Society of Nuclear Medicine 13th Annual Meeting, Niagara Falls, NY, April 25, 1992
87. "Imaging and Treatment with Radiolabeled Antibodies." William Beaumont Hospital, Royal Oak, MI, May 8, 1992
88. "The Applications of PET in Cancer Management." Fifth Symposium on the Use of Cyclotrons in Medicine, Turku, Finland, June 2, 1992
89. "PET Imaging of Cancer." Review Course, Society of Nuclear Medicine Annual Meeting, Los Angeles, CA, June 8, 1992

90. "PET Imaging of Cancer: A New Diagnostic Tool." Kettering Medical Center, Dayton, OH, June 25, 1992
91. "Overview of Experimental Radioimmunotherapy." 4th Conference on Radioimmuno-detection and Radioimmunotherapy of Cancer, Princeton, NJ, September 18, 1992
92. "Effect of Radiotherapy on Tumor Metabolism." Fourth Annual International PET Conference and Research Symposium, Washington, DC, October 5, 1992
93. "Breast Cancer: Staging and Treatment Follow-Up." Fourth Annual International PET Conference and Research Symposium, Washington, DC, October 7, 1992
94. "Detecting and Managing Cancer with Positron Emission Tomography." Medical Grand Rounds, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, November 9, 1992
95. "Imaging Cancer with PET." Review Course, Michigan State Medical Society Annual Meeting sponsored by the Michigan College of Nuclear Medicine Physicians, Dearborn, MI, November 19, 1992
96. "PET in Cancer: Review of Current State-of-the-Art and Views Regarding a National Research Agenda." National Cancer Institute Workshop, Chicago, IL, November 28, 1992
97. "PET Applications in Oncology." Review Course, Radiologic Society of North America, Chicago, IL, December 1, 1992
98. "PET Imaging of Lung Cancer." Creative Concepts Conference, Vail, CO, December 11, 1992
99. "Assessing Tumor Response with PET." Creative Concepts Conference, Vail, CO, December 12, 1992
100. "The Use of PET in Cancer Management." Fogarty Lecture, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, January 19, 1993
101. "New Horizons in Oncologic Nuclear Medicine." 7th Daniel R. Biello Memorial Lecture, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, February 8, 1993
102. "Imaging Cancer with PET." John Cochran V.A. Hospital, St. Louis, MO, February 9, 1993
103. "PET role in Breast Cancer Imaging." St. Louis University School of Medicine, St. Louis, MO, February 9, 1993
104. "Update on Radioimmunotherapy Lymphoma." High Country Nuclear Medicine Conference, Vail, CO, March 8, 1993
105. "PET Applications in Oncology." SW Chapter Society Nuclear Medicine, Dallas, TX, March 12, 1993
106. "Radioimmunotherapy of Cancer." SW Chapter Society Nuclear Medicine, Dallas, TX, March 13, 1993
107. "PET of Breast Cancer." President's Committee on Breast Cancer, Miami, FL, March 19, 1993
108. "Treatment of Cancer with Radiolabeled Antibodies." Albert Einstein School of Medicine, NY, NY, March 29, 1993
109. "PET in Cancer Management." Montefiore Hospital, NY, NY, March 30, 1993
110. "PET in Cancer Management." Albert Einstein School of Medicine, NY, NY, March 30, 1993
111. "Radioimmunotherapy and PET: New Techniques in Cancer Management." Kanazawa Medical University, Kanazawa, Japan, May 13, 1993
112. "PET Imaging of Breast Cancer." 2nd International Symposium on PET in Oncology, Sendai, Japan, May 17, 1993
113. "Oncologic Applications of PET." Korean Society of Nuclear Medicine, Seoul, Korea, May 21, 1993
114. "PET in Oncology." Korean Cancer Hospital, Seoul, Korea, May 22, 1993
115. "PET of Breast Carcinoma." review course, Society of Nuclear Medicine Annual Meeting, Toronto, Ontario, Canada, June 7, 1993
116. "Diagnostic imaging and current management with a special focus session for technologists." 7th Annual Symposium on Breast Disease, Grand Traverse, MI, July 11-13, 1993
117. "Practical Advances in Cancer Imaging and Therapy Using Radiopharmaceuticals." Oncology Care Symposium at St. Francis Hospital and Medical Center and Kansas Medical Education Foundation, Topeka KS, October 1, 1993

118. "Tumor Imaging in the 90's: PET or Immunoscintigraphy?" Plenary Lecture, European Association of Nuclear Medicine, Lausanne, Switzerland, October 12, 1993
119. "A Comparison of PET and Antibodies in Cancer Management." Technical University of Munich, Germany, October 18, 1993
120. "Overview of PET applications in Oncology." Institute for Clinical PET 5th Annual Meeting, Washington DC, October 30, 1993
121. "Managing Cancer using PET." Institute for Clinical PET 5th Annual Meeting, Washington DC, October 30, 1993
122. "A Comparison of PET and Monoclonal Antibodies for Tumor Imaging." Radiology Grand Rounds, University of Michigan Medical Center, Ann Arbor, MI, November 3, 1993
123. "Newer Forms of Nuclear Medicine Cancer Treatment." Indiana University, Indianapolis, IN, November 16, 1993
124. "PET Imaging of Cancer." Indiana University, Indianapolis, IN, November 16, 1993
125. "Review course on PET Oncology." 79th Annual Radiological Society of North America, Chicago, IL, December 3, 1993
126. "Radioimmunotherapy of Lymphoma." 6th University of Miami Symposium on Antibodies and Receptor Binding Agents for Diagnosis and Therapy, Key Biscayne, FL, January 12, 1994
127. "Imaging Cancer with PET." 6th University of Miami Symposium on Antibodies and Receptor Binding Agents for Diagnosis and Therapy, Key Biscayne, FL, January 14, 1994
128. "Cancer Imaging with PET." Radiology Grand Rounds, L.S.U. School of Medicine, Shreveport, LA, February 2, 1994
129. "Overview of PET Applications in Oncology." National Cancer Institute Workshop on Tumor Receptor Imaging, Bethesda, MD, February 16, 1994
130. "Localization of Abdominal Cancer." PET and SPECT Imaging in Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, March 9, 1994
131. "Monitoring Treatment in Prostate disease." PET and SPECT Imaging in Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, March 10, 1994
132. "New Tumor Seeking Nuclear Medicine Scans: PET, Antibodies and Somatostatin Binding Peptides." Advances in Internal Medicine Course, University of Michigan Medical Center, Ann Arbor, MI, April 26, 1994
133. "Treatment of Lymphoma with Radioantibodies." Plenary Lecture, 1st Swedish Symposium on Radiopharmaceutical Therapy, University of Upsalla, Upsalla, Sweden, April 29, 1994
134. "Imaging GU and other tumors with PET." St. Josephs Mercy Medical Center, Ann Arbor, MI, May 26, 1994
135. "New Nuclear Medicine Diagnostic and Therapeutic Techniques." Medical Grand Rounds, St. John's Hospital, Detroit, MI, May 31, 1994
136. "The Emerging Research and Clinical Role of PET in Cancer Imaging." Address to the National Cancer Advisory Board, National Institutes of Health, Bethesda, MD, June 7, 1994
137. "Review of Radioimmunotherapy." Continuing Education Course, Society of Nuclear Medicine Annual Meeting, Orlando, FL, June 4, 1994
138. "The Emerging Role of Nuclear Medicine Techniques in Breast Imaging." Department of Health and Human Services Workshop, Washington, DC, July 29, 1994
139. "PET Imaging of Cancer." Radiology Grand Rounds, Duke University School of Medicine, Durham, NC, September 15, 1994
140. "Imaging of Tumors Using PET." Plenary Lecture, The Japanese Society of Nuclear Medicine. Sapporo, Japan, September 26-October 2, 1994
141. "The Emerging Role of Nuclear Medicine Techniques in Breast Imaging." Rayburn House Office Building. Washington, DC, October 11, 1994
142. "PET of Breast Cancer." Institute for Clinical PET 6th Annual Meeting. Washington, DC, October 15, 1994

143. "The Emerging Role of PET in Melanoma, Lymphoma and Prostate Cancers." Institute for Clinical PET, 6th Annual Meeting. Washington, DC, October 15, 1994
144. "Is Cancer Diagnosis and Management Really Influenced by PET or SPECT?" "Pro Viewpoint" - Pre World-Congress Symposium "Emission Tomography - Controversies and Future Directions, Cairns, Queensland, Australia, October 20, 1994
145. "Treatment of Lymphoma with ¹³¹I-labeled Monoclonal Antibodies." International Colloquium on Radiopharmaceutical Therapy, Sydney, New South Wales, Australia, October 23, 1994
146. "Radioimmunotherapy of Lymphomas with ¹³¹I Anti-B1 Monoclonal Antibody." International Symposium on Tumor Targeting, Ludwig Cancer Institute, Melbourne, Victoria, Australia, October 31, 1994
147. "A Proposed PET Research Agenda to the Year 2000." NIH and Academy of Radiology Workshop on the Future of Imaging Research, Bethesda, MD, November 6, 1994
148. "New Approaches in Nuclear Medicine." Moderne Medizinische Radiologie Und Maligne Neoplasie, Swiss Society of Medical Radiology, Zurich, Switzerland, November 19, 1994
149. "Clinical PET." Refresher Course, Radiological Society of North America, 80th Scientific Assembly. Chicago, IL, November 30, 1994
150. "Use of PET in Cancer Management." Nuclear Medicine Grand Rounds at University of Buffalo School of Medicine, Buffalo, NY, January 25, 1995
151. "FDG Imaging of Cancer: PET or SPECT?" High Country Nuclear Medicine Conference, Vail, CO, March 5, 1995
152. "What period of Isolation, if any, is Appropriate Following Radionuclide Therapy?" High Country Nuclear Medicine Conference, Vail, CO, March 6, 1995
153. "Clinical Trial Design: Studies to Define Medical, Regulatory, and Financial Acceptability of Oncologic Radiopharmaceuticals in the 'New Environment.'" High Country Nuclear Medicine Conference, Vail, CO, March 6, 1995
154. "Radioimmunotherapy of Non-Hodgkin's Lymphomas." Central Chapter of the Society of Nuclear Medicine, Cleveland, OH, March 17, 1995
155. "Monitoring Breast Cancer Chemotherapy with PET." Thirty-Seventh Science Writers Seminar for the American Cancer Society, New Orleans, LA, March 29, 1995
156. "Nuclear Medicine Update - The Role of Functional Imaging in Clinical Practice: Lung Cancer." The Society of Nuclear Medicine 42nd Annual Meeting, Minneapolis Convention Center, Minneapolis, MN, June, 1995
157. "Cancer Evaluation with PET: Lung Cancer." The Society of Nuclear Medicine 42nd Annual Meeting, Minneapolis Convention Center, Minneapolis, MN, June, 1995
158. "Nuclear Oncology: Focus for Today's Challenges, Vision for Tomorrow's Solutions." Cytogen Corp., The Society of Nuclear Medicine 42nd Annual Meeting, Minneapolis Convention Center, Minneapolis, MN, June, 1995
159. "Whole body PET in patients with Lymphomas and Lung Cancer." International Congress - "New Trends in Nuclear Oncology" Meeting, Naples, Italy, September 29, 1995
160. "Positron Emission Tomography: The emerging role in breast cancer imaging." International Congress - "New Trends in Nuclear Oncology" Meeting, Naples, Italy, September 29, 1995
161. "PET in Oncology: Current status and future perspectives." Inauguration of the PET-Center, University of Ulm, Germany, September 30, 1995
162. "Nuclear Oncology: PET and Monoclonal Antibodies." Wartburg College, Waverly, IA, October 20, 1995
163. "Clinical PET." 81st Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, November 27, 1995
164. "Surgery with a Positron-Sensitive Probe." High Country Nuclear Medicine Meeting, Vail, CO, March 9, 1996
165. "¹³¹I anti B-1 Treatment of Non-Hodgkin's-Lymphoma." High Country Nuclear Medicine Meeting, Vail, CO, March 9, 1996

166. "Where has Nuclear Medicine Failed in Cancer Imaging?" High Country Nuclear Medicine Meeting, Vail, CO, March 9, 1996
167. "Radionuclide -Guided Breast Biopsy with Sterotactic Techniques." High Country Nuclear Medicine, Meeting, Vail, CO, March 11, 1996
168. "Applications of SPECT in the Patient with Cancer." Oklahoma State Radiological Society, Oklahoma City, OK, April 15, 1996
169. "The Emerging Role of PET in Cancer Management." Oklahoma State Radiological Society, Oklahoma City, OK, April 15, 1996
170. "New Nuclear Medicine Therapies of Cancer." Oklahoma State Radiological Society, Oklahoma City, OK, April 15, 1996
171. "Oncological Applications of PET." New York Academy of Medicine, New York, NY, May 14, 1996
172. "Nuclear Medicine Emerging Role in Breast Imaging." USPHS Office of Women's Health Conference on "New Fountier in Image-Guided Breast Cancer Diagnosis and Treatment." Washington, DC, May 20 & 21, 1996
173. "PET Scanning." Ontario Medical Association Annual Meeting, Toronto, Ontario, May 24, 1996
174. "PET in Lung Cancer." Review Course, Society of Nuclear Medicine 43rd Annual Meeting, Denver, CO, June 2, 1996
175. "PET of Breast, Head and Neck Melanoma and Lymphoma." Review Course, Society of Nuclear Medicine 43rd Annual Meeting, Denver, CO, June 5, 1996
176. "FDA and Radiology - Reaction to Draft White Paper." RSNA Symposium on the FDA and Radiology, Washington, DC, June 6, 1996
177. "PET Tumor Imaging - The Interface of Biology, Physics and Clinical Science." Biomedical Imaging Research Symposium on PET, SPECT and MRI, Fukui, Japan, August 28 - 30, 1996
178. "Nuclear Medicine and PET: Role in Breast Cancer Imaging." exhibit, Capitol Hill Briefing - Women's Health Program, Washington, DC, September 17, 1996
179. "Clinical Applications and Cost Effectiveness of PET in Oncology." University of West Virginia PET Center Symposium, Morgantown, WV, September 21, 1996
180. "Role of PET in Lung Cancer." National Cancer Institute of Naples, Naples, Italy, September 23, 1996
181. "Role of PET in Breast Cancer." National Cancer Institute of Naples, Naples, Italy, September 24, 1996
182. "Treatment of Lymphoma with I-131 Anti-B1." 6th Asia and Oceania Congress of Nuclear Medicine and Biology, Kyoto, Japan, September 30, 1996
183. "Nuclear Medicine: Present and Future." 6th Asia and Oceania Congress of Nuclear Medicine and Biology, Kyoto, Japan, October 1, 1996
184. "PET Imaging of Cancer: Where is it Cost Effective?" 6th Asia and Oceania Congress of Nuclear Medicine and Biology, Kyoto, Japan, October 4, 1996
185. "Solutions for Contemporary Nuclear Imaging." Central Chapter, Society of Nuclear Medicine, Minneapolis, MN, September 28, 1996
186. "Re-engineered Monoclonal Antibodies - An Overview." 4th Conference on Radioimmunodetection with Radioimmunotherapy, Princeton, NJ, October 11, 1996
187. "Clinical PET - Its Emerging Role and Cost - Effectiveness in Oncology." E.S. Garnett Lecture at McMaster University, Hamilton, Ontario, Canada, October 17, 1996
- 188.188. "New Applications of Radionuclides in Cancer Detection and Treatment." 7th Annual Cancer Research Conference, Innovations in Cancer Research and Treatment, University of Michigan, Ann Arbor, MI, November 22, 1996
189. "What's New in Tumor Imaging." University of Michigan Affiliated Hospital Visiting Program, St. Joseph Mercy Hospital, Pontiac, MI, February 14, 1997
190. "Update Results with I-131 anti-B1 RIT and Outpatient Radiopharmaceutical Therapy." High Country Nuclear Medicine Conference, Vail, CO, February 28, 1997

191. "PET Imaging of Breast Cancer, an Update." High Country Nuclear Medicine Conference, Vail, CO, February 28, 1997
192. "Does FDG Image Tumor Hypoxia?" High Country Nuclear Medicine Conference, Vail, CO, March 2, 1997
193. "The Present Status of I-131 MIBG Therapy of Cancer.:" High Country Nuclear Medicine Conference, Vail, CO, March 2, 1997
194. "Lymphomas: Diagnosis and Treatment." Nuclear Oncology: From Genotype to Patient Care, Johns Hopkins University, Baltimore, MD, April 7, 1997
195. "Technetium-99m Labeled Somatostatin Analogs." Nuclear Oncology: From Genotype to Patient Care, Johns Hopkins University, Baltimore, MD, April 8, 1997
196. "Solitary Pulmonary Nodules." Nuclear Oncology: From Genotype to Patient Care, Johns Hopkins University. Baltimore, MD, April 8, 1997
197. "Melanoma." Nuclear Oncology: From Genotype to Patient Care, Johns Hopkins University, Baltimore, MD, April 8, 1997
198. "Lung Cancer." Nuclear Oncology: From Genotype to Patient Care, Johns Hopkins University, Baltimore, MD, April 9, 1997
199. "Nuclear Oncology: Present and Future Techniques." Annual Meeting of the Central Chapter of the Society of Nuclear Medicine, James Quinn 3rd Memorial Lecture, Lake Geneva, WI, April 11, 1997
200. "Radioimmunotherapy." Annual Meeting of the Central Chapter of the Society of Nuclear Medicine, Lake Geneva, WI, April 12, 1997
201. "Lymphoma: The Clinical Application of PET in the Detection, Staging and Treatment of Lymphoma." PET in Clinical Oncology, Vince Lombardi Cancer Center, Georgetown University, Washington DC, April 24, 1997
202. "PET & SPECT in Nuclear Oncology." Delaware Academy of Medicine, Wilmington, DE, April 29, 1997.
203. "Radioimmunotherapy of Lymphoma." Advances in Internal Medicine, University of Michigan Medical School, Towsley Center, Ann Arbor, MI, April 30, 1997
204. "Phase I/II trial results of I-131 anti-B1 antibody (anti-CD20) non-myeloablative radioimmunotherapy (RIT) for relapsed and refractory B-cell lymphoma." Advances in the Application of Monoclonal Antibodies in Clinical Oncology, Thira, Santorini, Greece, May 6, 1997
205. "Imaging Tumor Metabolism." ICP Seminar at American Society of Clinical Oncology, Denver, CO May 15, 1997
206. "PET in Cancer Imaging." 16th Annual Philip M. Johnson Memorial Lecture. New York, NY, May 22, 1997
207. "PET Imaging of Melanoma," Review Lecture, Society of Nuclear Medicine, San Antonio, TX, May 31, 1997
208. "FDG Studies of Myocardial Viability." Emory University Nuclear Medicine, Review Conference, Sea Island, GA, July 2, 1997
209. "New Approach to Diagnosis Thyroid Cancer," Emory University Nuclear Medicine, Review Conference. Sea Island, GA, July 2, 1997
210. "FDG Tumor Imaging," Emory University Nuclear Medicine, Review Conference, Sea Island, GA, July 3, 1997
211. "Is the use of PET Cost-Effective?" 2nd Munich Nuclear Medicine Symposium, Munich, Germany, September 19, 1997
212. "Radioimmunotherapy of Lymphomas." 2nd Munich Nuclear Medicine Symposium, Munich, Germany, September 20, 1997
213. "Radioimmunotherapy of Lymphomas." Plenary Lecture: French Nuclear Medicine and Biophysics Society, St. Malo, France, October 2, 1997
214. "PET in Tumor Imaging: Research Only or a Cost Effective Clinical Tool?" Plenary Lecture: French Nuclear Medicine and Biophysics Society, St. Malo, France, October 2, 1997

215. "What's New in Nuclear Oncology?" Yale University, Department of Radiology, New Haven, CT, October 16, 1997
216. "Sentinel Lymph Node and FDG PET for Staging Breast Cancer." Yale University, Radiology Grand Rounds, New Haven, CT, October 16, 1997
217. "Update on Radiopharmaceutical Imaging in Cancer." University of Michigan Cancer Center, Fields of Dreams Symposium. Ann Arbor, MI, October 18, 1997
218. "PET - An Important Tool in Cancer Imaging." Radiology Grand Rounds, Brigham & Women's Hospital, Boston, MA, October 21, 1997
219. "Imaging Tumor Metabolism." Institute for Clinical PET, 9th Annual Inter'l PET Conference, San Diego, CA, October 31, 1997
220. "Workshop - Quantitation in Oncologic PET." Positron Imaging, A New Frontier in Diagnosis, ICP 9th Annual Inter'l PET Conference, San Diego, CA, October 31, 1997
221. "Image Guided Therapy Task Force." Harvard Medical School, Brigham & Women's Hospital, Boston, MA, November 6, 1997
222. "Advances in Nuclear Oncology." Plenary Lecture, Indian Society of Nuclear Medicine, Chandrigarth, India, November 17, 1997
223. "PET in Oncology: Clinical Tool or Expensive Research?" Special Focus Session, Panel participant: 83rd Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, December 4, 1997
224. "PET Imaging in Oncology." Symposium, The Future of Nuclear Medicine, University of Geneva, Geneva, Switzerland, December 11, 1997
225. "The Role of SPECT in Tumor Imaging." 50th Annual Midwinter Radiological Conference, Los Angeles, CA, January 17, 1998
226. "Radiolabeled Peptide & Monoclonal Antibody Imaging." 50th Annual Midwinter Radiological Conference, Los Angeles, CA, January 17, 1998
227. "An Update on Bone Imaging in Benign & Malignant Disease." 50th Annual Midwinter Radiological Conference, Los Angeles, CA, January 17, 1998
228. "The Emerging Clinical Role of PET Imaging." Emory University Medical Center, Radiology Grand Rounds, Atlanta GA, February 4, 1998
229. "The Role of PET in Surgical Oncology." Emory University Medical Center, Surgery Grand Rounds, Atlanta, GA, February 5, 1998
230. "Head and Neck Cancer and Melanoma Imaging with PET." Tenet Health Systems, Oncology Symposium, Ft. Lauderdale, FL, February 14, 1998
231. "Radioimmunotherapy of Non-Hodgkins Lymphoma." Tenet Health Systems, Oncology Symposium, Ft. Lauderdale, FL, February 14, 1998
232. "New Nuclear Imaging Procedures: ProstaScint and PET." Oakwood Hospital, Dearborn, MI, February 24, 1998
233. "Diagnosis and Treatment of Lymphomas." High Country Nuclear Medicine Conference, Vail, CO, March 8, 1998
234. "Nuclear Medicine and PET Clinical Perspective." NCI Imaging Workshop, Bethesda, MD, March 18, 1998
235. "New Nuclear Medicine Procedures: Diagnostic and Therapeutic." Temple University, Philadelphia PA, April 1, 1998
236. "Metabolic Imaging of Cancer." Temple University, Chamberlain Lecture, Philadelphia, PA, April 1, 1998
237. "PET in Drug Development." Sanofi Pharmaceuticals, Great Valley, PA, April 2, 1998
238. "Radionuclide Imaging of the Breast." ACR Breast Imaging Conference, Washington DC, April 20, 1998
239. "Melanoma Imaging with PET." PET Symposium, Advocate Medical Group, Chicago, IL, May 2, 1998

240. "PET Imaging of Cancer." University of North Carolina, Radiology Grand Rounds, Chapel Hill, NC, May 13, 1998
241. "New Nuclear Medicine Diagnosis and Pharmaceutical Agents." University of North Carolina, Radiology Grand Rounds, Chapel Hill, NC, May 13, 1998
242. "How Good is PET in Evaluating the Solitary Pulmonary Nodule and Staging Lung Cancer?" Session: Nuclear Oncology, Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 7, 1998
243. "FDG Imaging - Where Are We Going?" Session: FDG Imaging without PET, Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 7, 1998
244. "Emerging Role of I-131 Anti-B1 Antibody Radioimmunotherapy." Session: New NRC Patient Release Guidelines: Application to Radioimmunotherapy, Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 7, 1998
245. "Dedicated PET: The Standard Today & Tomorrow?" Session: FDG PET: The Realities and the Opportunities, Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 7, 1998
246. "Early Clinical Trials Presentation." NCI, Bethesda, MD, July 22, 1998
247. "Initial Clinical Experience with Two Coincidence Imaging System (MCD & ECAM+) versus Dedicated PET." Pre-congress WFNMB&B and EAMN Meeting, Bad Berka, Germany, August 29, 1998
248. "Lymphoma, Diagnosis and Monitoring." WFNMB&B and EANM Congress, Berlin, Germany, August 30, 1998
249. "Nal Coincidence: A Detectable Difference?" WFNMB&B and EANM Congress, Siemens User's Meeting, Berlin, Germany, August 31, 1998
250. "New Therapies in Nuclear Medicine." WFNMB&B and EANM Congress, The Marie Curie Lecture, Berlin, Germany, September 2, 1998
251. "Role of Breast Cancer Imaging Today." Post-Congress WFNMB&B and EAMN Meeting. Naples, Italy, September 5, 1998
252. "Radiolabeled Antibody Therapy." Society of Nuclear Medicine Central Chapter Meeting, Milwaukee, WI, September 26, 1998
253. "Therapy Monitoring with FDG." ICP 10th International Conference "PET Emerges into Mainstream Diagnostic Imaging", Boston, MA, October 26, 1998
254. "Infection and Inflammation Imaging." ICP 10th International Conference "PET Emerges into Mainstream Diagnostic Imaging" Boston, MA, October 27, 1998
255. Review Course Oncologic PET." Naval Academy, Bethesda, MD, October 29, 1998
256. "Bexxar Clinical Trials: Summary & Presentation of Results. Phase I Dose Determination Study." Nuclear Medicine Advisory Board, Scottsdale, AZ, November 6, 1998
257. "Role of Nuc Med in Bexxar Therapy, Individualized Patient Dosimetry and calculation." Nuclear Medicine Advisory Board, Scottsdale, AZ, November 7, 1998
258. "Radioimmunotherapy: Consideration in Developing the Treatment Method." University of Illinois Cancer Center, Chicago, IL, January 26, 1999
259. "Imaging of Pulmonary Emboli," Radiology Grand Rounds, University of Michigan Medical Center, Ann Arbor, MI, January 28, 1999
260. "Applications of PET in Oncology," Radiology Grand Rounds, University of Wisconsin Hospitals, Madison, WI, February 4, 1999
261. "New Methods in Nuclear Oncology," Radiology Grand Rounds, University of Wisconsin Hospitals, Madison, WI, February 5, 1999
262. "Radioimmunotherapy of Lymphoma," American College of Nuclear Physicians 25th Annual Meeting, Kona, Island of Hawaii, February 19, 1999
263. "A Clinical Update on PET: Imaging in the Management of Breast Cancer," Breast Cancer Forum, University of Michigan Medical Center, Ann Arbor, MI, February 24, 1999
264. "Should Radioimmunotherapy of NHL be Front-Line or as Salvage?", High Country Nuclear Medicine, Vail, CO, March 2, 1999
265. "What Can PET Do in the Clinic?" High Country Nuclear Medicine, Vail, CO, March 3, 1999

266. "The Role of ProstaScint for the Detection of Metastatic and Recurrent Prostate Cancer," Ingham County Regional Medical Center, Lansing, MI, March 9, 1999
267. "Radioimmunotherapy of Non-Hodgkin's Lymphoma with I-131 anti CD-20 and other Radiolabeled Antibodies," Accomplishments with Medical Isotopes: Advanced Health Care for the 21st Century, Washington, DC, March 12, 1999
268. "PET, the New 'Gold Standard' in Cancer Imaging," Internal Medicine Grand Rounds, Columbia University, School of Medicine, New York, NY, March 16, 1999
269. "Functional Imaging with Positron Emission Tomography: Canadian Society of Nuclear Medicine, Banff Springs, Alberta, Canada, March 24, 1999
270. "Diagnosis and Therapy of Cancer with Targeted Radiopharmaceuticals: Translation from Bench to Outpatient Procedures," Cancer Center Grand Rounds, Washington University, School of Medicine, St. Louis, MO, April 1, 1999
271. "Cancer Therapy with Radiolabeled Antibodies," National Council for Radiation Protection Annual Meeting, Washington, DC, April 7, 1999
272. "Radioimmunotherapy of Non-Hodgkin's Lymphoma," University of Connecticut Grand Rounds, Hartford, CT, April 13, 1999
273. "FDG Positron Emission Tomography in Oncology," Taiwan Society Nuclear Medicine, Taipei, Taiwan, April 14, 1999
274. "Imaging the Pancreatic Beta Cell," National Institute of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Foundation International (NIDDK), Washington DC, April 19, 1999
275. "Phospholipid Ether Analogues as Potential Radiotherapeutics," Berlex Biosciences, Richmond, CA, May 7, 1999
276. "PET Imaging in Cancer Staging and Therapy," American Society of Clinical Oncology Annual Meeting, Atlanta, GA, May 15, 1999
277. "PET Imaging in Cancer Staging and Therapy," American Society of Clinical Oncology Annual Meeting, Atlanta, GA, May 17, 1999
278. "PET, its Role in Lung Cancer," Bristol Myers Squibb Symposium, Chicago, IL, June 10, 1999
279. "PET of Melanoma," NICER Institute Imaging Symposium, Oslo, Norway, June 12, 1999
280. "PET of Lung Cancer," NICER Institute Imaging Symposium, Oslo, Norway, June 12, 1999
281. "PET of Other Cancers," NICER Institute Imaging Symposium, Oslo, Norway, June 12, 1999
282. "Metabolic Diagnosis of Cancer with Radiopharmaceuticals," NICER Institute Imaging Symposium, Oslo, Norway, June 12, 1999
283. "Recent Advances in Oncological PET Research", Life Sciences Division, Brookhaven National Laboratories, Long Island, NY, June 24, 1999
284. "PET's role in the Diagnosis and Staging of Lung Cancer", Dearborn, MI, September 10, 1999
285. "Clinical Value of PET in the Assessment of Pulmonary Nodules and Head and Neck Masses," International PET Symposium, Hokkaido, Japan, September 25, 1999
286. "Clinical Experience with Iodine-131 anti B1 Antibody for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma," 1999 European Association of Nuclear Medicine Congress, Barcelona, Spain, October 10, 1999
287. "Update on Clinical Experience with I-131 Tositumomab (anti-B1 Bexxar) in Non Hodgkins Lymphoma," 12th International Conference on Monoclonal Antibodies for Cancer, San Diego, CA, October 14, 1999
288. "The Emerging Role of PET in Cancer Imaging," Michigan State Radiology Society Conference, Mt. Pleasant, MI, October 15, 1999
289. "Emergency Nuclear Medicine Procedures: What you need to know," Radiology Society Conference, Mt. Pleasant, MI, October 16, 1999
290. "Clinical PET: Oncology: Staging Lung Cancer," ICP 11th Annual PET Conference, Vancouver, Canada, October 25, 1999
291. "Detection and Staging Algorithms for Lung Cancer," Southeastern Chapter, Society of Nuclear Medicine, Atlanta, GA, October 30, 1999

292. "Radioimmunotherapy for Malignancies" Southeastern Chapter, Society of Nuclear Medicine, Atlanta, GA, October 30, 1999
293. "PET and SPECT, Their role in Radiation Therapy Planning" Presidential Educational Session, American Society of Therapeutic Radiation Oncology Annual Meeting, San Antonio, TX, October 31, 1999
294. "Introduction to PET," Israeli Medical Society MEDAX Meeting, Nuclear Medicine Section, Tel Aviv, Israel, November 2, 1999
295. "The Role of PET in Oncology," Israeli Medical Society MEDAX Meeting, Nuclear Medicine Section, Tel Aviv, Israel, November 2, 1999
296. "PET's Role in the Brain," Israeli Medical Society MEDAX Meeting, Nuclear Medicine Section, Tel Aviv, Israel, November 2, 1999
297. "Therapy of Non-Hodgkin's Lymphoma with I-B1 anti-CD-20," Dana Farber Cancer Institute, Boston, MA, November 9, 1999
298. "PET, Its Role in Cancer Imaging," Medical Grand Rounds, Georgetown University Medical School, Washington DC, November 11, 1999
299. "Radioimmunotherapy of Non-Hodgkin's Lymphoma with I-131 anti CD-20 Antibodies," North Carolina Chapter, American College of Radiology, Research Triangle Park, NC, November 13, 1999
300. "The Role of PET in Cancer Management," Boca Raton Community Hospital, Boca Raton, FL, November 17, 1999
301. "Clinical PET," Subject Review Course, Radiological Society of North America, Annual Meeting, Chicago, IL, December 3, 1999
302. "I-131 Anti CD-20 Radioimmunotherapy of Non-Hodgkin's Lymphoma, Experience in Relapsed Disease and as Primary Therapy," Dana Farber Cancer Institute, Boston, MA, December 9, 1999
303. "New Nuclear Medicine Procedures for Cancer Diagnosis and Treatment," Long Island Jewish Medical Center, New York, NY, January 6, 2000
304. "PET, its Key Role in Cancer Management," Radiology Grand Rounds, Long Island Jewish Medical Center, New York, NY, January 6, 2000
305. "PET, The New 'Gold Standard' in Cancer Imaging." University Lecture Series, University of Missouri, Columbia, MO, February 15, 2000
306. "Overview of the Clinical Utility of FDG." High Country Nuclear Medicine, Vail, CO, March 7, 2000
307. "PET as an Early Marker of Cancer Therapy Response," King's College, London, England, March 15, 2000
308. "The Role of PET Scanning in the Cancer Patient," Medical Grand Rounds, University of South Florida, Tampa, FL, March 30, 2000
309. "PET: A Tool for Cancer Research." H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, March 30, 2000
310. "Radioantibody Therapy." Department of VA Education System Satellite TV Symposium, St. Louis MO, April 5, 2000
311. "Radioimmunotherapy of Non Hodgkins Lymphoma." New York Academy of Medicine, New York City, NY, April 17, 2000
312. "Oncologic PET Imaging, Including Coincidence Imaging vs. Dedicated PET." 30th Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 28, 2000
313. "New therapies in Nuclear Medicine (including radiolabeled antibody therapy)." 30th Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 29, 2000
314. "Newer Imaging Approaches in Oncology (peptides, antibodies, sentinel lymph node, lymphoscintigraphy)." 30th Jornada Paulista de Radiologia, Sao Paulo, Brazil, April 29, 2000
315. "Radioimmunotherapy of Lymphoma." Melbourne, Australia, May 20, 2000
316. "Therapeutic Nuclear Oncology." Australian & New Zealand Society of Nuclear Medicine, Adelaide, South Australia, May 22, 2000
317. "FDG PET in Oncology." Australian & New Zealand Society of Nuclear Medicine, Adelaide, South Australia, May 23, 2000

318. "PET Current Status and Future Trends." Australian & New Zealand Society of Nuclear Medicine, Adelaide, South Australia, May 24, 2000
319. "Overview of Molecular Imaging." Michigan State University, Lansing, MI, July 14, 2000
320. "PET as a tool in cancer Imaging" Ohio State University, Columbus, OH, August 18, 2000
321. "PET Imaging in Cancer." Mercy Medical Center, Cedar Rapids, IA, August 25, 2000
322. "Radioimmunotherapy in the Treatment of Non-Hodgkins Lymphoma." Hematology/Oncology Rounds, Dartmouth College, Norwich, VT, September 13, 2000
323. "Radiolabeled Antibody Therapy and Targeted Radiopharmaceutical Therapy: A Clinical Update." Cleveland Clinic, Cleveland, OH, September 20, 2000
324. "Prostascint Imaging" Ingham Regional Medical Center, Lansing, MI, September 28, 2000
325. "PET in Lymphoma and Melanoma." Institute for Clinical PET, Washington, DC, October 10, 2000
326. Course No. 811: Interpretation of FDG Scans. 86th Scientific Assembly & Annual Meeting, Radiological Society of North America, Chicago, IL, November 2000
327. "Advances in Research and Treatment of Non-Hodgkin's Lymphoma with Radioimmunotherapy", The American Society of Hematology 42nd Annual Meeting and Exposition, San Francisco, CA, December 1, 2000
328. "PET Imaging." Louisiana State University Health Sciences Center, New Orleans, LA, January 11, 2001
329. "PET Imaging Clinical Applications for the General Medicine Practitioner." Salik Lecture, Sinai Hospital of Baltimore Department of Medicine Grand Rounds, Baltimore, MD, February 8, 2001
330. "Melanoma/Lymphoma." Clinical Positron Emission Tomography: Applications and Case Presentation, 2001 Mid-Winter Symposium of the Society of Nuclear Medicine, Tampa, FL, February 11, 2001
331. Tampa, FL, February 11, 2001
332. "Dosimetry and Therapy in Non-Hodgkins Lymphoma." The 2001 Annual Midwinter Meeting, Northern California Chapter, Society of Nuclear Medicine, Oakland, CA, February 22, 2001
333. "Managing Hodgkin's Lymphoma in the New Millennium" 42nd Annual Symposium, American Society of Hematology, New York, NY, February 2001
334. "State of the Art workshop on Gastric Cancer; Investigational Drug Branch, NCI" Bethesda Marriott Hotel, Bethesda, MD, March 6-7, 2001
335. "American Pharmaceutical Association, 148th Annual Meeting and Exposition" San Francisco, CA, March 16 – 20, 2001
336. "PET Scanning in Breast Cancer." Current Perspectives in Breast Cancer: 2001, Washington, DC, March 31, 2001
337. "PET: The New "Gold Standard" for Cancer Imaging." Kaplan Lecture: Brigham and Women's Hospital, Harvard Medical School, Boston, MA, April 10, 2001
338. "MIBG Imaging." Clinical Nuclear Medicine 2001: Postgraduate Course, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, April 11, 2001
339. "Positron Emission Imaging in Oncology I: Lung Cancer." Clinical Nuclear Medicine 2001: Postgraduate Course, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, April 11, 2001
340. "Developments in Imaging Techniques", "Imaging Diagnostics", 1st Multidisciplinary Colorectal Cancer Congress, Leiden, The Netherlands, April 18, 2001
341. "Advances in the Multi-Modality Management of Lung Cancer." Johns Hopkins University School of Medicine, Continuing Medical Education Program, Baltimore, MD, April 30, 2001
342. "Cell Targeted Therapy with Radiation" U.S. Dept. of Energy, Hilton Arlington & Towers, Arlington VA, May 1-2 2001
343. "PET: A Molecular Rather than a Morphological Approach to Tumor Imaging." Molecular Imaging Symposium, University Hospital, Zurich, Switzerland, May 4, 2001
344. "14th IRIST Meeting" Nijmegen, Netherlands, May 18 – 19 2001

345. "Radioimmunotherapy of Lymphoma." Columbia University College of Physicians and Surgeons, Division of Medical Oncology, New York, NY, May 31, 2001
346. "The Current Rapidly Growing Role of PET in Cancer Imaging", Atlantic Medical Imaging, Marriott, Atlantic City, NJ, May 31 2001
347. "PET Scan Utility in Medical Oncology" Anaheim Hilton, Bellflower CA, June 8-9 2001
348. "Clinical Applications of PET Conference", British Columbia Cancer Agency, Wosk Centre, Vancouver British Columbia, June 11 2001
349. "Role of PET in Cancer Imaging." Multidisciplinary Breast Care Conference/Tumor Board, Cox Medical Systems, Springfield, MO, July 6, 2001
350. "Assessment of Treatment Response by PET." The University of Texas, MD Anderson Cancer Center, Grand Rounds presentation, Houston, TX, July 13, 2001
351. "Clinical Pearls and Pitfalls in PET Imaging." MedSolutions, Round table discussion, Franklin, TN, July 17, 2001
352. "Updated and Future Directions of Modalities." Keynote Lecturer, 4th International Symposium of the International Society for Strategic Studies in Radiology, San Francisco, CA, August 23-25, 2001
353. "Update on PET: Applications in Cancer." Radiology Grand Rounds, Johns Hopkins Medical Institutions, Baltimore, MD, September 25, 2001
354. "PET Applications in Oncology, Clinical and Research." Seminar at the Gerontology Research Center, National Institute on Aging, Johns Hopkins Bayview Medical Center, Baltimore, MD, September 25, 2001
355. "AnatoMolecular Imaging with FDG: Bench to Outpatient Center." Annual Meeting of the Academy of Molecular Imaging, Orlando, FL, October 24-28, 2001
356. "PET and US Techniques in the Evaluation of Tumor Angiogenesis." 87th Scientific Assembly & Annual Meeting, Radiological Society of North America, Chicago, IL, November 2001
357. "Interpretation of FDG PET Scans." 87th Scientific Assembly & Annual Meeting, Radiological Society of North America, Chicago, IL, November 2001
358. "The Role of PET/CT in Cancer Imaging." Washington Adventist Hospital, Takoma Park, MD, December 7, 2001
359. "Positron Emission Tomography: Current and Future Applications." 24th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, Dec. 12, 2001
360. "Needs and Issues related to the Development of Prognostic Tools", Detection and Measurement of Occult Disease for the Prognosis of Solid Tumors sponsored by the Diagnostics Research Branch, Cancer Diagnosis Program, National Cancer Institute, Rockville, MD, January 7- 8, 2002
361. "Applications of PET in Lymphoma and Melanoma", New Jersey Radiological Society, Robert W. Johnson Medical School, New Brunswick, NJ, January 17, 2002
362. "Molecular Imaging with FDG PET". American Association for Cancer Research special conference on Molecular Imaging in Cancer: Linking Biology, Function and Clinical Applications In Vivo, Lake Buena Vista, FL, January 23-27, 2002
363. "Experience with Bexxar". Update on Radiolabeled Antibody Therapy of Lymphoma. 2002 Mid-Winter Symposium of the Society of Nuclear Medicine, Scottsdale, AZ, Feb. 8-11, 2002
364. "Initial Clinical Experience with PET/CT Scanner at Johns Hopkins". Image Fusion: Hardware and Software Solutions, 2002 Mid-Winter Symposium of the Society of Nuclear Medicine, Scottsdale, AZ, Feb. 8-11, 2002
365. "The Role of PET/CT in Thoracic Malignancy". Computed Body Tomography 2002 The Cutting Edge, Lake Buena Vista, Orlando, FL, February 14-17, 2002
366. "The Role of PET/CT in Abdominal Malignancy". Computed Body Tomography 2002 The Cutting Edge, Lake Buena Vista, Orlando, FL, February 14-17, 2002
367. "New Strategies in Breast Cancer 2002 Symposium" Las Vegas, NV, March 7 – 10, 2002
368. "Use of PET in Clinical Medicine". Nuclear Medicine Commission Training 2001-2002. Queen Elizabeth Hospital, Hong Kong Hospital Authority, Hong Kong, March 20-23, 2002

369. "Nuclear Medicine Commission Training 2002-2002", Queen Elizabeth Hospital, Hong Kong, March 2002
370. "Lymphoma: Diagnosis and Treatment" Zurich Switzerland, April 6 – 11 2002
371. "PET Tumor Imaging" Mid Eastern Chapter, SNM, Ocean City, MD, April 19 – 20 2002
372. "Committee on Nuclear Medicine Accreditation" Reston, VA, June 5, 2002
373. "PET in Oncology 1: Diagnosis and Staging of Cancers" Harvard Review Course, Cambridge MA, April 29 – May 2, 2002
374. "New Approaches to Cancer Prevention and Therapy" Hopkins, May 6, 2002
375. "Novel Diagnostic Imaging Techniques in Gastroenterology", AstraZeneca, Barcelona, Spain, June 8, 2002
376. "Value of PET/CT SNM" LA Convention Center, June 15-18 2002
377. "FDG PET: Molecular Imaging of Glucose Metabolism in Cancers" JHU, May 8, 2002
378. "Radioimmunotherapy of Lymphoma", Killarney, Ireland, July 21 – 25, 2002
379. "PET Evaluation of Thoracic Neoplasms", Killarney, Ireland, July 21 – 25, 2002
380. "SPECT Imaging in Oncology", Killarney, Ireland, July 21 – 25, 2002
381. "MIBG Imaging and Therapy: an Update", Killarney, Ireland, July 21 – 25, 2002
382. "PET/CT", Hartford Hospital, Hartford, CT, August 15, 2002
383. "Overview of Clinical Applications in PET Scanning", New Britain General Hospital, New Briton, CT, September 5, 2002
384. "Role of PET Scan in Gastrointestinal Malignancies", Oakwood Hospital Educational Symposium, Troy MI, September 13, 2002
385. "PET in Cervical Cancer" IntraSPORE Prostate Cancer Meeting, Tysons Corner, VA, September 19, 2002
386. "PET/CT", Canadian Association of Radiology, Quebec City, Canada, September 19, 2002
387. "PET in Oncology", ACR, Miami Beach, FL, September 29, 2002
388. "Oncology Therapy Workshop, Radioimmunotherapy in Lymphoma, Read with the Experts, PET in Oncology", 8th WFNMB Congress, Santiago, Chile, September 29 – Oct. 4, 2002
389. "Functional Imaging of Cancer", American Society for Therapeutic Radiology and Oncology, Inc., New Orleans LA, October 10, 2002
390. "FDG as a Tumor-Seeking Tracer" Academy of Molecular Imaging, Sheraton, San Diego, CA, October 23 – 27, 2002
391. Japan Society of Nuclear Medicine Congress "PET & PET/CT" Kobe, Japan, November 3-6, 2002
392. "PET/CT" Caracas Venezuela, November 17 – 19, 2002
393. "Current Use of PET/CT", Tenet Physician Advisory Board, Park Hyatt Hotel, Chicago, IL, December 1, 2002
394. "PET/CT Imaging: RSNA", McCormick Place, Chicago, IL, December 1 – 6, 2002
395. "PET and US Techniques in the Evaluation of Tumor Angiogenesis", McCormick Place, Chicago IL. December 1 – 6, 2002
396. "Interpretation of FDG PET Scans", McCormick Place, Chicago IL. December 1 – 6, 2002
397. "Imaging Symposium – PET Imaging", McCormick Place, Chicago IL. December 1 – 6, 2002
398. "PET in Breast Cancer Imaging" Breast Symposium, Amelia Island, FL February 14, 2003
399. "Current Approaches to PET/CT Imaging of the Thorax", Computed Body Tomography 2003, Orlando FL. February 15, 2003
400. "Current Approaches to PET/CT Imaging of the Abdomen and Pelvis" Computed Body Tomography 2003, Orlando, FL. February 15, 2003
401. "Role of the PET Scan in Evaluation of the Colorectal Cancer Patient", Multidisciplinary Management of Colorectal Cancer, April 3, 2003
402. "PET CT Applications In Ontological Imaging" Drug Information Association Medical Imaging In Clinical Trials Meeting, Boston, MA, April 7, 2003

403. "PET/CT", Radiology Biennial Program, Johns Hopkins University, Baltimore, MD, May 2, 2003
404. "PET Fusion Scans – Does it Make a Difference?" Mid Eastern Chapter of the Society of Nuclear Medicine, Reston, VA, May 3, 2003
405. "New SPECT/PET Imaging" ACR Annual Meeting, Washington, DC, May 10, 2003
406. "Fundamentals of PET Imaging", Grand Rounds, Brown University, Providence, RI, May 12, 2003
407. "Head and Neck Cancers and Melanoma", Clinical nuclear medicine 2003, Boston, MA, May 13, 2003
408. "Gastrointestinal Cancers: Esophageal, Pancreatic, Colorectal", Clinical nuclear medicine 2003, Boston, MA, May 13, 2003
409. "Overview of FDG-PET in Cancer Detection in the USA", Society of Nuclear Medicine, New Orleans, LA, June 20 – 27, 2003
410. "Current Role of Nuclear Medicine", OREAR Institute, Kansas, MO, June 26 - 27, 2003
411. "Use of PET Scans in Clinical Practice" OREAR Institute, Kansas, MO, June 26 - 27, 2003
412. "PET Imaging" 11th SPORE Investigator's Workshop, Baltimore, MD July 8 – 10, 2003
413. "Diagnostic/Imaging/Staging – Utility of PET Scans Biomarkers and Detection", 10th World Conference on Lung Cancer, Vancouver, Canada, August 10 – 14, 2003
414. "Modern Technology and Lung Cancer Staging", 10th World Conference on Lung Cancer, Vancouver Canada, August 10 – 14, 2003
415. "State of the Art Imaging with PET/CT", 2003 Illinois Radiological Society Annual Meeting, Chicago, IL, September 13, 2003
416. "The New World of Molecular Imaging", 2003 Illinois Radiological Society Annual Meeting, Chicago, IL, September 13, 2003
417. "PET/CT Scanning", 29th Topics in Gastroenterology and Liver Disease, Baltimore, MD, September 23, 2003
418. "PET Indications", AMI 2003 International Conference, Madrid, Spain, September 26 – 30 2003
419. "Advances of PET in Breast Cancer", AMI 2003 International Conference, Madrid, Spain, September 26 – 30 2003
420. "PET/CT: How and When?" AMI 2003 International Conference, Madrid, Spain, September 26 – 30 2003
421. "Utility and Application of Positron Emission Tomography in Lung Cancer Staging and Management", Kjeldgaard Symposium XVII, Portland, ME, October 3, 2003
422. "Roles of PET Scanning", Innovations in Respiration, Baltimore, MD, October 8, 2003
423. "Is there a role for PET Scanning in HCC?", Society of Interventional Radiology, San Francisco, CA, October 17, 2003
424. "Functional Imaging of Cancer: Emphasis on PET and PET/CT Approaches", ASTRO Annual Meeting, Salt Lake City, UT, October 22, 2003
425. "PET/CT Techniques & Common Applications", Society of Computed Body Tomography and Magnetic Resonance, Boston, MA, October 24, 2003
426. "PET/CT Innovations and Advanced Applications" Society of Computed Body Tomography and Magnetic Resonance, Boston, MA, October 24, 2003
427. "Future Prospectives of Fusion Imaging", Japan Society of Nuclear Medicine, and PET Symposium, Hokkaido Japan, October 26 – November 3, 2003
428. "PET/CT Imaging of Cancer", Japan Society of Nuclear Medicine, and PET Symposium, Hokkaido Japan, October 26 – November 3, 2003
429. "PET/CT", Japan Society of Nuclear Medicine, and PET Symposium, Hokkaido, Japan, October 26 – November 3, 2003
430. "Clinical Utility of PET Scanning in Breast Cancer Management" School of Breast Oncology, Atlanta, GA, November 15, 2003
431. "PET/CT: Applications and Pitfalls", "Advances in Imaging and Gamma Guided Therapy" and "PET", RSNA, Chicago, IL. November 30 – December 3, 2003

432. "PET-CT Correlation in Oncology Imaging", Roentgen Ray Society Meeting, Philadelphia, PA. February 5, 2004
433. "Colorectal Cancer: Perspective of the Colorectal Surgeon", Fort Education Program and Fort Wayne Radiology, Fort Wayne, IN, February 10, 2004
434. "Impact of PET/CT on the Management of Cancer Patients", Mind Brain Conference 2004, Hamamatsu, Japan, February 24 – 27, 2004
435. "Treatment with 131I-Tositumomab", The Role of PET/CT and SPECT/CT Imaging in Medical, Radiation, Surgical and Nuclear Oncology, Baltimore, MD, March 19 – 20, 2004
436. "PET/CT Imaging". The Role of PET/CT and SPECT/CT Imaging in Medical, Radiation, Surgical and Nuclear Oncology, Baltimore, MD. March 19 – 20, 2004
437. "Applications of Oncologic PET and PET/CT: Review with the Experts: Breast Cancer", Academy of Molecular Imaging Annual Conference, Orlando, FL, March 29 – 20, 2004
438. "Clinical Value of PET/CT Imaging" Japan Radiological Society, Yokohama, Japan. April 8 – 10, 2004
439. "PET/CT - Basic Principles and Application in Head and Neck and Thorax", Colorado Radiology Association, Denver, CO, March 5, 2004
440. "PET/CT – Applications in the Abdomen and Pelvis", Colorado Radiology Association, Denver, CO, March 5, 2004
441. "PET/CT in Clinical Practice" Mid-Eastern Chapter, Society of Nuclear Medicine, Reston, VA, April 17, 2004
442. "Technologies: PET Scan in Endocrinology", GSK Advancetm Advanced Diabetes & Endocrinology Preceptorship, Baltimore, MD, April 21, 2004
443. "PET/CT Techniques and Applications", Betty F. Komer Cancer Seminar, Elmira, NY, April 28, 2004
444. "PET Scanning", 49th Annual Tumulty Topics in Clinical Investigation, Baltimore, MD, May 3, 2004
445. "PET in Breast Cancer", Miami Beach, FL, May 5-7, 2004
446. "PET in the Abdomen and Pelvis", Miami Beach, FL, May 5-7, 2004
447. "Non-Oncological Clinical PET", ARRS 104th Annual Meeting, Miami Beach, FL, May 5-7, 2004
448. "PET/CT Imaging in Cancer", Wilkinson Lecture, Durham, NC, May 6, 2004
449. "Challenging PET/CT Cases". Wilkinson Lecture, Durham, NC, May 6, 2004
450. "Patient Specific Dosing: The Critical Role of Dosimetry", Radioimmunotherapy for the Treatment of Indolent Non-Hodgkin's Lymphoma. Philadelphia, PA, May 15, 2004
451. "Radioimmunotherapy and non-Hodgkins Lymphoma", Society of Nuclear Medicine, Philadelphia, PA June 19 – 23, 2004
452. "Perspectives on PET and PET/CT" Society of Nuclear Medicine, Philadelphia, PA June 19 – 23, 2004
453. "PET/CT Imaging" 23rd International Congress of Radiology, Montreal, Canada, June 25, 2004
454. "PET Scanning", American Council of Life Insurers. Baltimore, MD, June 29, 2004
455. "Anti CD 20 Radioimmunotherapy of Non Hodgkins Lymphoma". Walter Reed Hospital, Washington, DC, July 20, 2004
456. "Radioimmunotherapy as the Primary Therapy for non-Hodgkin's Lymphoma" Annual Congress of the European Association of Nuclear Medicine, Helsinki, Finland, September 6, 2004
457. "PET for Guiding Therapeutic Choices in Cancer", Society of Molecular Imaging, St. Louis, MO, September 12, 2004
458. "I 131 Tositumomab Therapy of Non Hodgkins Lymphoma", Henry Ford Hospital Radiology Departmental Conference, Detroit, MI, September 14, 2004
459. "The Radiologist's Role in the Diagnosis, Staging and Treatment of Non Hodgkins Lymphoma" Detroit Metropolitan Nuclear Radiology Club Quarterly Meeting, Pontiac, MI, September 14, 2004
- 460.459. "Update on Bexxar Therapy of NHL", William Beaumont Hospital Radiology/Surgical Oncology Conference, Royal Oak, MI, September 15, 2004
461. "PET and PET/CT of Breast Carcinoma" William Beaumont Hospital Radiology/Surgical Oncology Conference, Royal Oak, MI, September 15, 2004

462. "Advances in Radioimmunotherapy of Lymphoma", Georgetown University Medical Center, Washington, DC, September 30, 2004
463. "Functional Imaging of Cancer: PET and PET/CT Approaches", ASTRO, Atlanta, GA, October 6, 2004
464. "Applications of PET/CT in management of the cancer patient", Bon Secours Health System, Richmond, VA. October 14, 2004
465. "PET/CT Imaging in Clinical Practice", a) 10/20: Norwegian Radiological Society, Technical Night Presentation, Oslo, Norway, October 20, 2004
466. "PET/CT Above the Diaphragm", New Horizons in Radiology Symposium, Charity Hospital and Humboldt University", Berlin, Germany, October 21, 2004
467. "Clinical Utility of PET Scanning in Breast Cancer Management", School of Breast Oncology Meeting, Emory Conference Center, Atlanta, GA, November 13, 2004
468. "PET in Clinical Practice Minicourse: Basic Principles", RSNA, Chicago IL, November 28 – December 3, 2004
469. "New PET Agents" "PET and PET/CT: New Tracers, New Methods", RSNA, Chicago, IL, November 28 – December 3, 2004
470. "Diagnosis and Pitfalls", RSNA, Chicago, IL, November 28 – December 3, 2004
471. "PET in Accessing Interventional Radiological Procedures", Society of Interventional Radiology, Rockville, MD, January 31, 2005
472. "PET/CT Thoracic Applications", Computed Body Tomography 2005, Orlando, FL, February 17-18, 2005
473. "PET/CT Abdominal Application", Computed Body Tomography 2005, Orlando, FL, February 17-18, 2005
474. "PET/CT Imaging in Cancer: Above the Diaphragm", Cross-Sectional Imaging Conference, US Virgin Islands, February 24-25, 2005
475. "PET/CT Imaging in Cancer: Below the Diaphragm", Cross-Sectional Imaging Conference, US Virgin Islands, February 24-25, 2005
476. "Applications of PET in the Brain, Heart and Non-Malignant Disease Processes", Cross-Sectional Imaging Conference, US Virgin Islands, February 24-25, 2005
477. "Update on Radioimmunotherapy of Non-Hodgkin's Lymphoma", Cross-Sectional Imaging Conference, US Virgin Islands, February 24-25, 2005
478. "SPECT/CT Imaging in Clinical Practice", Cross-Sectional Imaging Conference, US Virgin Islands, February 24-25, 2005
479. "How to Perform PET/CT and SPECT/CT Studies", PET/CT and SPECT/CT Imaging of Cancer for Radiologists and Nuclear Physicians Conference, Baltimore, MD, March 18 – 19, 2005
480. "Therapeutic Solutions", PET/CT and SPECT/CT Imaging of Cancer for Radiologists and Nuclear Physicians Conference, Baltimore, MD, March 18 – 19, 2005
481. "Imaging Studies from the Hopkins Files, Breast Cancer", "Imaging Studies from the Hopkins Files, Gynecological Malignancies", PET/CT and SPECT/CT Imaging of Cancer for Radiologists and Nuclear Physicians Conference, Baltimore, MD, March 18 – 19, 2005
482. "Role of the PET/CT scan in Evaluation of the Colorectal Cancer Patient", Current Concepts in the Multidisciplinary Management of Colorectal Cancer, Baltimore, MD, March 31, 2005
483. "Advantages of PET/CT in Oncology", Coimbra, Portugal, April 8, 2005
484. "PET/CT and FDG for Berlin", the PET Imaging in Oncology Workshop in Berlin, Germany, April 11th, 2005
485. "New and Pending Applications in PET", South Western Chapter of the Society of Nuclear Medicine, San Antonio, TX, April 15 – 16, 2005
486. "Non-Oncological Clinical PET", South Western Chapter of the Society of Nuclear Medicine, San Antonio, TX, April 15 – 16, 2005
487. "PET in Breast Cancer", South Western Chapter of the Society of Nuclear Medicine, San Antonio, TX, April 15 – 16, 2005

488. "Anatometabolic Tumor Imaging", The Art of Molecular Imaging, Melbourne Australia, April 30 – May 2, 2005
489. "Radioimmunotherapy of Non-Hodgkins Lymphoma", The Art of Molecular Imaging, Melbourne, Australia, April 30 – May 2, 2005
490. "New Oncologic Indications for PET", PET Society of Connecticut, Farmington, CT, May 10, 2005
491. "Non-Oncologic PET Imaging", PET Society of Connecticut, Farmington, CT, May 10, 2005
492. "Whole Body PET/PET/CT", ISMRM, Miami Beach, FL. May 13, 2005
493. "PET/CT in Colorectal Cancer", PET/CT Imaging Symposium, Mandalay Bay, Las Vegas, NV, May 14, 2005
494. "PET/CT in Lymphoma", PET/CT Imaging Symposium, Mandalay Bay, Las Vegas, NV, May 14, 2005
495. "PET/CT: Principles and Practice", ARRS Annual Meeting, New Orleans, LA, May 16, 2005
496. "Advances in PET/CT Imaging", St. Mary's Hospital, Richmond, VA, May 19, 2005
497. "PET/CT Science and Techniques", Neuroradiology Education and Research Foundation Symposium, Toronto, Canada, May 21, 2005
498. "Applications of Other Iodine Radioisotopes in Thyroid Cancer Management: Beyond 131-I", Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 18 – 23, 2005
499. "Correlative PET Imaging in Cancer with Other Cross Sectional Radiologic Imaging", Society of Nuclear Medicine Annual Meeting, Toronto, Canada, June 18 – 23, 2005
500. "Indications for PET/CT Fusion" Bethesda, MD, July 14, 2005
501. "PET/CT", Christ Hospital, Cincinnati, OH, September 15, 2005
502. "Clinical Applications: PET/CT in Lymphoma", 6th Munich Nuclear Medicine Symposium, Munich Germany, September 16, 2005
503. "Individualizing Cancer Management Using Nuclear Imaging Techniques", Nuclear Medicine Grand Rounds, Memorial Sloan Kettering, New York, NY, October 10, 2005
504. "PET Imaging in Cancer Shortcut to Oncologic Drug Approval", Novartis Institute, Cambridge, MA, October 12, 2005
505. "PET/CT and Breast Cancer", 19th Annual NE Regional Meeting of the Society of Nuclear Medicine, New Port, RI, October 28, 2005
506. "PET/CT and Lymphoma", 19th Annual NE Regional Meeting of the Society of Nuclear Medicine, New Port, RI, October 28, 2005
507. "PET/CT: Applications and Pitfalls" RSNA-2005, Chicago, IL, November 27, 2005
508. "PET/CT in Oncology II" RSNA-2005, Chicago, IL, November 28, 2005
509. "PET and PET/CT Imaging of the Extracranial Head and Neck", RSNA-2005, Chicago, IL, November 29, 2005
510. "PET/CT versus MR in the Postoperative and Previously Irradiated Neck", RSNA-2005, Chicago, IL, November 30, 2005
511. "Current and Near-Term Applications of Molecular Imaging", RSNA-2005, Chicago, IL, December 1, 2005
512. "FDG PET and PET/CT Imaging: Impact on Patient Care Course", RSNA2005, Chicago, IL, December 2, 2005
513. "PET/CT in Colorectal Cancer", National Diagnostic Imaging Symposium, Orlando, FL, December 7, 2005
514. "PET/CT in Breast Cancer" National Diagnostic Imaging Symposium, Orlando, FL, December 7, 2005
515. "Individualizing Cancer Therapies Using Quantitative Nuclear Medicine Techniques", Nuclear Medicine Grand Rounds, Albert Einstein School of Medicine, New York, NY, February 13, 2006
516. "Update of PET/CT Imaging", Radiology Grand Rounds, Montefiore Medical Park, New York, NY, February 14, 2006
517. "PET/CT: Thoracic Applications", Computed Body Tomography 2006, The Cutting Edge PET/CT, Orlando, FL, February 17, 2006

518. "PET/CT: Abdominal Applications", Computed Body Tomography 2006, The Cutting Edge PET/CT, Orlando, FL, February 17, 2006
519. "Advances in Imaging", 2006 Prostate Cancer Symposium, San Francisco, CA, February 24, 2006
520. "Clinical PET in Oncology" Lecture, Long Island Jewish Medical Center, New York, NY, March 9, 2006
521. "Non-Oncologic Applications of PET/CT", Grand Rounds, Long Island Jewish Medical Center, New York, NY, March 9, 2006
522. "Future of PET/CT Imaging", Society of Surgical Oncology, San Diego, CA, March 23, 2006
523. "Clinical Experience with SPECT/CT Protocols and Applications", Mid-Eastern Chapter, Society of Nuclear Medicine, Baltimore, MD, April 8, 2006
524. "PET/CT in Thyroid Cancer", 4th Annual PET/CT Imaging Symposium, Las Vegas, NV, May 6, 2006
525. "PET/CT in Lymphoma", 4th Annual PET/CT Imaging Symposium, Las Vegas, NV, May 6, 2006
526. "PET/CT in Colorectal Cancer", 4th Annual PET/CT Imaging Symposium, Las Vegas, NV, May 6, 2006
527. "Clinical Applications of PET/CT: Breast Cancer", Annual Meeting Society of Nuclear Medicine. San Diego, CA. June 5, 2006
528. "SPECT/CT for Molecular Imaging of Cancer Patients", Cluster for Molecular Imaging, Copenhagen, Denmark, June 15, 2006
529. "Initial Experience with High Resolution SPECT/CT" Danish Society of Nuclear Medicine, Odense, Denmark. June 16, 2006
530. "PET/CT Myocardial and Vascular Imaging". NYU Cardiothoracic CME meeting. Santa Fe, NM. June 26, 2006
531. "Role of PET/CT in the Evaluation of Thoracic Neoplasia". NYU Cardiothoracic CME meeting. Santa Fe, NM. June 26, 2006
532. "Gated Radionuclide Cardiac Imaging: Does it have a role?" NYU Cardiothoracic CME meeting. Santa Fe, NM. June 27, 2006
533. "SPECT Myocardial Imaging and the emerging Role of Hybrid SPECT/CT Systems." NYU Cardiothoracic CME meeting. Santa Fe, NM. June 27, 2006
534. "Status of PET/CT in Oncology" The ISTC Scientific Advisory Committee of the International Science and Technology Center (ISTC SAC). St. Petersburg Russia. September 19, 2006
535. "PET/CT in Lymphoma. EANM Athens Greece. October 1, 2006
536. "Five Years of Experience with PET/CT in Breast Cancer, Strengths, Limitations and Opportunities", Nuclear Radiology of Breast Cancer Workshop. San Diego, CA. November 4, 2006
537. "Advances in Molecular Imaging of Cancer": Kyushu University, Fukuoka, Japan. November 7, 2006
538. "Newer and Evolving Uses for PET and PET/CT" Delaware Society of Clinical Oncology, Delaware. November 21, 2006
539. "New Applications of PET/CT in Cancer" St. Luke's Roosevelt Hospital Center, New York, NY. December 18, 2006
540. "Current Applications of PET/CT in Clinical Oncology"; New York Academy of Medicine, New York, NY. December 18, 2006
541. "PET/Ct in the Evaluation of Melanoma, Occult Malignancies, and Inflammatory Processes". Los Angeles Radiological Society, Mid Winter Conference. Los Angeles, CA. January 21, 2007
542. "PET/CT in the Evaluation of GI Malignancies". Los Angeles Radiological Society, Mid Winter Conference. Los Angeles, CA. January 21, 2007
543. "PET/CT in the Evaluation of Head and Neck Malignancies". Los Angeles Radiological Society, Mid Winter Conference. Los Angeles, CA. January 21, 2007
544. "PET/CT Evaluation of Lymphoma". Los Angeles Radiological Society, Mid Winter Conference. Los Angeles, CA. January 21, 2007
545. "PET/CT: Current Role in Thoracic Diseases". Computed Body Tomography. Orlando FL. February 16, 2007

546. "PET/CT: Clinical Applications in the Abdomen". Computed Body Tomography. Orlando Fl. February 17, 2007
547. "PET & PET/CT: Breast Cancer." Women's Imaging & Lymphoma. Charleston, SC. March 25, 2007
548. "PET & PET/CT: In Oncology: Diagnosis." Practical Issues. Charleston, SC March 25, 2007
549. "PET& PET/CT: Beyond FDG." Workshop Sessions. Charleston, SC March 25, 2007
- 550.549. "PET/CT: Of the Head and Neck: Normal Anatomy and Disease" PET-CT Imaging Symposium. Las Vegas, Nevada, April 26-28 , 2007
551. "PET/CT: In Lymphoma" PET-CT Imaging Symposium. Las Vegas, Nevada, April 26-28 , 2007
552. "PET/CT: In Colorectal Cancer." PET-CT Imaging Symposium. Las Vegas, Nevada, April 26-28 , 2007
553. "PET/CT: In Pediatric Cancers." PET-CT Imaging Symposium. Las Vegas, Nevada, April 26-28 , 2007
554. "PET, PET/CT& and the Future of Molecular Imaging. Special Session: Oncologic Indications for PET- CT in 2007." Advanced Breast Imaging and Interventions 2007. Las Vegas, Nevada, May 5, 2007
555. "PET, PET/CT& and the Future of Molecular Imaging: Update and Future of Equipment for PET and PET-CT." Advanced Breast Imaging and Interventions 2007. Las Vegas, NV, May 5, 2007
556. "PET, PET/CT& and the Future of Molecular Imaging: Difficult Breast Cancer Cases on PET-CT." Advanced Breast Imaging and Interventions 2007. Las Vegas, NV, May 5, 2007
557. "PET, PET/CT& and the Future of Molecular Imaging: Molecular Imaging and Future of Nuclear Medicine Imaging of Cancer." Advanced Breast Imaging and Interventions 2007. Las Vegas, NV, May 5, 2007
558. "PET, PET/CT& and the Future of Molecular Imaging: Questions and Answers on Nuclear Medicine Imaging of Breast and Other Cancers" Advanced Breast Imaging and Interventions 2007. Las Vegas, NV, May 5, 2007
559. "Current Status and Emerging Opportunities for PET/CT Imaging. Greater Kansas Radiological Society. Kansas City, KS, May 9 2007
560. "Cancer Imaging: Predicting Clinical Outcome" Lung Cancer Medical Education Conference. Baltimore, MD. May 16, 2007
561. "Imaging Caveats and Pitfalls Following Interventional Oncology Therapies: PET and PET/CT. ACR Oncologic Imaging and Image Guided Intervention. Washington DC. May 19, 2007
562. "PET & PET/CT in the Management of Non-Hodgkin Lymphoma." SNM. Washington, D.C. June 2, 2007
- 563.562. "Radioimmunotherapy of Lymphomas: Review and Considerations for Pediatric Lymphomas." SNM. Washington, D.C. June 2, 2007
564. "Implications of Response-Adapted Therapy Using PET/CT in NHL." SNM. Washington, D.C. June 5, 2007
565. "Individualizing Cancer Therapies Using PET Imaging". AACR Meeting. Functional and Molecular Imaging. Atlanta GA. September 17, 2007
566. "Individualizing Cancer Therapies with Anatomomolecular Imaging." Whitehouse Lecture", University of Michigan. Ann Arbor MI. September 19, 2007
567. "Imaging Response Assessment Teams (IRAT) Update. AACI-CCAF Annual Meeting. Washington DC. October 28 - 29, 2007
568. "Tools and Technologies for Imaging and Intervention in Cancer: PET". RSNA Meeting. Chicago, IL. November 25-30, 2007
569. "Categorical Course in Diagnostic Radiology: Clinical PET and PET/CT Imaging Basics: Biological Targets and Radiotracers for PET. RSNA Meeting." Chicago, IL. November 25-30, 2007
570. "Categorical Course in Diagnostic Radiology Physics: Imaging Technologies in Oncology-Imaging Brain Tumors: PET in Brain." RSNA Meeting. Chicago, IL. November 25-30, 2007
571. "PET/CT in Oncology 2: Head and Neck, Breast, Melanoma: PET/CT in Melanoma" RSNA Meeting, Chicago, IL, November 25-30, 2007
572. "PET of Extracranial Head and Neck and Thyroid Cancer: Thyroid Cancer". RSNA Meeting. Chicago, IL. November 25-30, 2007

573. "Lung Cancer Diagnosis and Staging". PET/CT and SPECT/CT Imaging, Albert Einstein School of Medicine, Nuclear Medicine Course, St. Kitts, January 28, 2008
574. "Case Presentations" PET/CT and SPECT/CT Imaging, Albert Einstein School of Medicine, Nuclear Medicine Course, St. Kitts, January 28, 2008
575. "Head and Neck" PET/CT and SPECT/CT Imaging, Albert Einstein School of Medicine, Nuclear Medicine Course, St. Kitts, January 29, 2008
576. "Brain: Emphasis on Dementia" PET/CT and SPECT/CT Imaging, Albert Einstein School of Medicine, Nuclear Medicine Course, St. Kitts, January 29, 2008
577. "PET/CT: Current Role in Thoracic Disease". Computed Body Tomography 2008. Orlando, FL. February 15, 2008
578. "PET/CT: Current Role in Abdominal Disease". Computed Body Tomography 2008, Orlando, FL. February 15, 2008
579. "Abdominopelvic PET/CT & Update on the Medicare Registry". RSNA Highlights Clinical Issues 2008. Grande Lakes, FL. February 20, 2008
580. "FDG PET/CT: The Fundamentals and The Future", Stanford Radiology Meeting, Las Vegas, NV, February 27, 2008
581. "If There Were RECIST criteria for PET, It would be Defined as...", Stanford Radiology Meeting, Las Vegas, NV, February 27, 2008
582. "SPECT/CT to Plan Therapy", Nuclear Oncology: From Genotype to Phenotype to Targeted Therapy, Baltimore, MD, March 14, 2008
583. "Treatment response and PET/CT", Mideastern Society of Nuclear Medicine. Fairfax VA, April 12, 2008
584. "First line therapy radioimmunotherapy of lymphoma – will it become standard?", International Symposium, Bad Berka, May 3, 2008
585. "Functional Imaging: Current and Future Roles for Assisting Drug Development and Assessing Patient Outcome" ASCO Annual Meeting, Chicago, IL, May 31, 2008
586. "FDG PET and other Functional Imaging Modalities to Assess Agents Targeting P13K-AKT-mTor Pathway". ASCO Annual Meeting, Chicago, IL, May 31, 2008
587. "Henry Wagner Lectureship: Personalized Therapies: Opportunities and Challenges for Nuclear Medicine" Society of Nuclear Medicine Annual Meeting. New Orleans, LA. June 15, 2008
588. "FDG-PET, Role in Do Disease". Issues in Clinical Prostate Cancer: Role of Imaging. Rockville, MD. June 24, 2008
589. "Oncologic Imaging", Memorial University Medical Center and The Curtis and Elizabeth Anderson Cancer Institute, ACI Grand Rounds. November 14, 2008
590. "Diagnostic Radiology: Clinical PET and PET/CT Imaging—PET Basics". RSNA Annual Meeting. Chicago, IL. November 30, 2008
591. "Biological Targets and Radiotracers for PET".RSNA Annual Meeting. Chicago, IL. November 30, 2008
592. "Clinical PET and PET/CT Imaging—CNS PET".Chicago, IL. December 1, 2008
593. "Clinical PET and PET/CT Imaging—PET of the Thorax". RSNA Annual Meeting. Chicago, IL. December 2, 2008
594. "Imaging Response Assessments Teams". RSNA Annual Meeting. Chicago, IL. December 2, 2008
595. "Clinical PET and PET/CT Imaging—Abdominopelvic PET/CT and the Medicare PET Registry". RSNA Annual Meeting. Chicago, IL. December 2, 2008
596. "Quantitative Structured Reporting in Cancer Imaging: Get Ready: It Is Coming". RSNA Annual Meeting. Chicago, IL. December 3, 2008
597. "Clinical PET and PET/CT Imaging—PET of Extracranial Head and Neck and Thyroid Cancer". RSNA Annual Meeting. Chicago, IL. December 3, 2008
598. "Thyroid Cancer". RSNA Annual Meeting. Chicago, IL. December 3, 2008
599. "Clinical PET and PET/CT Imaging—Lymphoma, Melanoma, Sarcomas". RSNA Annual Meeting. Chicago, IL. December 4, 2008

600. "Clinical PET and PET/CT Imaging—Clinical Cardiac PET/CT". RSNA Annual Meeting. Chicago, IL. December 4, 2008
601. "A Systematic Review of 18F Fluoro-Deoxyglucose Positron Emission Tomography for Mid-Treatment Evaluation of Malignant Lymphoma". RSNA Annual Meeting. Chicago, IL. December 4, 2008
602. "Clinical PET and PET/CT Imaging—Emerging PET Applications". RSNA Annual Meeting. Chicago, IL. December 5, 2008
603. "To Describe the most Common Reasons for PET Imaging in the Thorax". 25th Annual Computed Body Tomography 2009: the Cutting Edge. Orlando FL. February 13, 2009
604. "To Define the Most Frequent Reasons for PET/CT in the Abdomen in Clinical Practice". 25th Annual Computed Body Tomography 2009: the Cutting Edge. Orlando FL. February 13, 2009. February 14, 2009
605. "PET/CT with FDG in Metastatic Prostate Cancer" SNM MidWinter Meeting. Newport Beach CA. February 18, 2009
606. "The Use of PET/CT in Thoracic Neoplasms". Advances in Whole Body Fusion Imaging: PET/CT and SPECT/CT. Baltimore, MD March 13, 2009
607. "SPECT/CT to Plan Therapy" Advances in Whole Body Fusion Imaging: PET/CT and SPECT/CT. Baltimore, MD March 14, 2009
608. "Assessing the Treatment of Breast Cancer". Advances in Whole Body Fusion Imaging: PET/CT and SPECT/CT. Baltimore, MD March 14, 2009
609. "Melanoma". Advances in Whole Body Fusion Imaging: PET/CT and SPECT/CT. Baltimore, MD March 14, 2009
610. "Planning and Monitoring Treatment with PET/CT Images". Advances in Whole Body Fusion Imaging: PET/CT and SPECT/CT. Baltimore, MD. March 14, 2009
611. "How is Molecular Imaging Relevant to Your Clinical Practice? Mid-Eastern Chapter Society of Nuclear Medicine. Ocean City, MD. April 12, 2009
612. "Radioimmunotherapy". 14th Annual Update in Hematologic Malignancies. Baltimore, MD. May 1, 2009
613. "Radioimmunotherapy- An Overview and Update". Molecular Imaging in Radiation Oncology Clinical Trials. Haifa, Israel. May 14, 2009
614. "Measuring Tumor Response with PET". ASCO. Orlando, FL. May 30, 2009
615. "Molecular Imaging vis-à-vis Conventional Imaging in Clinical Trials; Challenges and Opportunities". Society of Medicine Annual Meeting. Toronto, Canada. June 13, 2009
616. "PET in Breast Cancer or PET in GI Malignancies". Presentation. Clinica Las Condes. Santiago, Chile. December 15, 2009
617. "PET in the Management of Lung Cancer". Presentation. Clinica Las Condes. Santiago, Chile. December 15, 2009
618. "PET in the Management of Lymphoma". Presentation. Clinica Las Condes. Santiago, Chile. December 15, 2009
619. "PET/CT in Gynecological Malignancies". Presentation. Clinica Las Condes. Santiago, Chile. December 16, 2009
620. "PET/CT and Cancer Treatment Response Assessment. New York University, 28th Annual Head-to-Toe Conference. New York, NY. December 19, 2009
621. "PET/CT" in Gynecological Malignancies". New York University, 28th Annual Head-to-Toe Conference. New York, NY. December 19, 2009
622. "Imaging as a Predictor of Therapeutic Response". Clinical Trials Methodology Workshop, RSNA. Arizona. January 9-15, 2010
623. "Molecular Imaging & Nuclear Medicine Conference Arab Health 2010". Arab Health Congress. Dubai. January 25-27, 2010
624. "Nanomedicine and Molecular Imaging Summit". Educational Symposium, SNM Conjoint Mid-Winter Clinical Trials. Albuquerque, NM. January 27-February 2, 2010

625. "Metabolic Criteria: EORTC and PERCIST". HCNM. Steamboat Springs, CO. February 27, 2010
626. "Functional Imaging in Drug Development". Molecular Frontiers: Molecular Cancer Therapies. Madrid, Spain. March 8-10. 2010
627. "Cardiac PET/CT and SPECT/CT: New Technology for Improved Patient Care". CME Event, JHU-Advances in Nuclear Medicine. Baltimore, Maryland . March 12, 2010
628. "Imaging Cell Death: Microscopic vs. Macroscopic Detection". Best Practices in PET Symposium. Sonoma, CA. April 8, 2010
629. "A RECIST for Metabolic Response". Best Practices in PET Symposium. Sonoma, CA. April 9, 2010
630. "Enhancing Patient Care Through Advances in Biomedical Imaging". ARRAC Legislative Forum; NIH Forum. Washington, DC. April 12, 2010
631. "Standards for Imaging Endpoints in Clinical Trials". NIH Imagng Workshop. NIH Campus, Bethesda, MD. April 13, 2010
632. "Manufacturing of Positron Emission Tomography (PET) Radiopharmaceutical Products". NIH Imagng Workshop. NIH Campus, Bethesda, MD. April 14, 2010
633. "Molecular Imaging Guided Radiation Therapy". American Radium Society. Cancun, Mexico. May 1-5, 2010
634. "PET/CT and Cancer Treatment Assessment". Oncology Grand Round, Sinai Medical Ctr, Baltimore, Maryland. May 11, 2010
635. "Novel Imaging Techniques and Emerging Trends in Therapy". SNM Annual Meeting. Salt Lake City, Utah. June 5, 2010
636. "Advanced PET/CT/MR and SPECT/CT Scanners: Need or Extravaganza?" SNM Annual Meeting. Salt Lake City, Utah. June 8, 2010
637. "Data Analysis & Management: Oncology-Quantitative Methods & Applications". SNM Annual Meeting. Salt Lake City, Utah. June 8, 2010
638. "What Can Biological Treatment Assessment Tell Us?" ITART(Imaging for Treatment Assessment Symposium). Washington, DC. June 21, 2010
639. "Imaging Biomarkers in Therapeutic Trials". AACR. Denver, CO. September 27, 2010
640. "Advancing Cancer Research Through Imaging". AACI-CCAF Annual Meeting, Chicago IL. Oct 5, 2010
641. "Recent Advances in Clinical PET/CT Imaging." Peninsula Imaging. Salisbury, MD October 26, 2010
642. "Oncology & Response Evaluation". RSNA Annual Meeting, Chicago, Illinois. November 29, 2010
643. "Characteristics of FDG Avid Lymph Nodes". RSNA Annual Meeting, Chicago, Illinois. November 29, 2010
644. "Prognostic Value of 18F-FDG". RSNA Annual Meeting, Chicago, Illinois. November 29, 2010
645. "PET for Assessing Cancer Treatment Response". RSNA Annual Meeting, Chicago, Illinois. November 29, 2010
646. "PET Scans, Today and in the Future". MDACP – Turf Valley Country Club. Baltimore, Maryland February 4, 2011
647. "Lung: PET/CT". Advances in Clinical Methods, PET/CT & SPECT/CT IMAGING. CME-JHU. Baltimore, Maryland. February 10, 2011
648. "Bone: All Modalities, Emphasis on PET". Advances in Clinical Methods, PET/CT & SPECT/CT IMAGING. CME-JHU. Baltimore, Maryland. February 11, 2011
649. "PET/CT in Breast and Female Disorders". Advances in Clinical Methods, PET/CT & SPECT/CT IMAGING. CME-JHU. Baltimore, Maryland. February 11, 2011
650. "PET/CT of the G-I Tract". Advances in Clinical Methods, PET/CT & SPECT/CT IMAGING. CME-JHU. Baltimore, Maryland. February 12, 2011
651. "PET of the Brain". 5th Annual Meeting of American Society of Functional Neuroradiology. Phoenix, Arizona. March 2, 2011
652. CME from JHU: need listing
653. "PET/CT in Clinical Trials". Mid-Eastern Chapter SNM-41st Annual Meeting. Ocean City, Maryland. April 9, 2011

654. "PET-MRI : A New Era in Imaging". Turkish Society of Nuclear Medicine. Istanbul, Turkey. April 28, 2011
655. "Lost and Found in Translation: Developing Molecular Diagnostics and Therapeutics for Human Use". SNM Annual Meeting. San Antonio, Texas. May 4, 2011
656. "Personalizing Cancer Therapies using Quantitative Imaging including PERCIST". C-TRIC Lecture Series, University of Colorado, Denver. September 7, 2011
657. "Molecular Imaging: Oncology". RSNA Annual Meeting, McCormick Place, Chicago, Illinois. November 27, 2011.
658. "Breast/Nuclear Medicine/Molecular Imaging Series: Breast Imaging in the Era of Nuclear Medicine". RSNA Annual Meeting, McCormick Place, Chicago, Illinois. November 28, 2011.
659. "Current Emerging Roles of Whole Body PET Imaging in Breast Cancer". RSNA Annual Meeting, McCormick Place, Chicago, Illinois. November 28, 2011
660. "Update on radiopharmaceutical treatment of lymphoma", SNMMI Mid-Winter Meeting. January 26, 2012.
661. "Imaging Endpoints in Therapeutic Clinical Trials". SNM Mid-Winter meeting, Orlando, Florida. January 27, 2012.
662. "Imaging and Radioimmunotherapy". SNM Mid-Winter meeting, Orlando, FL. January 28, 2012
663. "Quantitative Phenotyping of Cancer and its Response to Therapy with PERCIST" Hamamatsu Meeting, Hamamatsu, Japan. February 15, 2012.
664. "Chest, Abdomen and Pelvis: What's new?" Advances in Nuclear Medicine-JHU, Baltimore, Maryland. March 10, 2012.
665. "Standardizing PET/CT to Plan and Monitor Treatment". Advances in Nuclear Medicine-JHU, Baltimore, Maryland. March 10, 2012.
666. "Quantitative Imaging to Personalize Cancer Management". Stanford Grand Rounds, Stanford, California. March 15, 2012.
667. "PET in Cancer Management". Oncology Fellows Lecture~JHU, Baltimore, Maryland. April 18, 2012.
668. "SNM Highlights Plenary Session Lecturer". SNM Annual Meeting 2012. Miami, Florida. June 13, 2012.
669. "Hybrid imaging: Improving therapeutic decisions". IAEA Technical Meeting on Hybrid Imaging and Radioguided Surgery, Vienna, Austria. September 5, 2012
670. "RECIST, RECIST 1and PERCIST". ECOG-ACRIN Imaging Researchers' Workshop, Ritz Carton, Arlington, CA. October, 4, 2012.
671. "Quantitative Imaging to Personalize Cancer Management". SNMMI- NorthEast Chapter, Stamford, CT. October 12, 2012.
672. "New PET Tracers and Imaging Instrumentation". SNMMI-NorthEast Chapter, Stamford, CT. October 12, 2012.
673. "Personalized and Targeted Radiopharmaceutical Therapies – Current Status and Emerging Opportunities". Emeritus Celebration of Professor Luc Mortelmans. Leuven, Belgium. November 15, 2012
674. "Imaging Infection with PET". Montefiore Radiology Grand Rounds, Bronx, New York. March 11, 2013.
675. "When should PET be used in Cancer Patients?" Mid-Eastern Chapter, SNMMI, Ocean City, Maryland. April 13, 2013.
676. "PET in CA Management". Oncology Fellows Lecture, Johns Hopkins, Baltimore, Maryland. April 17, 2013.
677. "Uses and Misuses of PET Scanning". 58th Annual Philip A. Tumulty Topics in Clinical Medicine. Johns Hopkins, Baltimore, Maryland. May 7, 2013
678. "Rethinking How We Look at Response and Progression: When to Resist RECIST", ASCO Annual 2013 meeting. McCormick Place, Chicago, Illinois. June 4, 2013.

679. "Update on Tumor Imaging and Therapy". SNMMI 2013 Annual Meeting. Van Couver, CA. June 8, 2013.
680. "History Tribute for Henry Wagner, MD". SNMMI 2013 Annual Meeting. Van Couver, CA. June 9, 2013.
681. "Molecular Imaging – Part II". SNMMI 2013 Annual Meeting, Van Couver. CA. June 9, 2013.
682. "SNM Highlights Plenary Session Lecturer ". SNM Annual Meeting 2012. Miami, Florida. June 13, 2012 SNMMI 2013 Annual Meeting, Vancouver, CA. June 12, 2013.
683. "Quantitative Cancer Imaging Biomarkers – Nuclear". Summer Frontiers Meeting, Vanderbilt University, Nashville, TN. July 18, 2013
684. "Grand Rounds – MSKCC". Memorial Sloan Kettering, New York, November 4, 2013.
685. "Overview of Multi-Modality Quantitative Imaging for Evaluation of Response to Cancer Therapy". Johns Hopkins ICMIC Seminar. Johns Hopkins. November 25, 2013.
686. "PET in CA Management". Oncology Fellow Lecture, Johns Hopkins. January 8, 2014.
687. "Advances in Quantitative Nuclear Medicine Imaging of Cancer". Mid-Eastern Society of Nuclear Medicine 2014 Annual Meeting. Ocean City, Maryland. April 13, 2014
688. "Targeted Radiopharmaceuticals for Cancer Diagnosis and Therapy" presented at the Johns Hopkins 4th Quarter Course: New Approaches to Cancer Prevention and Therapy. Johns Hopkins Univeristy. April 23, 2014.
689. "Uses and Misuses of PET Scanning". Harbor Hospital Grand Rounds. Baltimore, Maryland. April 25, 2014.
690. "Clinical Applications of Quantitative Imaging in Planning and Assessing Cancer Therapies". Eastern Virginia Medical School. May 12, 2014.
691. "Quantitation of PET Images". ICRU Commission Meeting. Bethesda, Maryland. May 13, 2014
692. "Quantitative Nuclear Medicine: Emphasis of PET/CT and SPECT/CT". Spectrum Health Radiology Grand Rounds. Grand Rapids, Michigan. May 16, 2014.
693. "Clinical Applications of Quantitative Imaging in Planning and Assessing Cancer Therapies". Society of Nuclear Medicine Molecular Imaging Annual Meeting. St. Louis, Missouri. June 9, 2014.
694. "Alpha Particle Radiopharmaceutical Therapies – A New Beginning". Swiss Congress of Radiology and Nuclear Medicine 2014 Meeting. Montreux, Switzerland. June 12, 2014.
695. "PET in CA Management". Oncology Fellow Lecture, Johns Hopkins. September 4, 2014.
696. "Minimal Standards for FDG-PET Detection of Brown Fat in Humans". National Institute of Diabetes and Digestive and Kidney Diseases Meeting. Bethesda, Maryland. November 4, 2014.
697. "Recent Developments in Oncologic PET Imaging". Radiological Society of North America. Chicago, Illinois. November 30, 2014.
698. "FDG-PET for Cancer Staging and Monitoring". Radiological Society of North America. Chicago, Illinois. December 1, 2014.
699. "Clinical applications of quantitative imaging in planning and assessing cancer therapies". AACR-SNMMI Joint Conference State-of-the-Art Molecular Imaging in Cancer Biology and Therapy. San Diego, California, February 11-14, 2014.
700. "Image-Guided Precision Medicine". University of Maryland School of Medicine Grand Rounds, Baltimore, March 4, 2015.
701. Third Theranostics World Congress on Ga-68 and PRRT. Baltimore, Maryland, March 12-14, 2015.
702. International Year of Light, SPECTRA. St. Louis, Missouri, April 9, 2015.
703. "Quantitative in Vivo Phenotyping of Cancer using PET, SPECT Molecular Imaging and PERCIST 1.0 to Personalize Ocologic Therapies". 15th International Congress of Radiation Research (ICRR 2015). Kyoto, Japan. May 26, 2015.
704. "Precision Medicine Using Quantitative PET and SPECT Imaging". International Symposium on Radiopharmaceutical Sciences (ISRS2015). Columbia, MO. May 30, 2015.
705. "Targeted Radionuclide Therapy in Lymphoma". ASCO Annual 2015 meeting. McCormick Place, Chicago, Illinois. June 1, 2015.

706. "Prognostic Utility of PET in Lymphoma". Society of Nuclear Medicine Molecular Imaging Annual Meeting. Baltimore, MD. June 6, 2015.
707. "Precision Medicine Informed by Quantitative Imaging". Chaudhuri Lecture, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, September 17, 2015.
708. "Emerging Imaging Tools on the Horizon". ASCO at ECCO meeting, Vienna, Austria, September 28, 2015.
709. AJCC Expert Melanoma Panel Meeting, San Francisco, California, November 17, 2015.
710. "Quantitative Imaging Biomarkers". Radiological Society of North America. Chicago, Illinois. November 30, 2015.
711. "Breast Cancer with PET -CT". Radiological Society of North America. Chicago, Illinois. December 3, 2015.
712. "Defining Tumour Biology through Quantitative Nuclear Medicine". ANZSNM Victorian & Tasmanian Branch Pre-Conference Scientific Meeting. Melbourne, Australia. April 18, 2016.
713. "Quantitative PET: lessons learned from PERCIST 1.0". ANZSNM Pre-Conference Symposium. Taupo, New Zealand, April 22, 2016.
714. "Advances in precision nuclear medicine". ANZSNM Plenary Presentation. Rotorua, New Zealand. April 23, 2016.
715. "Defining Tumor Biology through Quantitative Nuclear Medicine". AANMS Symposium. Rotorua, New Zealand. April 23, 2016.
716. "Lymphoma and Leukaemia RIT: Lessons Learned and New Directions". Rotorua, Radionuclide Therapy Workshop. New Zealand. April 25, 2016.
717. "Advancing our Current Imaging Options" Panel leader at NCI/SNMMI Workshop: Immune Modulation and Imaging: What can we do in Clinical Trials Now? Rockville, MD, May 2, 2016.
718. "Inclusion of Breast Cancer Patients with Bone-only Metastasis in Clinical Trials Consensus Development Meeting" ASCO. Chicago, Illinois, June 2, 2016.
719. "Update on PERCIST". SNMMI 2016 Annual Meeting, San Diego, CA, June 12, 2016.
720. "Capturing New Business Opportunities". SNMMI 2016 Annual Meeting, San Diego, CA, June 13, 2016.
721. "From Genome to Phenome using PET... 'PERCISTence' Pays". Peter Valk Memorial Lecture, SNMMI 2016 Annual Meeting. San Diego, CA. June 14, 2016.
722. "Quantitative Imaging to Personalize Cancer Care". International Congress of Radiology. Buenos Aires, Argentina, September 22, 2016.
723. "How do we Assess the Value of Imaging". Fuchs Plenary Session, International Congress of Radiology, Buenos Aires, Argentina, September 22, 2016.
724. "PET/CT Imaging in Thoracic Neoplasms". International Congress of Radiology. Buenos Aires, Argentina, September 23, 2016.
725. "PET/CT, PET/MRI, and Cyclotrons: Making Them All Assets". SCARD Fall 2016. Annapolis, Maryland, September 30, 2016.
726. "The Renaissance of Radiopharmaceutical Therapy." Larry Williams Memorial Lecture in Targeted Radiopharmaceuticals. City of Hope, California, October 7, 2016.
727. "An International Perspective on PET and Theranostics". Keynote at Peter Mac Symposium. Melbourne, Australia, November 6, 2016.
728. "The Success and Failure of Radioimmunotherapy for Lymphoma". 4th World Theranostics Congress, Melbourne, Australia, November 9, 2016.
729. "Optimizing Peptide Receptor Radionuclide Therapy (PRRT)". Session Chair. 4th World Theranostics Congress, Melbourne, Australia, November 7, 2016.
730. "Quantitative Imaging Biomarkers Multisession Course". Radiological Society of North America. Chicago, Illinois. November 28, 2016.
731. "Quantitation of Cancer Treatment Response by FDG PET/CT: Multi-Center Assessment of Variability". Poster Session. Radiological Society of North America. Chicago, Illinois. December 1, 2016.

732. “PET in the Management of Lymphoma” for course *Enhance Patient Care with Nuclear Medicine and Molecular Imaging*. Johns Hopkins University School of Medicine. Baltimore, Maryland, March 10, 2017.
733. “Recruiting Lessons from Baseball”. SCARD/RRA session at AUR Annual Meeting. Hollywood, Florida, May 9, 2017.
734. “Standardization of Advanced PET/SPECT Data Acquisition and Analysis” QIN session at SNMMI 2017 Annual meeting, Denver CO, June 15, 2017.
735. “Technology Transfer and Commercialization, the fourth aim of the ‘tripartite’ mission”. MIR Education Seminar Series. September 7, 2017.
736. “Quantitative Imaging Biomarker Alliance (QIBA): Overview and Emphasis on Nuclear Medicine Based Approaches” The 12th Asia Oceania Congress of Nuclear Medicine and Biology, Yokohama, Japan, October 7, 2017.
737. “Should SCARD Promote an ‘Early Specialization’ for All Subspecialties?” SCARD Fall 2017, Coronado, CA, October 13, 2017.
738. 2017 RSNA Creating an Optimizing the Research Enterprise (CORE) Workshop: “Developing Clinician Scientists in Radiology” October 20, 2017; “Moving to the ‘Top Ten’” October 20, 2017; “Funding Strategies” October 21, 2017, Oak Brook, Illinois.
739. “QIN tools including auto PERCIST for lymphoma” QIN-NCTN Meeting at Alliance for Clinical Trials in Oncology, Chicago, IL, November 3, 2017.
740. “Nuclear Imaging and Treatment for NETs” Indianapolis NET Patient and Caregiver Education Conference hosted by the Neuroendocrine Tumor Research Foundation Indianapolis, Indianapolis, IN, November 11, 2017.
741. “Breast Cancer with PET-CT”. Radiomics: Mini-Course: Oncologic Applications. Radiological Society of North America. Chicago, Illinois. November 27, 2017.
742. “The Added Value of Quantitative Imaging in Clinical Practice”. Radiological Society of North America. Chicago, Illinois. November 27, 2017.
743. “Measurement Repeatability of Cold-Activated Brown Adipose Tissue Volume on [18F]FDG-PET Using both PET/CT and PET/MRI” Radiological Society of North America. Chicago, Illinois. November 23, 2017.

Consulting Relationships and Board Memberships:

Nihon-Medi Physics Co. Ltd (Japan) (current)
 Cellectar (Novelos) Pharmaceuticals
 Coulter Pharmaceuticals, Inc.
 PET Net Pharmaceuticals
 Corixa Corporation
 Berlex/Diatide Laboratories
 Actinium Pharmaceuticals (SAB)
 Transmolecular Imaging (ad hoc)
 Millenium Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. (SAB)
 TRIUMF Life Science Program (Vancouver, BC) 1998-2001
 Human Genome Sciences
 Sitman Cancer Center (Washington University External Advisory Board (2005-2014)
 MD Anderson Cancer Center (External Advisory Board) (2001-2013)
 Department of Energy (BERAC Advisory Committee)
 GlaxoSmithKlein
 Lilly Corporations
 GE Healthcare
 Spectrum Pharmaceuticals

Research Support:

ACTIVE

WhiteRabbit.ai, Inc Contract	06/01/2017 \$1,076,510	
NIBIB (Woodard/Wahl/Achilefu) T32 EBo21955 01A1, Training Opportunities in Translational Imaging Education and Research (Top-Tier)	2017	
NIH/NCI (Shoghi/Ackerman/Wahl/Li) U24-CA209837 WASHINGTON UNIVERSITY CO-CLINICAL IMAGING RESEARCH RESOURCE (WU-C2IR2) The objective of this the WU-C2IR2 is to develop and validate quantitative imaging (QI) techniques that transcend species and modalities. QI techniques will be optimized in preclinical models of patient derived tumor xenografts (PDX) and implemented in a co-clinical trial to assess response to therapy in triple negative breast cancer (TNBC). Multi-scale bioanalytic data will be further integrated with QI metrics to refine metrics of prediction. The WU-C2IR2 will also develop a modular web-accessible database to house all data, methods, workflow documentation, and results from the co-clinical investigation.	3/1/17-2/28/22	
NIH (Marcus, Wahl) 1U24CA204854-01 Integrative Imaging Informatics for Cancer Research The goal of the I3CR is to develop data and knowledge management platforms to support the collection, analysis, and sharing of imaging and related data for use in cancer research.	5/16/16-4/30/21 \$ 2,005,376	

PREVIOUS GRANTS

NIH/NCI (Wahl, Jacobs, Frey) 1U01CA140204-01A2 Multi-Modality Quantitative Imaging for Evaluation of Response to Cancer Therapy The goal of this study is to evaluate multi-modality quantitative imaging for evaluation of response to cancer therapy	09/19/11 – 08/31/17 \$412,425	1.8 calendar
SBIR HHSN261201500054C (PI: J. Berniac, Co-Investigator: R. Wahl) calendar DHHS/NIH/CDC Pre-Targeting of Acute Myeloid Lymphoma Cells & Subsequent Delivery of High Payloads of Radionuclides The goal of this project is to develop a CD123-targeted imaging agent and radioimmunotherapy for acute myeloid leukemia.	10/01/15-06/30/16 SubDC \$65,451	0.60
R01HL092985 (Wahl/Abraham) NHLBI Imaging of the Myocardial Microenvironment to Facilitate Stem Cell Enfragment The goal of this study is to optimize cell therapeutic benefit based on imaging of individual disease biology.	01/15/10-12/31/15 \$222,750	0.8 calendar
NIH (Madar/Wahl) R21DK09078 Non-Invasive Imaging of UCP1-Mediated Brown Fat Thermogenesis The goal of this study is to facilitate the design of a clinically relevant and accurate non-invasive technology for quantitative imaging of a key mechanism of energy expenditure, using F-18 FBnTP and PET. This technology will markedly advance the development of effective anti-obesity pharmacologic strategies	09/30/10-08/31/14 \$148,500 NCE	0.6 calendar
Actinium Pharmaceuticals (Wahl) A Phase I/II study of low dose Cytarabine and Lintuzumab-Ac225 in older patients The goal of this study is to evaluation older patient response to Cytarabine and Lintuzumab-Ac225	09/26/2012-09/25/15 \$453,080	0.48 calendar

2P50CA103175-06A2(Bujwalla) NCI JHU-ICMIC PROGRAM To accelerate clinical roles for molecular imaging in cancer models and cancer care	09/22/11-07/31/16 \$890,668	0.77 calendar
NIH (Frey) R01CA109234 Quantitative SPECT for Targeted Radionuclide Therapy The major goal of this grant is to study quantitative SPECT for targeted radionuclide therapy	09/15/11-07/31/16 \$247,497	0.24 calendar
NCI(Nelson) P30CA006973 Regional Oncology Research Center The goal of this study is to evaluate regional oncology research center—IRAT core director	08/09/12-04/30/17 \$4,404,077	1.2 calendar
NCI (Matsui) R01CA174951 Role of multiple myeloma cancer stem cells in clinical disease The goal of this study is to develop novel oxysterol Hedgehog pathway inhibitors and anti-tumor agents	05/01/14-04/30/19 \$358,168	0.72 calendar
NCI (Brahmer) U10CA180802 Johns Hopkins University NCTN Lead Academic Site Program To develop new cancer therapies through the National Clinical Trials Network program	04/15/14-02/28/19 \$400,903	0.12 calendar
Molecular Insight Pharmaceuticals (Wahl) A Phase I-II Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, And Efficacy Of Ultratrace™ Iobenguane I 131 In Patients With Malignant Pheochromocytoma/Paraganglioma. The goal of this study to evaluate the tolerated dose, dosimetry, safety, and efficacy of ultratrace™ iobenguane i 131 in patients with malignant pheochromocytoma/paraganglioma.	10/14/09 – 07/31/15 \$447,543	0.12 calendar
GSK (Wahl) 007066 Multi-center, randomized, phase 3 study of Iodine-I31 Tositumomab therapeutic regimen versus Ibritumomab Tiuxetan therapeutic regimen for subjects w/relapse or transformed follicular NHL The goal of this study is to evaluate the study of Iodine-I31 Tositumomab therapeutic regimen versus Ibritumomab Tiuxetan therapeutic regimen for subjects w/relapse or transformed follicular NHL	09/01/06-08/31/16 \$197,590	.06 calendar
GUEBERT (Geschwind) Lipiodol as an imaging biomarker of drug delivery (tumor uptake) and tumor viability after transcatheter chemoembolization therapy in patients with primary and metastatic liver cancer The goal of the study is to utilize Lipiodol as an imaging biomarker	02/27/2013-08/31/2018 \$1,649,525	0.12 calendar
SIEMENS (Rahmim) Multi-pass clinical FDG PET/CT imaging To develop and evaluate novel quantitative imaging using dynamic multi-bed PET/CT acquisition in clinical oncologic studies. The project aims to develop enhanced surrogate markers of cancers using novel parametric imaging as applied to multi-bed imaging	08/01/13-07/31/15 \$131,835	0.24 calendar
Melanoma Research Alliance (Pardoll) Combinatorial Immunotherapy for Melanoma Vaccines Plus B7-H1/PD-1 Blocked The goals of this study is to measure the success of combinatorial therapies including with PET	07/15/09-08/31/14 \$500,000	0.5 calendar

Siemens (Szabo) JHU-2011-MI-110-01-39543 Multi-Modal Reconstruction and Quantitative SPECT Imaging Collaboration Provide multi-modal patient data of bone studies and for the evaluation of quantitative SPECT and provide clinical feedback and conduct clinical evaluations.	2/16/12-12/15/14 \$475,792	0.12 calendar
NCI (Wahl) N01CM27018 Early Clinical Trials of Imaging Agents This grant's goal is to provide the services of Molecular Imaging Trial Center focusing on performance of Phase I & II clinical trials molecularly targeted Imaging agents.	09/30/02 – 09/29/12 \$722,335yr TDC	0.6 calendar
NBIB (Tsui) R01EB000168 Corrective Image Reconstruction Methods for ECT The major goal of this project is to develop three and four-dimensional reconstruction methods that correct for the image degrading factors in SPECT.	09/06/07-06/30/13 \$331,464	0.6 calendar
RSNA (Wahl) NIH (Prime) Analysis of SARC 11 Trial Data by PERCIST with Linkage to Clinical Outcomes The goal of this study is to analyze SARC 11 Trial PET Data.	04/01/11-09/29/12 \$57,500	0.22 calendar
ACR (Wahl) 1 ACRIN 6682 Phase II Trial 64Cu_ATSM PET/CT in Cervical Cancer The goal of this study is monitor the effects of the compound, 64Cu_ATSM in Cervical Cancer through PET/CT imaging.	1/01/11-10/31/13 \$51,492	0.19 calendar
MMTC (Wahl) HBAT Brown Adipose Tissue The goal of this study to test the microwave radiometer in comparison to FDG PET in the presence of brown adipose tissue.	9/30/10-8/31/12 \$79,696	0.6 calendar
JHU-2006-Mr-37-01 (Jacobs) Siemens Medical Solutions Usa Inc Whole Body Diffusion Weighted Imaging for the Detection of Metastatic tumors The goal of this study is to evaluate whole body diffusion weighted imaging for the detection of metastatic tumors	02/01/2008-01/30/2009	
3 P30 CA006973-43S2 (Baylin) NIH/NCI Imaging Response Assessment Teams in Cancer Center Supplement. (IRAT) The major goal is to provide a specialized resource for imaging radiological assessment team.	12/01/05 – 04/30/09 \$154,393	
Nucletron BC (Herman) Pilot Study:High-Dose-Rate Endorectal Brachtherapy in the Treatment of Locally Advanced Low Rectal Cancer This is a clinical trial to study high-dose-rate endorectal brachtherapy in the treatment of locally advanced low rectal cancer.	10/21/10-10/20/13 \$82,089	0.24 calendar
American College of Radiology (Wahl) Multicenter Phase II Assessment of Tumor Hypoxia The goal of this Phase II Study is to assess tumor Hypoxia	05/26/11-05/25/12 \$154,132	0.24 calendar

Abraxis Bioscience, Inc. (Stearns) Clinical Trial	12/15/07-12/14/12	0.24 calendar
A Multi-Institutional randomized Phase II Study evaluating response and surrogate biomarkers to Carboplatin and nab-Paclitaxel (CP) with or without Vorinostat (SAHA) as preoperative chemotherapy in primary operable breast cancer		
NIH (Madar/Wahl) R21DK09078	09/30/10-08/31/13 \$148,500	.6 calendar
Non-Invasive Imaging of UCP1-Mediated Brown Fat Thermogenesis		
The goal of this study is to facilitate the design of a clinically relevant and accurate non-invasive technology for quantitative imaging of a key mechanism of energy expenditure, BAT, using F-18 FBNTP and PET. This technology will markedly advance the development of effective anti-obesity pharmacologic strategies		
1RO1 CA10923-01A2 (Frey) NCI	03-01-06 – 9/14/11 \$268,171	
Quantitative SPECT for Targeted Radionuclide Therapy		
The goal of this grant is to develop and evaluate improved quantitative imaging methods aimed at targeted radionuclide therapy dosimetry.		
Wahl Univ NC	12/01/07 – 11/30/12 \$20,000	
Carotid Occlusion Surgery Study		
The goal of this study is to perform the preliminary study to determine whether JHU will be a sub site for your COSS clinical trial.		
NIH Co-Investigator	TDC \$296,418	
Quantitative SPECT for Targeted Radionuclide Therapy.		
The major goal of this grant is to study quantitative SPECT for targeted radionuclide therapy.		
DE-FG02-05ER63967 (Sgouros, G Ph.D.) Wahl RL: Co-Investigator	12/1/04-11/30/07	
Department of Energy (DOE)	TDC \$1,149,017	
“Patient-Specific Dosimetry and Radiobiological Modeling of Targeted Radionuclide Therapy”		
P50CA096888 (Ambinder) NCI	09/20/02 – 06/30/07	
Co-Investigator (PI subproject) “Internal SPORE in Lymphoma”	\$1,803,488	
The major goal of this study is to evaluate the safety and efficacy of the combination regimens of (TRAIL/Apo2L with targeted delivery of ionizing radiation via radiolabeled anti-CD20 antibodies & NF- κ B with agents that target the I κ B kinase complex) will be investigated in Phase I/II clinical trials in patients with chemotherapy-refractory B-cell malignancies. Such antibody- and ligand-based combinatorial therapy may provide effective and physiologic approaches for inducing tumor cell death that are not complicated by the immediate and long-term toxicities of high dose therapy requiring stem cell transplantation.		
Tm601-002 (Wahl) Transmolecular	07/21/06 – 12/31/08 \$399,231	
A Phase II Open-Label, Multiple-Dose Study Of Intracavitary Administered 131i-Tm-601 In Adults Patients With Recurrent High-Grade Glioma”		
The goal of this study is to evaluate a phase II open-label, multiple-dose study of intracavitary administered 131i-tm-601 in adult patients with recurrent high-grade glioma.		

<p>(Wahl) Seattle Genetics PET Data Analysis Proposal</p>	<p>08/01/05 – 12/31/07 \$14,876</p>
<p>1P50 CA103175 (Bhujwalla) Wahl, RL: Co-Investigator NIH TDC \$6,184,080 “The JHU ICMIC Center” Principle Investigator: Zaver Bhujwalla Ph.D. The major goal of this study is to study the techniques of Anatomolecular Imaging</p>	<p>08/01/03 - 07/31/08</p>
<p>R01 CA098488 (Sharkey) Wahl, RL: P.I. on Sub-Contract CMMI MUN - NIH/NCI Pharmacokinetics, Biodistribution And Targeting Of In-111-Labeled Humanized Pam4 Igg In Pre-Surgical Pancreataic Cancer In Patients: An Examination Of Protein Dose The primary aim of this proposal is to initiate a PHASE I Clinical trial that will explore the safety and possible efficacy of a single intravenous injection of In-111 - humanized PAM4 IgG in pancreatic cancer patients. The trial is designed to first test a suitable protein dose of hPAM4 to be used in the next step of clinical testing – to determine the maximum tolerated dose for 90Y-hPAM4 therapy.</p>	<p>7/19/05 – 6/30/08 TDC \$212,947</p>
<p>9 R01 EB 000168-19 (Tsui) Wahl, RL: Co-Investigator NIBIB Corrective Image Reconstruction Methods for ECT The major goal of this project is to develop three and four-dimensional reconstruction methods that correct for the image degrading factors in SPECT.</p>	<p>7/1/02-3/31/08 TDC \$354,566</p>
<p>5R24CA92871-06 (Pomper) Wahl, RL: Co-PI NCI Interdisciplinary Small Animal Imaging For Oncology An important feature of our new molecular imaging center is the imaging of small animals with PET, MR and optical techniques, funded through this Small Animal Imaging Resource Program (SAIRP) grant.</p>	<p>08/27/01 – 02/29/11 \$545,472.</p>
<p>DAMD17-02-1-0112(Tsui) Wahl, RL: Co:P.I. U.S. Army CDMRP Corrective In-111 Capromab Pendetide SPECT Image Reconstruction Methods for Improved Detection of Recurrent Prostate Cancer The major goals of this project are to develop simulation tools and methods that allow efficient generation of accurate In-111 PS projection data from the human pelvic area, to study the effects of 3D image degrading factors on In-111 PS SPECT images, to develop 3D corrective image reconstruction methods for In-111 SPECT, to evaluate the 3D corrective image reconstruction methods for clinical In-111 PS SPECT studies, to evaluate the clinical efficacy of the corrective image reconstruction methods as applied to In-111 PS SPECT using patient data.</p>	<p>2/1/02-5/30/06 TDC \$73,487.</p>
<p>P50CA58236 (Coffey) Wahl, RL: P.I. on Supplemental project, “Prostate SPORE” NIH/NCI Comparison of Novel PET/CT Imaging Agents and MR/MRS in Metastatic and High Risk Prostate Cancer: An inter-SPORE Collaboration SPORE grant (specialized program of research excellence: prostate) supports a highly interactive and multidisciplinary study to impact on the control of human prostate cancer.</p>	<p>8/1/02 – 7/31/06</p>
<p>ANG206 (Wahl) GE Healthcare</p>	<p>07/01/05 – 08/31/06 \$228,448</p>

“An Open-Label, Multi-Center, Phase 2a Study to Assess the Feasibility and Safety of Intravenous Bolus Administration of 99mTc-NC100692 Injection in Imaging Metastases in Late Stage Cancer Patients (ANG206)”

The major goal of this study is to assess the feasibility and safety of intravenous bolus administration of 99mTc-nc100692 injection in imaging metastases in late stage cancer patients.

DEFG0205ER63967 (Sgouros, George) 12/15/04 – 12/14/05

Wahl RL, Co-Investigator

DOE \$226,611

Patient Specific Dosimetry and Radiobiological Modeling of Targeted Radionuclide Therapy”

The goal of this study is to analyze patient-specific dosimetry and radiobiological modeling of targeted radionuclide.

6792192 (Wahl) 07/01/02 - 12/31/05

GE \$82,645

GE Medical Systems PET Clinical Evaluate Studies

7R01CA052880-09 4/1/03 – 3/31/05

Wahl RL: PI \$367,014

NCI

Positron Emission of Breast Carcinoma

BMRP IBD-0122R (Ginsburg, Philip) 9/1/04 – 8/30/05

Wahl RL, Co-Investigator TDC \$91,075

The Eli and Edythe L. Broad Foundation

Differentiating Fibrostenosing from Inflammatory Small Bowel Disease in Patients with Crohn’s Disease Using Combined 18F-fluorodeoxyglucose Positron Emission Tomography and Computed Tomography

I P50 CA96888-01 (Ambinder) 06/29/02 – 6/30/04

Wahl, RL: P.I. on Project 4

NIH/NCI

SPORE in Lymphoma

CDC 200-2001-08015(Hendrix) 10/1/01 – 12/30/04

Wahl, RL: Co-Investigator

Centers for Disease Control

A U.S. Clinical Trial Site to Conduct Evaluations of Topical Microbicides in Men who Have Sex with Men

CA-88843-AV-15 (Stearns) 7/03 – 6/05

Wahl, RL: Co-investigator,

NCI (Avon-NCI Progress for Patients Initiative)

Response To Preoperative Therapy In Breast Cancer

CPR01018P (Tsui) 01/01/03 – 12/31/03

Wahl, RL: Co-Investigator

\$9,000

ATOMIC

IAEA Preliminary Clinical Evaluation Of Corrective Image Reconstruction Methods For Myocardial Perfusion Spect.

N490102199 (Gerstenblith) 02/08/02 – 01/07/03

PHARMUPJ

A Crossover Study Of Safety, Tolerability & Renal Effects Of Celecoxib V.Ibuprofen In Subjects With Mild To Moderate Congestive Heart Failure

Wahl, RL: Co-Investigator \$332,563

NIH/NCI 1 P50 CA96888-01

“SPORE in Lymphoma” Project 2 “Treatment of Lymphoma by Death Receptor-Induced Apoptosis”

	9/20/02 – 6/30/07	10%
Principal Investigator: Richard Ambinder, M.D.		
Project I. PI Richard L. Wahl (with A. Bedi and I. Flinn)		
Total annual direct costs of entire project:	\$1,355,078	
Annual Direct cost:	\$ 73,459 (project 2)	
NIH 5R01 CA66560-05		
"Staging Breast Cancer with PET"		
	9/30/95-7/31/01	20%
Principal Investigator: Richard L. Wahl, M.D.		
Total direct costs of entire project:	\$3,516,235	
Annual direct cost:	\$695,600	
Extension requested thru 12/04		
Centers for Disease Control contract 200-2001-08015 (Co-Investigator, R.L. Wahl; Principal Investigator C. Hendrix) A U.S. Clinical Trial Site to Conduct Evaluations of Topical Therapies)		
	10/01/01 - 09/30/04	
Total direct costs of entire project:	\$1,748,272 (TDC)	
GE M022005		
"GE Medical Systems PET/CT Clinical Evaluative Studies"		
	5/1/01 - 12/31/04	
Principal Investigator: Richard Wahl, M.D.		
Total Direct Cost of entire project:	\$300,000	
The goal of this grant is to investigate and develop Functional Imaging.		
NIH 5R01 CA 52880-08		
"Positron Emission Tomography of Breast Carcinoma"		
	06/23/92 – 03/31/04	
Total direct costs of entire project:	\$1,718,795	
Annual direct cost:	\$355,077	
Coulter Pharmaceutical, Inc.#98-2852 (Co-Principal Investigator, R.L. Wahl, Principal Investigator, M. Kaminski)		
"Re-treatment Study of Patients with Non-Hodgkin's Lymphoma who have previously responded to Iodine-131 Anti-B1 Antibody"		
	7/1/98-12/31/00	
Total direct costs of entire project:	\$62,286	
Annual direct cost:	\$31,764	
Coulter Pharmaceutical, Inc.#98-2248 (Co-Principal Investigator, R.L. Wahl, Principal Investigator, M. Kaminski)		
"Multi-Center Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (murine) radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies."		
	12/01/96 – 12/33/00	
Total direct cost of entire project:	\$287,725	
Coulter Pharmaceutical, Inc. (Co-Principal Investigator, R.L. Wahl, Principal Investigator, M. Kaminski)		
"Randomized Controlled Study to determine incremental activity and safety of 131 Iodine-radiolabeling of anti-B1 (Murine) in chemotherapy-refractory low-grade non-Hodgkin's lymphoma (NHL) in Comparison to unlabeled anti-B1 (murine)"		
	11/7/97 – 12/31/99	
Total direct cost of entire project:	\$198,470 (TDC/yr)	
NIH 2 RO1-CA60711-03 (Co-Investigator, R.L. Wahl, Principal Investigator, Jeff Fessler, Ph.D.)		
"Statistical Methods for Attenuation Correction in ECT"		

	6/1/98-4/30/03
Total direct costs of entire project:	\$349,087
Annual direct cost:	\$114,914
NIH Multi-center trial (Co-Investigator, R.L. Wahl; Principal Investigator, J Weg, MD) "Prospective Investigation of Pulmonary Embolism Diagnosis II (PIOPEDII)"	
	7/1/00-6/30/03
Total direct costs of entire project:	\$618,174
Annual direct cost:	\$164,639
Coulter Pharmaceutical, Inc. "Dosimetry of Clinical Radioimmunotherapy"	
	2/1/99-10/31/99
Total direct costs of entire project:	\$546,938
Annual direct cost:	\$346,093
Siemens Medical System, Inc. "Clinical Validation Trials of E.CAM+Nal Coincidence Package"	
	11/1/98-12/31/99
Total direct costs of entire project:	\$46,268
Coulter Pharmaceutical, Inc. "Dosimetry of Clinical Radioimmunotherapy Supplemental Agreement"	
	9/1/98-11/30/99
Total direct costs of entire project:	\$87,996
PC970288 U.S. Army Medical Research and Material Command "Pre-clinical & Clinical Evaluation of Novel Agents for Noninvasive Imaging of Prostate CA"	
	8/01/98-02/28/01
Total direct costs of entire project:	\$271,325
NIH2P30 CA46592 (Project Director: Radiopharmaceuticals Program, R. L. Wahl; Principal Investigator, Max Wicha) "Cancer Center Support Grant"	
	6/1/96-5/31/01
Total direct costs of entire project:	\$9,817,488
Annual direct cost:	\$1,967,124
NIH/NCI 5 R01 CA38790-14 (Co-Investigator, R.L. Wahl; Principal Investigator, Ken Koral, Ph.D.) "Developing Dosimetry of Radionuclides Given for Therapy"	
	12/01/00-11/30/03
Total direct costs of entire project:	\$856,011
Annual direct cost:	\$286,394
NIH/NCI 5R01 CA56794 (Co-Principal Investigator, R.L. Wahl; Principal Investigator, M.S. Kaminski) "Radioimmunotherapy of Lymphoma"	
	12/1/96-11/30/01
Total direct costs of entire project:	\$1,034,708
Annual direct cost:	\$313,766
Office of the Vice President for Research (OVPR), University of Michigan Construction of Working Prototype Hand Held Intraoperative Positron Sensitive Probe, Based on Ion Implanted Silicon Detector Technology"	
	5/1/97-1/31/99
Total direct costs:	\$30,000

Comprehensive Cancer Center Adrenal Cancer Research (R.L. Wahl)
"I-131 Phospholipidether therapy of adrenal cancer"

1/1/98-12/31/98
Total direct costs: \$10,000

Coulter Pharmaceutical, Inc. (Co-Principal Investigator, R.L. Wahl, Principal Investigator, M. Kaminski)
"Multi-Center phase II dosimetry/validation study of 131-Iodine-Anti-B1 (murine) radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies"

1/15/96 - 12/1/98
Total direct cost of entire project: \$187,264 (TDC/yr)

NIH 1 RO1 CA56731-04
"Staging Non-Small Cell Lung Cancer with PET"

9/30/93-7/31/98
Total direct costs of entire project: \$615,853.
Annual direct cost: \$161,070

NIH/NCI 5 RO1 CA33802
"Monoclonal Antibody Detection and Therapy of Cancer"

3/1/85-2/28/91
Total direct costs of entire project: \$656,088

NIH/NCI 1 RO1 CA40497
"Monoclonal Antibody Lymphoscintigraphy in Melanoma"

8/1/85-7/31/88
Total direct costs of entire project: \$405,539

Immunomedics Corporation
"Detection of Occult Colorectal Carcinoma by Diagnostic Imaging of Fab Fragment of the Anti-CEA Antibody MMU-4 Labeled With Tc99m"

2/28/91-10/31/91
Total direct costs of entire project: \$24,000

NeoRx Corporation
"Clinical Evaluation of PIP Moabs in Ovarian Cancer"

11/1/88-10/31/91
Total direct costs of entire project: \$38,462

NIH/NCI
"Radioimmunodiagnosis and Radiotherapy of Ovarian Cancer"

12/1/85-11/30/89
Total direct costs of entire project: \$404,186

NIH/NCI #5 P01 CA42768-04
"Radiopharmaceuticals for the Diagnosis and Treatment of Cancer"

9/30/87-2/29/92
Total direct costs of entire project: \$2,999,528

ACS #PDT-400
"Radiolabeled Monoclonal Antibody Directed Management of Melanoma"

7/1/90-6/30/92
Total direct costs of entire project: \$160,000

NIH (1 R55 CA52880-01A1) (Shannon Award)
"Positron Emission Tomography of Breast Cancer"

Total direct costs of entire project:	9/30/91-9/29/92 \$40,000
Mallinckrodt Medical, Inc. (92-0340) "Rhenium 186 Etidronate Therapy of Bone Metastases"	
Total direct cost of entire project:	8/15/91-8/1/93 \$31,304
Mallinckrodt Medical, Inc. "Rhenium 186 Etidronate Therapy of Bone Metastases-Breast Cancer"	
Total direct cost of entire project:	8/15/91-8/1/93 \$17,391
Diatech, Inc. "Pre-Clinical Testing of Tc-99 Labeled Peptides for Tumor Localization"	
Total direct cost of entire project:	5/1/93-7/15/94 \$109,352
Mallinckrodt, Inc. "Octreoscan in Lymphoma"	
Total direct cost of entire project:	5/25/93-5/24/94 \$43,180
NIH 5 RO1 CA 08349-25 (Co-Investigator, R.L. Wahl; Principal Investigator, R.E. Counsell) "Potential Tumor for Organ Imaging Agents"	
Total direct costs of entire project:	9/1/91-6/30/95 \$562,281
Annual direct cost:	\$188,527
dcNIH 5RO1 CA53172-05 "Positron Emission Tomography of GU Malignancies"	
Total direct costs of entire project:	3/1/91-2/29/97 \$811,186
Annual direct cost:	\$174,053
Patents:	
1/21/97	U.S. Patent No: 5,595,721 - "Radioimmunotherapy of Lymphoma Using Anti-CD20"
4/28/98	U.S. Patent No: 5,744,805 - "Solid State Beta-Sensitive Surgical Probe"
12/01/98	U.S. Patent No: 5,843,398 - "Radioimmunotherapy of Lymphoma Using Anti-CD20"
8/3/99	U.S. Patent No: 5,932,879 - "Solid State Beta-Sensitive Surgical Probe"
10/5/99	U.S. Patent No: 5,961,457 - "Method and Apparatus for Radiopharmaceutical Guided Biopsy"
1/18/00	U.S. Patent No: 6,015,542 - "Radioimmunotherapy of Lymphoma Using Anti-CD20"
2/8/00	U.S. Patent No: 6,022,521 - "Method of Establishing the Optimal Radiation Dose for Radiopharmaceutical Treatment of Disease"
6/13/00	U.S. Patent No: 6,076,009 "Solid State Beta Sensitive Probe"
7/18/00	U.S. Patent No: 6,090,365 "Radioimmunotherapy of Lymphoma Using Anti-CD20 Antibodies"
5/22/01	U.S. Patent No: 6,236,880 "Radiation-Sensitive Surgical Probe with Interchangeable Tips"
6/26/01	U.S. Patent No: 6,251,362 "Method of Establishing the Optimal Radiation Dose"
9/11/01	U.S. Patent No: 6,287,537 "Radioimmunotherapy of Lymphoma Using Anti-CD20 Antibodies"
10/2/01	U.S. Patent No: 6,295,680 "Method for Detecting Early Atherosclerosis and Vascular Damage Using Radioactive Tracers and Intravascular Radiation Detection Devices"
9/24/02	U.S. Patent No: 6,456,869 "Solid State Beta-Sensitive Surgical Probe"

5/20/03	U.S. Patent No: 6,565,827	“Anticarcinogenic Agents”
9/30/03	U.S. Patent No: 6,628,982	“Internal Marker Device of Biological Substances”
2/23/10	U.S. Patent No: 7,668,662	“Patient-specific dosimetry”
3/10/10	U.S. Patent No: 7,672,712	“Internal Marker Device of Biological Substances”
12/15/13	U.S. Patent No: 6,565,827	“Computer-aided detection (cad) system for personalized disease detection, assessment, and tracking, in medical imaging based on user selectable criteria”
10/27/15	U.S. Patent No. 9,171,369	“Computer-aided detection (CAD) system for personalized disease detection, assessment, and tracking, in medical imaging based on user selectable criteria”

Clinical Title and Responsibilities:

1/2015 Barnes-Jewish Hospital Active – Active Staff
2/2015 St. Louis Children's Hospital – Consulting Staff
2/2015 Barnes-Jewish West County Hospital – Contractual Staff

Teaching Title and Responsibilities/Educational:

NATIONAL

1987-1989 RSNA Refresher Course, "Radiolabeled Antibodies" and slide/tape series
1992- RSNA Refresher Course, "PET Imaging of Cancer"
1992-1994 Society of Nuclear Medicine, "PET Imaging of Cancer"
1994-1996 Society of Nuclear Medicine “Antibody Immunology SubChair”
1994-1998 RSNA Program Committee
1994-1999 RSNA Refresher Course, "Clinical PET"
1995 Scientific Program Chair: Institute for Clinical PET annual Meeting, San Francisco, CA
1995-1998 Society of Nuclear Medicine, “Oncology, Non-Antibody Chairman”
1998 Society of Nuclear Medicine, “Nuclear Oncology: The Future is Now”
1998 - Society of Nuclear Medicine, “FDG Imaging Without PET”

(See also invited presentations above)

UNIVERSITY OF MICHIGAN

Coordinator: Radiology Resident Teaching (Board Reviews)
(See Also Invited Lectures)

Teaching:	
Clinical Days	61
Administrative Days	66
Academic Days	92
Academic Days off-site	44
Instruction	----

DOCTORAL DISSERTATION COMMITTEE

Jeffrey Barrett (Pharmacology Program, Rackham Ph.D.)
Nichole M. Maughan (Biomedical Engineering, St. Louis, 2017)
Tuulia Vallius, M.D., University of Turku, Finland

POST DOCTORAL TRAINEES/SABBATICAL TRAINEES:

1983-1984 David A. Schultz, M.D., University of Michigan, Flint, MI
1983-1985 Marga Styra, Ph.D., University of Michigan, Flint, MI
1984-1985 Onelio Geatti, M.D., Ospedale Udine, Udine, Italy
1984-1986 Barry L. Shulkin, M.D., University of Michigan, Flint, MI
1985-1986 Ralph W. Stevens, Ph.D., University of Michigan, Flint, MI
1986-1987 Lisa VonMoll, M.D., University of Michigan, Flint, MI

1986-1988 Renato B. del Rosario, Ph.D., Purdue University, W. Lafayette, IN
 1987-1988 Maryanne Himmelsbach, Ph.D., University of California, Berkeley, Berkeley CA
 1988-1990 Lorraine M. Fig, M.B., Ch.B., University of Michigan, Flint, MI
 1989-1990 Bruce Carr, M.D., University of Michigan, Flint, MI
 1990-1991 Kotaro Higashi, M.D., Kanazawa Medical University, Kanazawa, Japan
 1990-1991 Robert Greenough, M.D., University of Sydney, NSW, Australia
 1991-1992 Lyndon Gritters, M.D., University of Michigan, Flint, MI
 1992-1993 Alan Weissman, M.D., University of Michigan, Flint, MI
 1992-1993 Morand Piert, M.D., University of Tubingen, Germany
 1993-1994 Heikki R.I. Minn, M.D., University of Turku, Finland
 1993-1994 John R. Miller, M.D., University of Southern California, Los Angeles, CA
 1993-1995 David Macfarlane, M.B., B.S., University of Queensland, Queensland, Australia
 1994-1994 Angelica Bischof Delaloye, University of Lausanne, Lausanne, Switzerland
 1994-1996 Tsutomu Miyauchi, M.D., Kanazawa Medical University, Kanazawa, Japan
 1995-1996 Shigeru Kosuda, M.D. National Defense University, Tokyo, Japan
 1995-1998 Tatsuo Torizuka, M.D., Kyoto University, Kyoto, Japan
 1996-1999 Yoshifumi Sugawara, M.D., Ehime University, Ehime, Japan
 1998-1999 Tatsuya Higashi, M.D., Kyoto University, Kyoto, Japan
 1998-2000 Kunihiko Nakada, M.D., Hokkaido, Japan
 1998-1999 Adam Tonakie, M.D., University of Queensland, Australia
 1999-2000 Tetsuya Higuchi, Gunma University, Japan
 1999-2002 Yuji Nakamoto, Kyoto University, Japan
 2000-2002 Medhat Osman, M.D., Ph.D., JHU Maryland, Baltimore, MD
 2000-2003 Christian Cohade, Laval University in Quebec City
 2001-2004 Mitsuaki Tatsumi, Ph.D. Osaka University, Japan
 2001-2004 Pavni Patel, M.D., Pranmkh Swami, Medical College, India
 2001-2002 Shelley Quarless, University of Osteopathic Medicine and Health Sciences
 2002-2005 Heather Jacene, M.D., UMDNJ-Robert Wood Johnson Medical School
 2002-2005 Kent Friedman, M.D., University of Connecticut School of Medicine
 2003-2003 Karen Mourtzikos, M.D., Albany Medical College
 2002-2002 Dima Hamoud, M.D., American University of Beirut
 2003-2005 Takayoshi Ishimori, M.D., Ph.D., Kyoto University, Kyoto, Japan
 2003-2007 Steve Cho, M.D., New York University School of Medicine
 2003-2006 William Lavelly, M.D., University of Tennessee
 2003-2004 Ron Rosen M.D., Sackler School of Medicine Tel-Aviv, Israel
 2003-2005 Sybil Goetze, M.D., Philipps University, Marburg, Germany
 2004-2004 Chi Ping Wong, M.D. Queen Elizabeth Hospital, Hong Kong
 2004-2005 Daniel Chatzifotiadis, MD, Aristotelion University, Thessaloniki, Greece
 2005-2006 Christopher Mosley, MD. St. Louis University, St. Louis, MO
 2005-2007 Tracy Brown, MD, PhD, University of Iowa, Iowa City, IA
 2005-2008 Dacian Bonta, MD, Bucharest University, Romania
 2006-2007 Ankit Chander, MD, Johns Hopkins University, Baltimore, MD
 2007- 2008 Mehrbod Javadi, MD, St. Georges University Bay Shore, NY
 2007-2008 Hubert, Chuang, MD, PhD, Washington University SOM, St.Louis, MO
 2008-2009 Thomas Heston, MD, Saint Louis University, St Louis, MO
 2008 - 2011 Muhammad Chaudhry, MD, Nishtar Medical College, Bahauddin Zakariya University
 Multan, Pakistan
 2008 - 2011 Paco Bravo, MD, Colombia, South America
 2008 - 2012 Andy Lee, MD, Georgetown University, Washington, DC
 2008 - 2011 James Ntambi, MD, Johns Hopkins University, Baltimore, MD
 2008 - 2010 Don Udall, MD, Vanderbilt University, Nashville, TN
 2008 - 2011 David Chien, MD, University of California, Davis, CA
 2008 - 2010 Ovsev Uzuner, MD, Ankara University School of Medicine, Ankara, Turkey
 2008 - 2009 Dan Mollura, MD, Johns Hopkins University, Baltimore, MD
 2009 - 2012 Abdel Tahari, MD, Ph.D, University of Illinois, Urbana-Champaign, Urbana, IL
 2009- 2011 Beryl Gok, MD, Hacettepe University, Ankara Turkey
 2009-2011 Kari Hopfer, DO, Oklahoma State. Tulsa, OK

2011-2013	Jose Baricanal, MD, Ph.D, Temple University, Washington, DC
2011-2013	Uzma Rana, MD, Ross University, North Brunswick, NJ
2011-2013	Alin Chirindel, MD, Unmiversity of Medicine & Pharmacy, Bucharest, Romania
2011-2013	Mahesh Rajaram, MD, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, India
2012-2013	Aileen Green, MD, PhD, Stanford University, Stanford, CA
2012-2014	Anthony Fotenos, MD, PhD, Washington University, St. Louis, MO
2011-2014	Michael McDonald, MD, PhD, University of Illinois, Urbana-Champaign, Urbana, IL
2012-2013	Kenneth Gage, MD, PhD, University of Pittsburgh, Pittsburgh, PA
2012-2014	Matthew Kruse, MD, University of Nebraska College of Medicine, Omaha, NE
2011-2013	Joyce Mhlanga, MB.ChB, University of Liverpool Medical School, United Kingdom
2013-2014	Anthony Ciarallo, MD, McGill University, Montreal, Canada
2013-2014	Diego Davila, MD, Universided Central del Caribe, PR (USA)
2013	Alexander Antoniou, MD, Tufts University SOM, Boston, MA
2013	Abdelkader Mohammedi, MD, University of Algiers, Algeria
2013	Riham El-Khouli, MD, Suez Canal University SOM, Ismailia, Egypt
2013	Elcin Zan, MD, Ankara University School of Medicine, Ankara, Turkey
2013	Esther Mena Gonzales, MD, Autonomous University of Barcelona, Barcelona, Spain
2014	Bernard O'Malley, MD, SUNY Upstate Medical Center, Syracuse, NY
2014	Evrin Turkbey, MD, Gazi University SOM, Ankara, Turkey
2014	Rick Wray, MD, New York Medical College, Valhalla, NY
2014	Wael Marshdeh, MD, University of Jordan SOM, Amman, Jordan
2014	Avner Meoded, MD, University of Torino, Torino, Italy
2014	Xiaofei Wang, MD, Nanjing Railway Medical College
2014	Ingrid Wu, MD, Johns Hopkins

CONTINUING MEDICAL EDUCATION (CME) LOG

Course	# Hours	Date
Ingham Regional Medical Center/Michigan State Medical Society Pulmonary Medicine Conference	2	09/29/2000
RSNA 86 th Scientific Assembly & Annual Meeting		
Interpretation of FDG PET Scans, IL	1.5	12/31/2000
Johns Hopkins Univ School of Medicine	3.5	09/21/2001
Hematologic Malignancies & Bone Marrow SNM		
Academy of Mol. ImagAnnual Conference, FL	20.25	10/24-28/2001
Amer Society for Therapeutic Radiology & Oncology, VA	3	11/07/2001
Refresher courses #401C/492C/403C/404/405/406C/407/408/409/410/411/412/; Scientific Session Z/AA/BB/CC/DD		
RSNA: NIBIB: Introduction to the National Institute of Biomedical Imaging & Bioengineering, IL	8.25	11/09/2001
The Univ of Arizona College of Medicine, AZ	2.0	11/15/2001
PET in Oncology: What a Clinician Needs to Know		
JHU SOM Nuclear Medicine Practicum	29.5	02/18-22/2002
JHU SOM Nuclear Medicine Practicum	18	5/13 - 15/2002
JHU SOM Nuclear Medicine Practicum	25.5	5/20 -24/2002
JHU SOM Nuclear Medicine Practicum	26.5	8/19 - 23/2002
"PET" (IR ²), Tyson's Corner, VA	10.25	9/19/2002
JHU SOM Nuclear Medicine Practicum	25.5	9/23 - 27/2002
8 th World Congress of WFNMB, Santiago Chile	1.5	9/29 - 10/4 2002
JHU SOM Nuclear Medicine Practicum	26.50	10/14 - 18/2002
RSNA, Chicago Illinois Interpretation of FDG PET Scans	1.50	12/1 - 6/2002
JHU SOM Nuclear Medicine Practicum	26.50	3/17 -21/2003
Current Concepts in the Multidisciplinary Management Of Colorectal Cancer	1	4/3 - 4/2003
JHU SOM Nuclear Medicine Practicum	26.5	5/19 - 23/2003

JHU SOM Nuclear Medicine Practicum	26.5	9/8 – 12/2003
Illinois Radiological Society, Chicago IL	7.25	9/13 - 14/2003
From Translational Research to Clinical Applications: State-of-the-Art PET and PET/CT- Madrid Spain	14	9/26 – 27/2003
“Functional Imaging of Cancer: Emphasis on PET and PET/CT Approaches” ASTRO, Salt Lake City, UT	1	10/22/2003
JHU SOM Nuclear Medicine Practicum	26.5	11/10 - 14/2003
RSNA Annual Meeting, Chicago, IL	8	11/30-12/5/2003
Fort Wayne Medical Education Program, Fort Wayne, IN2.0		2/11/2004
JHU SOM Nuclear Medicine Practicum	25	2/16 - 20/2004
The Role of PET/CT and SPECT/CT Imaging, Baltimore, MD	13.5	3/19 – 20/2004
“Mid Eastern Chapter Meeting, Society of Nuclear Medicine”	2	4/16 – 18/2004
JHU SOM Nuclear Medicine Practicum	31.5	4/19 - 23/2004
AOMC – PET/CT: Techniques and Applications	2	4/28/2004
“PET/CT in Clinical Practice” “PET/CT in Radiation Therapy Planning”, Society of Nuclear Medicine”, Philadelphia, PA.	2	6/20 – 6/23/2004
23 rd International Congress of Radiology, Montreal Canada	1	6/25 – 27/2004
ACLI Meeting “PET Scanning”, Baltimore, MD	1	6/29/2004
**Breast Center Case Conference/Tumor Board Meetings Baltimore, MD	5	7/103 – 6/30/04
RSNA Faculty Development Workshop	6.5	9/18/2004
JHU SOM Nuclear Medicine Practicum	26	9/20 – 9/24/2004
JHU SOM Nuclear Medicine Practicum	25	11/8 - 12/2004
RSNA, Chicago Illinois Annual Meeting	19.75	11/28-12/3/2004
JHU SOM Nuclear Medicine Practicum	25	2/7 – 11/2005
JHU SOM Nuclear Medicine PET/CT Practicum	26.50	4/18 – 22/2005
Cross-Sectional Imaging Conference, U.S Virgin Islands	21	2/24-25/2005
2005 PET Imaging Symposium at Mandalay Bay Las Vegas	5	5/13-14/2005
2005 Breast Center’s Case Conference/Tumor Board	2	2005
19 th Annual Northeast Regional Scientific Meeting	3.25	10/28-30/2005
JHU SOM Nuclear Medicine PET/CT Practicum	26.5	11/7-11/2005
RSNA Annual Meeting, Chicago, IL	18	11/28-12/02/2005
National Diagnostic Imaging Symposium	6	12/4 -8/2005
22 nd Annual Computed Body Tomography, Orlando, FL	12.75	2/16 - 19/2006
Society of Surgical Oncology, San Diego, CA	3.5	2/23-26/2006
Educational Symposia, Las Vegas, NV	9	5/5-6/2006
SNM 53 rd Annual Meeting	10.5	6/3-7/2006
Using an Integrated Approach I Evaluating Cardio Thoracic Disease, NYU, New York, NY	2	06/26-30/2006
Eleventh Conference of Cancer Therapy with Antibodies And Immunoconjugates	16.25	10/12-14/2006
Clinical PET/CT and SPECT/CT: To Plan and Monitor The Treatment of Cancer	13	10/27-28/2006
Los Angeles Radiological Society, Mid Winter Conference	6.5	1/20 – 21/2007
23 rd Annual Computed Body Tomography 2007: The Cutting Edge	19	2/15-18/2007
Oncologic Imaging for the Practicing Radiologist: PET&PET/CT	7.5	3/24-25/2007
“Role of PET Scans in Lymphoma: Staging and Treatment Monitoring”: Hematologic Malignancies	1	4/20/2007
2007 PET-CT Imaging Symposium	5.5	4/27-28/2007
8 th Annual Advances in Breast Conference	7	5/2-5/2007
Biomarkers Methodology Workshop	9.5	5/3-4/2007
New Molecular Imaging & Therapy Approaches in		

Radiology	1.5	5/16/2007
RSNA Faculty Development Workshop	4.75	9/14/2007
Perspectives in Melanoma XI	9	10/4/2007
Impact of PET/CT on Oncologic Imaging	5	10/05/2007
AACI Annual Meeting 2007	2.75	10/28/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Interventional Oncology Series: Tools & Technologies for Imaging and Intervention in Cancer, Chicago, IL	4	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Cat Crs Diag Rad: Clinical PET & PET/CT-CNS PET	1.50	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Nuclear Med. (PET/CT in Breast Cancer & Genitourinary Malignancies)	1.50	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Breast Imaging (Mammography)	1	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Cat Crs Diag Rad: Clinical PET & PET/CT-PET of the Thorax	1.50	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Radiation Oncology and Radiobiology (Lymphoma/Sarcoma)	1.50	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Annual Oration In Diagnostic Radiology and Gold Medal Awards	1.25	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Nuclear Medicine (PET/CT in Lymphoma, Melanoma and Sarcomas)	1	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Cat Crs Diag Rad: Clinical PET & PET/CT –Abdominopelvic PET/CT And the Medicare PET Registry	1.50	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Cat Crs Diag Rad: Clinical PET & PET/CT-PET of Extracranial Head & Neck And Thyroid Cancer	1.50	11/25-30/2007
RSNA 93 rd Scientific Assembly & Annual Meeting: Gastrointestinal (Liver MR: Miscellaneous)	1.50	11/25-30/2007
Nuclear Medicine Symposium 2008, St. Kitts & Nevis	13.5	1/27-31/2008
24 th Annual Computed Body Tomography 2008: The Cutting Edge, Orlando, FL	12	2/14-17/2008
Nuclear Oncology: From Genotype to Phenotype to Targeted Therapy, Baltimore, MD	13.75	3/14-15/2008
Oncology Grand Rounds, “Mind the Gap: Pathology and Targeted Cancer Therapy”	2	3/14-15/2008
Abdominal and Pelvic CT and PET/CT Anatomy for Nuclear Medicine, Read with the Experts Session - Part II	1.25	6/15/2008
Data Analysis & Management: Quantative Methods	.75	6/15/2008
SNM Plenary Session – Cassen Lectureship	.75	6/16/2008
Dosimetry/Radiobiology: Clinical Dosimetry	1.50	6/16/2008
Cardio-Basic Science: New Approaches Using SPECT, PET and Hybrid Imaging	.25	6/16/2008
Neurology: Dementia I – Diagnosis Of Alzheimers Disease	1.50	6/16/2008
New Instrumentation for Molecular Imaging	.25	6/17/2008
TMI: Technical Issues, Reproductivity And Quantification	.75	6/17/2008
New Chemistry – Oncology I: Peptides	.50	6/17/2008
Cardio Clinic: New Software, Hardware and Tracer Development II	.50	6/17/2008
Basic Science: Correlative Studies	1.25	6/17/2008
Data Analysis & Management: Oncology	.25	6/17/2008
Meet the Author III	.75	6/17/2008
Meet the Author IV	.00	6/17/2008
TMI: Imaging for Assessment of Response Therapy Planning	1.5	6/18/2008
Oncology Grand Rounds	2	8/1/2007-7/31/2008
JHU: In Vivo and Cellular Molecular Imagin Center Seminar	1	8/1/2007-7/31/2008

JNUMED/2008/056713: Manuscript Review	1	8/23/2008
JAMA & Archives: Neurologic Manifestations of von Hippel-Lindau Disease	1.0	9/22/08
Oncologic Imaging	1.0	11/14/2008
PET-CT in Radiation Treatment Planning – EANM	1.0	12/2008
CT Review for Nuclear Medicine Physicians - Nuero Radiology (cases 1-12)	2	2/6/2009
CT Review for Nuclear Medicine Physicians - Nuero Radiology (cases 13-25)	2	2/6/2009
CT Review for Nuclear Medicine Physicians - CT Chest (cases 26-37)	2	2/6/2009
CT Review for Nuclear Medicine Physicians - CT Abdomen (cases 38-50)	2	2/6/2009
CT Review for Nuclear Medicine Physicians - CT of Pelvis (cases 76-100)	0.5	2/7/2009
CT Review for Nuclear Medicine Physicians - CT Abdomen (cases 64-75)	2	2/7/2009
CT Review for Nuclear Medicine Physicians - CT Chest (cases 51-63)	2	2/7/2009
"Radiation Therapy: From External Beam to Systemic Approaches – Current Status and Future Prospects - Session 1: Systemic Radiotherapy"	1.5	2/7/2009
"Radiation Therapy: From External Beam to Systemic Approaches – Current Status and Future Prospects - Session 2: Molecular Imaging in Guiding Externam Beam Therapy"	1.5	2/7/2009
"Monitoring Cancer Therapy: Response to Toxicity - Potential for "Personalizing Patient Management"" - Evaluating Response to Cancer Therapy"	1.5	2/8/2009
"Monitoring Cancer Therapy: Response to Toxicity - Potential for "Personalizing Patient Management" - Evaluating Cardiac Toxicity of Cancer Chemotherapy"	1.5	2/8/2009
25th Annual Computed Body Tomography 2009: The Cutting Edge	16.75	2/12-15/2009
Advances in Whole Body Fusion Imaging: PET/CT and SPECT/CT	12	3/13 - 14/2009
Panel Discussion: The Future of Nuclear Medicine:		
“Where do you want to go?”	0.5	4/18/2009
“Lymphoscintigraphy and Sentinel Node Imaging in Breast Cancer:	1.0	4/18/2009
“How is Molecular Imaging Relevant to Your Clinical Practice?”	1.0	4/18/2009
“Evolving Role of Imaging in Oncology Drug Development”	1.0	4/18/2009
“The Government and You:	1.0	4/18/2009
“Update on the National PET Database Project”	1.0	4/18/2009
How Low Can You Go? To Reduce the Radiation Dose of Pediatric PET/CT and SPECT/CT”	1.0	4/18/2009
Now that you have it, What do you do? PET/CT Installation, Acceptance and Getting Started	1.0	4/18/2009
Contrast Reactions	1.0	4/19/2009
Radioimmunotherapy of Non-Hodgkins Lymphoma	1.0	4/19/2009
Imaging Strategies for Neuroendocrine Tumors	1.0	4/19/2009
Molecular Imaging Facilitating Development of New Cancer Therapeutic Agents-cost-effective Solutio for Clinical Trials - Morning Session	1.0	6/13/2009
Molecular Imaging Facilitating Development of New Cancer Therapeutic Agents-cost-effective Solutio for Clinical Trials – Afternoon Session	1.50	6/13/2009
Molecular Imaging of Hypoxia Biology – Afternoon Session	.75	6/13/2009
Computer Presentation: Session 1	1.50	6/14/2009
Plenary Sessiona and Formal Opening	.25	6/14/2009
Gynecology	1.50	6/15/2009

Meet the Author Poster Session 1: Educational Exhibits.		
Cardiovascular & Neuroscience Track Posters	.50	6/15/2009
Special Plenary Session	.50	6/15/2009
Advances in Endocrine Diseases	1.25	6/16/2009
Dosimetry/Radiology III: Radioimmunotherapy	1.50	6/16/2009
Recent Developments and Advances in Cardiac Imaginig Instrumentation	.25	6/15/2009
PET/MR	1.25	6/16/2009
Oncology Grand Rounds	1.0	8/1/2008-7/31/2009
EANM: Inflammation/Infection Imaging: Consolidated Points and New Approaches	1.6	10/15/2009
EANM: Therapy/Dosimetry RIT of Lymphomas: anti CD 20 and beyond	1.6	10/15/2009
RSNA: Clinical Trials Methodology Workshop	18.5	1/9/2010-1/15/2010
4 th Molecular Imaging and Nuclear Medicine Conference	6.0	1/28/2010
SNM: The Development of a Radiopharmaceutical for Molecular Imaging – from Bench to Bedside – Part I	3.0	1/30/2010
SNM: Advances in Molecular Imaging of the Brain	2.0	1/30/2010
SNM: Contribution of Molecular Imaging to Management Of Heart Failure	2.75	1/31/2010
JHU: Cardiac PET/CT and SPECT/CT: New Technology for Improved Patient care in Baltimore, MD	11.75	3/12/2009-3/13/2010
American Radium Society: 92 nd Annual Meeting	13.25	5/1/2010-5/4/2010
SNM: Novel Imaging Techniques and Emerging Trends In Therapy – Part I	2.25	6/05/2010
SNM: GI Non-colorectal Tumors	1.5	6/06/2010
SNM: Plenary Session and Formal Opening	.5	6/06/2010
SNM: PET/CT Anatomy, Chest, Read with the Experts	1.25	6/06/2010
SNM: Breast Cancer II	1.5	6/07/2010
SNM: Oncology: Radiopharmaceutical Therapy Radioimmunotherapy	1.0	6/07/2010
SNM: Meet the Author Poster Session III: Radiopharmaceutical Chemistry, and General Clinical Specialties Posters	.75	6/08/2010
SNM: Oncology-Basic Science: Biomarkers/Drug Delivery	1.5	6/08/2010
SNM: Advanced PET/CT/MR and SPECT/CT Scanners: Need or Extravaganza	1.25	6/08/2010
SNM: Correlative Breast Imaging: Clinical and Imaging Correlation, Different Modalities, Pro & Cons	1.5	6/08/2010
SNM: Annual Meeting Highlights	1.5	6/09/3010
SNM: Operations/Practice-Based /Outcomes Research	1.0	6/09/2010
SNM: General Practice Oncology: Non PET Topics	1.25	6/09/2010
RSNA: Opening Session: Chest, Molecular Imaging, Oncologic Imaging, Radiation Oncology	1.50	11/28/2010
RSNA: High Resolution Radionuclide Breast Imaging	1.50	11/28/2010
RSNA: Breast Imaging (MR Image Interpretation)	1.50	11/28/2010
RSNA: Scientific Poster/Education Exhibit – Chest	.50	11/28/2010
RSNA: Scientific Poster/Education Exhibit – Molecular Imaging	.50	11/28/2010
RSNA: Pendergrass New Horizons Special Lecture	1.25	11/29/2010
RSNA: Improving Your PET Practice	1.50	11/29/2010
RSNA: Imaging Biomarkers for Clinical Care	1.50	11/29/2010
RSNA: Nuclear Medicine (Chest and Cardiovascular)	1.00	11/29/2010
RSNA: PET Brain Imaging	1.50	11/30/2010
RSNA: Nuclear Imaging (Oncology: Neck and Body)	1.50	11/30/2010
RSNA: Nuclear Medicine (Endocrine)	1.00	11/30/2010
RSNA: Annual Oration in Radiation Oncology	1.25	12/01/2010
RSNA: Advances in Cardiac Nuclear Imaging: SPECT/CT and PET/CT	1.50	12/01/2010

RSNA: Nuclear Medicine (Oncology: Body)	1.50	12/01/2010
RSNA: Nuclear Medicine (Oncology: PET)	1.00	12/01/2010
RSNA: Practical Clinical Radionuclide Therapies: Thyroid, Bone, and Lymphoma	1.50	12/02/2010
RSNA: Radionuclide Imaging of Inflammation and Infection	1.50	12/02/2010
RSNA: Nuclear Medicine (Therapy and Inflammation)	1.50	12/02/2010
RSNA: Pet for Assessing Cancer Treatment Response	1.50	12/03/2010
CTMW: Introduction to Elements of a Protocol	.75	1/15/2011
CTMW: Protocol Group Meetings	2.0	1/15/2011
CTMW: Unstructured Time for Concept Development	1.0	1/16/2011
CTMW: Designing Studies of Diagnostic Imaging	1.0	1/16/2011
CTMW: Review of Statistics Concepts for Imaging	1.0	1/16/2011
CTMW: Informatics Tools for Protocol Development	.5	1/16/2011
CTMW: Diagnostic Technology Assessment – Principles and Approaches	.75	1/16/2011
CTMW: Introduction to Clinical Trials of Therapy	.75	1/16/2011
CTMW: Protocol Group Meetings	2.0	1/16/2011
CTMW: Introduction to ROC Analysis	.75	1/17/2011
CTMW: Sample Size Considerations	.75	1/17/2011
CTMW: Biases and Their Control	.75	1/17/2011
CTMW: Assessing the Predictive Value of Imaging Modalities	.75	1/17/2011
CTMW: Evidence-based Diagnostic Imaging	.75	1/17/2011
CTMW: Protocol Group Meetings	1.75	1/17/2011
CTMW: Multi-reader, Multi-modality Studies	.75	1/18/2011
CTMW: Q & A on Statistical Methods for Protocol Design	.75	1/18/2011
CTMW: Quantitative Imaging: Protocol Development and Quality Assurance Issues for Medical Imaging in Clinical Trials	.75	1/18/2011
CTMW: Image Guided Intervention (IGI) Studies	.75	1/18/2011
CTMW: Medical Ethics	1.00	1/19/2011
CTMW: Protocol Group Meetings	2.00	1/18/2011
CTMW: Unstructured Time for Protocol Development	1.00	1/18/2011
CTMW: Outcome Studies	.75	1/19/2011
CTMW: Incorporating Quality-of-Life Assessment into a Clinical Research Study	.75	1/19/2011
CTMW: Methodologic Overview of Screening Studies	.75	1/19/2011
CTMW: Introduction to Cost Effectiveness Analysis	.75	1/19/2011
CTMW: Protocol Group	3.0	1/19/2011
CTMW: Unstructured Time for Protocol Development	1.0	1/19/2011
CTMW: Sponsorship and Economics of Imaging	.75	1/20/2011
CTMW: Regulatory and Compliance Issues	.75	1/20/2011
CTMW: FDA Regulation of Imaging Modalities	.50	1/20/2011
CTMW: General Q & A Session	.25	1/20/2011
CTMW: Protocol Group Meeting	3.50	1/20/2011
Albert Einstein College of Medicine: Advances in Clinical Methods: PET/CT and SPECT/CT Imaging	20.0	2/09/2011 – 2/13/2011
SNM: Development of Isotopes for Molecular Imaging in Cancer	1.0	2/19/2011
SNM: Tc-99m Shortage: Lessons Learned	1.0	2/19/2011
SNM: Oncologic PET: Part II	1.0	2/19/2011
SNM: Oncologic PET: Part I	1.0	2/19/2011
SNM: Complementary Roles of Cardiac CT and Nuclear Cardiac Imaging in Guiding Patient Management: Navigating in Multimodality World	1.0	2/19/2011
SNM: Hepatobiliary Imaging: Case Studies	1.0	2/19/2011
ASFNR: 5 th Annual Meeting: Educational Symposium	10.0	3/02/2011 – 3/04/2011
JHU: Quantitative Nuclear Medicine to Improve Patient Outcomes	10.25	3/11/2011 – 3/12/2011
SNM: Case-Based Reviews with Emphasis on Physiologic Aspects of General Nuclear Medicine Studies	1.0	4/08/2011

SNM: Imaging CAD: The Role of MR and CT	1.0	4/08/2011
SNM: Molecular Imaging of Dementia	1.0	4/08/2011
SNM: PET-CT in Gynecological Malignancies	1.0	4/08/2011
SNM: Molecular Imaging of Movement Disorders	1.0	4/08/2011
SNM: PET/CT Reporting	1.0	4/08/2011
SNM: Introduction to GCP and 21CFR312: Research in Imaging	1.0	4/09/2011
SNM: Controversies in the Management of Thyroid Cancer	1.0	4/09/2011
SNM: Update of the Use of Sialagogues and 124I PET-CT Imaging in Differentiated Thyroid Cancer	1.0	4/09/2011
SNM: FDG-PET in Solid Tumors	1.0	4/09/2011
SNM: PET/CT in Clinical Trials	1.0	4/09/2011
SNM: 18F NaF PET CT: Principles and Practice	1.0	4/09/2011
SNM: SPECT/CT	1.0	4/09/2011
SNM: Pediatric Renal Imaging	1.0	4/10/2011
SNM: Standardization of Gastric Emptying and Sincalide Infusion Procedures	1.0	4/10/2011
SNM: Minimizing and Communicating Risk in Pediatric Nuclear Medicine	1.0	4/10/2011
SNM: Session 2: Local Staging	2.0	4/21/2011
SNM: Session 3: Locoregional and Total Body Staging	2.0	4/21/2011
SNM: Session 4: Neoadjuvant Treatment of Breast Cancer	2.0	4/21/2011
SNM: Session 5: Treatment for Metastatic Breast Cancer	2.25	4/22/2011
SNM: Session 6: Cost Effectiveness and Risks	1.25	4/22/2011
JNUMED: Manuscript Review JNUMED/2011/095471	1.0	9//01/2011
RSNA: Opening Session Panel	1.75	11/27/2011
RSNA: Hot Topics in Thoracic Imaging	1.50	11/27/2011
RSNA: Molecular Imaging (Oncology)	1.50	11/27/2011
RSNA: NM Scientific Poster/Education Exhibit	.50	11/28/2011
RSNA: Breast Imaging in the Era of Molecular Medicine	3.25	11/28/2011
RSNA: New Horizons Lecture – Pendergrass	1.25	11/28/2011
RSNA: Nuclear Medicine (Neurology)	1.0	11/28/2011
RSNA: Annual Oration in Radiation Oncology	1.25	11/30/2011
FDAF: Introduction to Elements of a Protocol	0.75	1/14/2012
RSNA: Protocol Group Meeting	2.0	1/14/2012
RSNA: Unstructured Time for Concept Development	1.0	1/15/2012
RSNA: Designing Studies for Diagnostic Imaging	1.0	1/15/2012
RSNA: Review of Statistical Concepts and Imaging	1.0	1/15/2012
RSNA: Informatics Tools for Protocol Development	0.75	1/15/2012
RSNA: Diagnostics Technology Assessment	0.75	1/15/2012
RSNA: Protocol Group Meetings	2.0	1/15/2012
RSNA: Biases and Their Control	0.75	1/16/2012
RSNA: Introduction to ROC Analysis	0.75	1/16/2012
RSNA: Sample Size Consideration	0.75	1/16/2012
RSNA: Assessing the Predictive Value of Imaging Modalities	0.75	1/16/2012
RSNA: Imaging as a Predictor of Therapeutic Response	0.75	1/16/2012
RSNA: Evidence-based Diagnostic Imaging	0.50	1/16/2012
RSNA: Protocol Group Meetings	1.75	1/16/2012
RSNA: One-on-One: Protocol Developments Appointments	0.25	1/16/2012
RSNA: Multi-reader, Multi-Modality Studies	0.50	1/17/2012
RSNA: Quantitative Imaging: Protocol Development and Quality Assurance Issues for Medical Imaging in Clinical Trials	0.75	1/17/2012
RSNA: Image Guided Intervention (IGI) Studies	0.75	1/17/2012
RSNA: Regulatory, Compliance Ethics and Informed Consent	1.0	1/17/2012
RSNA: Protocol Group Meetings	2.0	1/17/2012
RSNA: Unstructured time for Protocol Development	1.0	1/17/2012
RSNA: Outcomes Studies	0.75	1/18/2012

RSNA: Incorporating Quality-of-Life Assessment into a Clinical Research Study	0.75	1/18/2012
RSNA: Methodologic Overview of Screening Studies	0.50	1/18/2012
RSNA: Introduction to Cost Effectiveness Analysis	0.50	1/18/2012
RSNA: Protocol Group Meetings	3.0	1/18/2012
RSNA: Unstructured Time for Protocol Development	1.0	1/18/2012
RSNA: Sponsorship and Economics of Imaging	0.75	1/19/2012
RSNA: FDA Regulation of Imaging Modalities	0.75	1/19/2012
RSNA: The Best Laid Plans	0.50	1/19/2012
RSNA: Protocol Group Meeting	3.25	1/19/2012
SNM: CT Case Review Workshop: Head & Neck (Cases1-25)	4.0	1/27/2012
SNM: Session II – Integrating Imaging into Therapeutic Clinical Trials	3.75	1/27/2012
SNM: What is the future? Revised USP Chapter 823 and PET Monograph	2.0	1/27/2012
SNM: Theronastics	3.0	1/28/2012
SNM: Musculoskeletal Disease: F-18 Sodium Fluoride, Pediatric Bone Imaging and Infection Imaging	3.75	1/28/2012
SNM: CT Case Review: Musculoskeletal System (Cases76-100)	4.0	1/28/2012
SNM: Imaging Cancer versus Inflammation	1.0	1/29/2012
SNM: CT Case Review Workshop: Head & Neck (Cases1-25)	4.0	2/07/2012
SNM: Case Review: Musculoskeletal System (Cases76-100)	4.0	2/07/2012
JHU: CME Nuclear Medicine		3/9/2012 - 3/10/2012
SNMMI: Sarcoma, Melanoma & Other Tumors	1.50	6/11/2012
SNMMI: Meet the Author Poster Session II	0.50	6/12/2012
SNMMI: Molecular Imaging in Breast Cancer II	1.50	6/12/2012
SNMMI: Molecular Imaging Basic Science Summary Session	1.0	6/12/2012
SNMMI: Lymphoma and PET/CT: A Good Marriage?	1.25	6/12/2012
SNMMI: Musculoskeletal: Assessment of the Joint	0.50	6/13/2012
SNMMI: Technological Advances, Methodology, Quantifications	0.50	6/13/2012
SNMMI: Presentation of Annual Meeting Highlights	1.75	6/13/2012
RSNA: High Resolution Radionuclide, Breast Imaging	1.50	11/25/2012
RSNA: MI Scientific Poster/Education	0.50	11/25/2012
RSNA: Special Session:What Imaging Measurements Are needed in Clinical Practice	1.50	11/26/2012
RSNA: Critical Issues Facing the Profession of Radiology An ACR Leadership Perspective	1.50	11/26/2012
RSNA: MI Scientific Poster/Education	0.50	11/26/2012
RSNA: Monday Plenary Session	1.25	11/26/2012
RSNA: Compensation Plans	1.50	11/28/2012
RSNA: Molecular Imaging (Oncology III)	1.50	11/28/2012
RSNA: Wednesday Plenary Session	1.25	11/28/2012
RSNA: CTMW Workshop Overview	0.50	1/12/2013
RSNA: CTMW Protocol Group Meetings	2.25	1/12/2013
RSNA: CTMW Unstructured Time for Concept Development	1.00	1/13/2013
RSNA: CTMW Designing Studies of Diagnostic Imaging	1.0	1/13/2013
RSNA: CTMW Review of Statistical Concepts for Imaging	1.0	1/13/2013
RSNA: CTMW Informatics Tools for Protocol Development	0.50	1/13/2013
RSNA: CTMW Diagnostic Technology Assessment- Principles and Approaches	0.75	1/13/2013
RSNA: CTMW Introduction to Clinical Trials of Therapy	0.75	1/13/2013
RSNA: CTMW Working Lunch/Protocol Group	2.75	1/13/2013
RSNA: CTMW Outcomes Studies	0.75	1/14/2013
RSNA: CTMW Biases and Their Control	0.75	1/14/2013
RSNA: CTMW Assessing the Predictive Value of Imaging Modalities	0.75	1/14/2013
RSNA: CTMW One-on-One Protocol Development Appointments	1.00	1/14/2013
RSNA: CTMW Working Lunch/Protocol Group Meeting	2.25	1/14/2013

RSNA: CTMW Image Guided Intervention (IGI) Studies	0.75	1/14/2013
RSNA: CTMW Introduction to ROC Analysis	0.50	1/14/2013
RSNA: CTMW Regulatory, Compliance, Ethics and Informed Consent	0.75	1/15/2013
RSNA: CTMW Quantitative Imaging: Protocol Development and Quality Assurance Issues for Medical Imaging in Clinical Trials	0.75	1/15/2013
RSNA: CTMW Imaging as a Predictor of Therapeutic Response	0.75	1/15/2013
RSNA: CTMW Working Lunch/Protocol Group Meeting	2.00	1/15/2013
RSNA: CTMW Multi-reader, Multi-modality Studies	0.75	1/15/2013
RSNA: CTMW One-on-One appointments with Faculty	0.25	1/15/2013
RSNA: CTMW Sample Size Considerations	0.75	1/15/2013
RSNA: CTMW Unstructured Time for Protocol Development	1.00	1/15/2013
RSNA: CTMW Working Lunch and Protocol Group Meetings	3.25	1/16/2013
RSNA: CTMW Unstructured Time for Protocol Development	1.00	1/16/2013
RSNA: CTMW Methodologic Overview of Screening Studies	0.50	1/16/2013
RSNA: CTMW Incorporating Quality of Life Assessments Into a Clinical Research Study	0.75	1/16/2013
RSNA: CTMW Statistical Modeling	0.75	1/16/2013
RSNA: CTMW Introduction of Cost Effectiveness Analysis	0.75	1/16/2013
RSNA: CTMW Sponsorship of Economics of Imaging	0.75	1/17/2013
RSNA: CTMW Post-Test	1.00	1/17/2013
RSNA: CTMW PDG Group Meeting and time to finalize projects	3.25	1/17/2013
RSNA: CTMW FDA Regulations of Imaging Modalities	0.50	1/17/2013
RSNA: CTMW Question and Answer Session Panel	0.50	1/17/2013
SNMMI: New PET Pharmaceuticals in Brain Imaging	1.0	1/27/2013
SNMMI: Update in Targeted Radionuclide Cancer Therapy	4.0	2/26/2013
AACR-SNMMI: State of the Art Molecular Imaging in Cancer Biology and Therapy	16.0	2/27/2013-3/02/2013
JHU: CME Nuclear Medicine March 2013		3/8/2013 – 3/09/2013
SNMMI: General Nuclear Medicine Update: The Tried and True – Getting Better with Age	3.0	3/19/2013
SNMMI: Advances in Clinical Nuclear Cardiology	3.0	3/19/2013
SNMMI: Translational Cardiovascular Molecular Imaging	1.0	3/19/2013
SNMMI: PET Quantification	2.0	3/19/2013
SNMMI: CT Case Review: Musculoskeletal(Cases 88-100)	1.0	3/19/2013
SNMMI: Gallbladder Ejection Fraction in Chronic Abdominal Pain with Review of Challenging Cases	1.0	4/13/2013
SNMMI: When Should PET be used in Cancer Patient?	1.0	4/13/2013
SNMMI: PET/Ct Methods, Pitfalls and Incidentalomas	1.0	4/13/2013
SNMMI: PET/CT Applications in Breast Cancer	1.0	4/13/2013
SNMMI: Will Metabolic and Autonomic Molecular Imaging Approaches Keep Nuclear Cardiology Relevant?	1.00	4/13/2013
SNMMI: CZT-SPECT as compared to other currently available Cardiac perfusion imaging options	1.0	4/13/2013
SNMMI: Radionuclide Thyroid Therapy: 123I Diagnostic Scans And Second Primary Cancer after Therapy	1.0	4/13/2013
SNMMI: CFR vs. FFR: Exploring the Interface between PET And the Catheterization Laboratory	1.0	4/13/2013
RSNA: CTMW – Pre-Test	1.0	1/11/2014
RSNA: CTMW – Protocol Group Meetings	2.25	1/11/2014
RSNA: CTMW – Workshop Overview	0.50	1/11/2014
RSNA: CTMW – Designing Studies of Diagnostic Imaging	1.0	1/12/2014
RSNA: CTMW – Review of Statistical Concepts for Imaging	0.75	1/12/2014
RSNA: CTMW- Informatics Tools for Protocol Development	.050	1/12/2014
RSNA: CTMW – Introduction to Clinical Trials of Therapy	0.75	1/12/2014

RSNA: CTMW- Diagnostic Technology Assessment -Principles and Approaches	1.0	1/12/2014
RSNA: CTMW- Unstructured Time for Concept Development	1.0	1/12/2014
RSNA: CTMW- Working Lunch/ Protocol Group Meetings	2.75	1/12/2014
RSNA: CTMW- One-on-One Protocol Development Appointments	1.0	1/13/2014
RSNA: CTMW- Working Lunch/Protocol Group Meetings	2.25	1/13/2014
RSNA: CTMW- Outcome Studies	1.0	1/13/2014
RSNA: CTMW- Introduction to ROC Analysis	0.75	1/13/2014
RSNA: CTMW- Biases and Their Control	0.75	1/13/2014
RSNA: CTMW- Image Guided Intervention (IGI) Studies	0.75	1/13/2014
RSNA: CTMW- Statistical Modeling	0.75	1/13/2014
RSNA: CTMW- Imaging as a Predictor of Therapeutic Response	0.75	1/14/2014
RSNA: CTMW- Sample Size Considerations	0.75	1/14/2014
RSNA: CTMW- Multi-reader, multi-modality Studies	0.75	1/14/2014
RSNA: CTMW- Working Lunch/Protocol Group Meetings	2.0	1/14/2014
RSNA: CTMW- One-on-One appointments with Faculty	1.0	1/14/2014
RSNA: CTMW- Assessing New Quantitative Imaging Biomarkers	0.75	1/14/2014
RSNA: CTMW- Methodologic Overview of Screening Studies	1.0	1/14/2014
RSNA: CTMW- Unstructured Time for Protocol Development	1.0	1/14/2014
RSNA: CTMW- Unstructured Time for Protocol Development	1.0	1/15/2014
RSNA: CTMW- Working Lunch and Protocol Group Meetings	2.75	1/15/2014
RSNA: CTMW- Regulatory, Compliance, Ethics/Informed Consent	0.75	1/15/2014
RSNA: CTMW- Incorporating Quality-of-Life Assessment Into a Clinical Research Study	0.75	1/15/2014
RSNA: CTMW- Quantitative Imaging: Protocol Development and Quality Assurance Issues	0.75	1/15/2014
RSNA: CTMW- Introduction to Cost Effective Analysis	0.75	1/15/2014
RSNA: CTMW- Question and Answer Session Panel	0.75	1/16/2014
RSNA: CTMW- PDG group meetings/time to finalize protocols	2.75	1/16/2014
RSNA: CTMW- Post-Test	1.0	1/16/2014
RSNA: CTMW- Sponsorship and Economics of Imaging	0.75	1/16/2014
RSNA: CTMW- The Best Laid Plans – Health Policy	0.75	1/16/2014
AACR: Clinical Trials Design Workshop, Part I: Design and Implementation of Innovative Clinical Trials	2.0	4/05/2014
AACR: Novel Approaches to Re-Awakening the Immune System	2.0	4/05/2014
AACR: Immune Modulation for the Treatment of Lung Cancer	2.0	4/05/2014
AACR: Approaches and Challenges in Studying Cancer Metabolism	2.0	4/05/2014
AACR: Harnessing Breakthroughs, Targeting Cures	3.0	4/06/2014
AACR: Beyond Big Data: Empowering Cancer Omics with Regulatory Models	2.0	4/06/2014
AACR: Blocking the PD-1/PD-L1 Pathway in Cancer Therapy	2.0	4/07/2014
AACR: Eighth Annual AACR Princess Takamatsu Memorial Lectureship	1.0	4/07/2014
AACR: Neuroendocrine Cancer: Current Molecular and Genomic Strategies in Diagnosis and Management	2.0	4/08/2014
AACR: CIMT-AACR-CIMM Joint Session on Deciphering and Modulating T-Cell Specificity in Clinically Effective Antitumor Responses	2.0	4/08/2014
AACR: Nineteenth Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Res	1.0	4/08/2014
SCARD: Leadership and Management in Radiology Program	8.25	10/15/2014-10/16/2014
WUSM: Discussions in Nuclear Medicine	3.0	1/1/2014-12/31-2014
RSNA: CTMW-Clinical Trials Methodology Workshop	33.75	1/10/2015-1/16/2015
AACR-SNMMI: State of the Art Molecular Imaging in Cancer Biology and Therapy	18.25	2/11/2015-2/14/2015
JHU: Third Theranostics World congress on Gallium-68	6.75	3/12/2015

JHU:	Third Theranostics World congress on Gallium-68	7.25	3/13/2015
JHU:	Third Theranostics World congress on Gallium-68	5.75	3/14/2015
RSNA: AUR	Poster Discussion Session	1.25	4/14/15-4/17/15
RSNA: AUR	Engaging Medical Students: Beyond the Gross Lab and the Reading Room	1.50	4/14/15-4/17/15
RSNA: AUR	AUR Plenary: Radiologists' Value in a Changing World	1.50	4/14/15-4/17/15
RSNA: AUR	Vydareny Imaging Interpretation Competition 2	.75	4/14/15-4/17/15
RSNA: AUR	Making Lemons into Lemonade: The Milestones And Recruiting the Next Generation of Radiologists	1.50	4/14/15-4/17/15
RSNA: AUR	Collaborators outside of your Radiology Department	1.50	4/14/15-4/17/15
RSNA: AUR	The New Interventional Radiology Residency: Innovations in Academic Radiology Program: Imaging and Teamwork	2.0	4/14/15-4/17/15
RSNA: AUR	SS03: Education of Residents	1.50	4/14/15-4/17/15
AACR:	What Can Proteomics Teach Us that Genetics Cannot?	2.0	4/18/2015
AACR:	Detecting Treatment Response and Investigating the Tumor Microenvironment Using Magnetic Resonance Imaging	2.0	4/18/2015
AACR:	Principles of Immunotherapy: Stepping on the Accelerator	2.0	4/18/2015
AACR:	Systems Approachs to Cancer Metabolism	2.0	4/18/2015
AACR:	Tumor Dormancy and Recurrence	1.0	4/19/2015
AACR:	Opening Plenary: The Genome and Beyond	3.25	4/19/2015
AACR:	Imaging of Immunotherapy in Action	2.0	4/19/2015
AACR:	Drug Discovery: New Targets and Antibody Drug conjugates	1.25	4/19/2015
AACR:	Therapy of Lymphoma Inspired by Functional and Structural Genomics	1.0	4/20/2015
AACR:	Precision Medicine comes to Cancer Prevention and Screening	2.0	4/20/2015
AACR:	Mechanistic Targets and Intervention Strategies for Breaking the Obesity-Cancer Link	2.0	4/20/2015
SNMMI:	PET/MRI Has Arrived . . . But Where Do We Go From Here?	6.5	6/6/2015
ASCO:	New Evidence on the Role of Surgery and PET Scans After Primary Chemoradiotherapy	1.5	6/1/2015
ASCO:	ASCO/Society of Nuclear Medicine and Molecular Imaging (SNMMI) Joint Session: Targeted Radionuclide Therapy	1.25	6/1/2015
ASCO:	Controversies in Neoadjuvant Therapy for Breast Cancer: Surgery, Radiation, and Therapeutic Trials	.75	6/1/2015
MedRisk	Risk Management Rounds: Radiology, Second Edition	5.00	11/9/2015
SCARD	Society of Chairs of Academic Radiology Departments Fall	10.75	10/15-17, 2015
RSNA: AUR	Finance Strategies for Radiology Research	1.5	3/29/16-4/1/16
RSNA: AUR	How do We Enhance the Diversity of Radiology? Chairs' Perspectives	1.5	3/29/16-4/1/16
RSNA: AUR	The Future of Nuclear Medicine Training	1.5	3/29/16-4/1/16
RSNA: AUR	AUR Plenary Session	1.5	3/29/16-4/1/16
RSNA: AUR	Can Radiologists Do Health Care Disparities Research?	1.5	3/29/16-4/1/16
RSNA: AUR	A Challenge for Radiology Leadership: A More Diverse Field by 2020	1.5	3/29/16-4/1/16
RSNA: AUR	GERRAF Session 3: Collaboration in Health Services Research Training and ED, RS Mentoring	1.5	3/29/16-4/1/16
ASCO	American Society of Clinical Oncology 2016 meeting	23.75	6/3/16-6/6/16
SNMMI	PL4: Henry N. Wagner, Jr., MD Highlights Symposium	1.75	6/15/2016
SNMMI	SS95: Leukemia/Lymphoma/Myeloma II	1.25	6/15/2016
SNMMI	SS85: First-in-Human Imaging Studies	1.25	6/15/2016
SNMMI	SS80: Infectious Disease/Hematology	1.5	6/14/2016

SNMMI	CE83: Loewinger-Berman Award: Clinical Significance of Cell Level Dosimetry for Treating Prostate and Breast Cancer with Alpha Particle Emitters	0.5	6/14/2016
SNMMI	CE69: First-in-Human Imaging Tracers: Fluorescent Optical Tracers	1.5	6/14/2016
SNMMI	CE62: Peter E. Valk, MD Memorial Lectureship and Award	1.25	6/14/2016
SNMMI	CE56: Saul Hertz Award Symposium: Theranostics	1.5	6/13/2016
SNMMI	CE49: Management and Leadership in Nuclear Medicine and Molecular Imaging II	1.5	6/13/2016
SNMMI	CE35: Management and Leadership in Nuclear Medicine and Molecular Imaging, I	1.25	6/13/2016
SNMMI	CE23: Radium-223 Dichloride Therapy: What We Have Learned Since ALSYMPCA		1.5 6/12/2016
RSNA	MIS-MOA Molecular Imaging Monday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	MIS-MOB Molecular Imaging Monday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	MIS-SUA Molecular Imaging Sunday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	MIS-SUB Molecular Imaging Sunday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	MIS-TUB Molecular Imaging Tuesday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	MSMI21 Molecular Imaging Symposium: Basics of Molecular Imaging	1.5	11/27/16-12/2/16
RSNA	MSMI22 Molecular Imaging Symposium: Oncologic MI Applications	1.5	11/27/16-12/2/16
RSNA	MSMI24 Molecular Imaging Symposium: Teaching Residents and Their Teachers about Molecular Imaging with Cases: Has the Time Come?		1.5 11/27/16-12/2/16
RSNA	MSSR41 RSNA/ESR Hybrid Imaging Symposium: The ABCs of Hybrid Imaging	1.5	11/27/16-12/2/16
RSNA	NMS-THA Nuclear Medicine Thursday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	NMS-THB Nuclear Medicine Thursday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	NMS-TUA Nuclear Medicine Tuesday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	NMS-WEA Nuclear Medicine Wednesday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	NMS-WEB Nuclear Medicine Wednesday Poster Discussions	0.5	11/27/16-12/2/16
RSNA	PS12 Sunday Afternoon Plenary Session	1.75	11/27/16-12/2/16
RSNA	PS20 Monday Plenary Session	1.25	11/27/16-12/2/16
RSNA	PS30 Tuesday Plenary Session	1.25	11/27/16-12/2/16
RSNA	PS40 Wednesday Plenary Session	1.25	11/27/16-12/2/16
RSNA	PS50 Thursday Plenary Session	1.25	11/27/16-12/2/16
RSNA	RC101 A Practical Guide to Lung Cancer Screening	1.5	11/27/16-12/2/16
RSNA	RC323 Molecular Imaging Mini-Course: Basics of Molecular Imaging	1.5	11/27/16-12/2/16
RSNA	RC417 Emerging Technologies: Prostate Cancer Imaging & Management	1.5	11/27/16-12/2/16
RSNA	RC618 Interactive Game: Challenging Cases in Body Oncologic Imaging	1.5	11/27/16-12/2/16
RSNA	SSGo8 Science Session with Keynote: Molecular Imaging (Brain)	1.5	11/27/16-12/2/16
RSNA	SSJ14 Molecular Imaging (Inflammation/Metabolism/Musculoskeletal)	1	11/27/16-12/2/16
RSNA	SSK13 Nuclear Medicine (Central Nervous System and Head and Neck Imaging)	1.5	11/27/16-12/2/16
RSNA	SSM15 Nuclear Medicine (Comparative Methodologies and Emerging Technologies)		1 11/27/16-12/2/16
RSNA	SSQ11 Molecular Imaging (New Tracers/Methods)	1.5	11/27/16-12/2/16
RSNA:	CTMW-Clinical Trials Methodology Workshop	37.75	1/7/2013-1/13/2017
JHMI	Enhance Patient Care with Nuclear Medicine and Molecular Imaging	12	3/10/2017-3/11/2017
SCARD		14.5	10/12/17-10/14/17
RSNA	Creating and Optimizing the Research Enterprise (CORE) Workshop	11.75	10/20/17-10/21/17

Bibliography:

Peer reviewed manuscripts (“h”–index approx 91, Google Scholar)

1. Wahl RL, Meo T, Shreffler D, et al. C2 deficiency and a lupus erythematosus-like illness: family re-evaluation. *Ann Intern Med.* Apr 1979; 90(4):717-718
2. Wahl RL, Bliznak J, Gilula L. Roentgen Rounds #56 (Klippel-Feil Syndrome). *Orthopedic Rev* 1981; X:61-65
3. Wahl RL, Philpott G, Parker CW. Monoclonal antibody radioimmunodetection of human-derived colon cancer. *Invest Radiol.* Jan-Feb 1983;18(1):58-62
4. Wahl RL, Parker CW, Philpott GW. Improved radioimaging and tumor localization with monoclonal F(ab')₂. *J Nucl Med* 1983; 24:316-325
5. Wahl RL, Lee ME. Pelvic radionuclide angiography in the diagnosis of gastrointestinal bleeding. *Radiology* 1984; 151:793-794
6. Wahl RL, Lee ME. Increased genital uptake of 99mTc red blood cells: A potential cause of false-positive studies for gastrointestinal bleeding. *Eur J Nucl Med* 1984; 9:245-246
7. Wahl RL, The "Water-Ida": A simple means to separate duodenal from gallbladder activity on cholescintigraphic studies. *Eur J Nucl Med* 1984; 9:335-336
8. Wahl RL, Ziessman HA, Juni J, Lahti D. Gastric air contrast: Useful adjunct to hepatic artery scintigraphy. *Amer J Roent* 1984; 143:321-325
9. Wahl RL, Sherman P, Fisher S. The Effect of specimen processing on radiolabeled monoclonal antibody biodistribution. *Eur J Nucl Med* 1984; 9(8):382-384
10. Wilton GP, Wahl RL, Juni JE, Froelich JW. Detection of gastritis by 99m-Tc labelled red blood cell scintigraphy. *Am J Roentology* 1984; 143:759-760
11. Stya M, Wahl RL, Beierwaltes WH. Dot-based Elisa and RIA: Two rapid assays that screen hybridoma supernatants against whole live cells. *J Immunol*, 1984; 73:75-81
12. Glowniak JV, Wahl RL. Patient motion artifacts on scintigraphic gastric emptying studies. *Radiology.* 1985; 154:537-538
13. Ziessman HA, Gyves JW, Juni JE, Wahl RL, Thrall JH, Ensminger WD, Goldstein HA and Dubiansky V. Atlas of hepatic arterial perfusion scintigraphy. *Clin Nucl Med* 1985; 10(9): 675-681
14. Wahl RL, Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy. *J Nucl Med* 1985; 26(2):208-209
15. Wahl RL, Parker CW. Monoclonal antibody radioimmunodetection of transplant rejection. *Transplantation.* 1985; 40(4):451-454.
16. Ziessman HA, Wahl RL, Juni JE, Gyves JE, Ensminger WD, Thrall JH, Keyes JW and Walker SC. The utility of SPECT for Tc-99m MAA hepatic arterial perfusion scintigraphy. *Am J Roent* 1985; 145:747-751
17. Tuscan MJ, Wahl RL, Botti J. Dynamic graded subtraction: A simple method to background correct and display multicompartamental radiopharmaceutical scintigrams. *J Nucl Med Tech* 1985; 13(3):121-124
18. Schultz DA, Shapiro B, Amendola M, Sherman, Wahl RL. Tomographic renal cortical scintigraphy: Correlation with intravenous urography, computed tomography, ultrasonography, angiography and nuclear magnetic resonance. *Eur J Nucl Med* 1985; 11(6-7):217-220
19. Ziessman HA, Forastiere AA, Wheeler RH, Juni JE, Wahl RL, Medvec BR, Ackermann RJ, Baker SR, Thrall JH, Keyes JW. The use of a vasoconstrictor to improve tumor blood flow in intra-arterial chemotherapy. Preliminary Report, *Nucl Med Comm* 1985; 6(12):777-786
20. Taasan V, Shapiro B, Taren JA, Beierwaltes WH, McKeever P, Wahl RL, Carey JE, Petry N and Mallette S. Phosphorus-32 therapy of cystic grade IV astrocytomas: Technique and preliminary application. *J Nucl Med* 1985; 26:1335-1338
21. Schultz DA, Wahl RL, Juni JE, Buda AJ, McMeekin JD, Struble LR. Scintigraphic phase analysis of left anterior hemiblock. *Nucl Med Comm* 1986; 7(3):191-196
22. Schultz DA, Wahl RL, Juni JE, Buda AJ, McMeekin JD, Struble LR, Tuscan MJ. Diagnosis of exercise-induced left bundle branch block at rest by scintigraphic phase analysis. *Eur J Nucl Med* 1986; 11(11):434-437
23. Steffey DT, Wahl RL, Shapiro B. Diabetic esophagoparesis: Assessment by solid phase radionuclide scintigraphy. *Nucl Med Comm* 1986; 7(3):165-171
24. Tuscan MJ, Wahl RL, Juni JE, Swanson DP. Validation of diagnostic software. *J Nucl Med* 1986; 27(3):436

25. Wahl RL, Tuscan MJ, Botti JM. Dynamic variable background subtraction: A simple means of displaying radiolabeled monoclonal antibody scintigraphy. *J Nucl Med* 1986; 27:545-548
26. McMeekin JD, Wahl RL, LeGrand V, Juni JE, Wu-Connolly L, Wathen BD. Left ventricular potentiation at a reduced exercise level: A cause of false negative radionuclide ventriculography. *Am J Physiol Imaging* 1986; 1:59-66
27. Wahl RL, Kumar B, Biello D, Miller TR. The (F) utility of the thallium-201 quantitative lung/myocardial ratio in the detection of coronary artery disease. *Eur J Nucl Med* 1986; 12(1):5-8
28. Wahl RL, Gastric Xenon trapping mimicing COPD: Recognition using an effervescent agent. *Eur J Nucl Med* 1986; 12:155-157
29. Lynn MD, Braunstein EM, Wahl RL, Shapiro B, Gross MD, Rabbani R. Bone metastases in pheochromocytoma: Comparative studies of efficacy of imaging. *Radiology*. 1986; 160:701-706
30. Shapiro B, Carey JE, Taasan V, Taren JA, Beierwaltes WH, McKeever P, Wahl RL, Petry N, Mallette S: Dosimetry for cystic-type tumors. Reply to letter to the Editor. *J Nucl Med* 1986; 27(9):1501-1503
31. Shapiro B, Carey JE, Taasan V, Taren JA, Beierwaltes WH, McKeever P, Wahl RL, Petry N, Mallette S. Phosphorus-32 therapy of cystic brain tumors. Reply to Letter to the Editor. *J Nucl Med* 1986; 27(9):1503-1504
32. Sulkin B, Dafoe DC, Wahl RL. Simultaneous pancreatic-renal transplant scintigraphy. *Am J Roent* 1986; 147:1193-1196
33. Wahl RL, Liebert M, Wilson BS. The influence of radiolabeled monoclonal antibody dose on tumor uptake of radiolabeled antibody. *Cancer Drug Deliv*. 1986; 3(4):243-249
34. Amstein NB, Wahl RL, Cochran M, Gyves J. Adenocarcinoma of the alimentary tract: Peritoneal distribution scintigraphy. *Radiology*. 1987; 162:439-441
35. McKeever PE, Hood TW, Varani J, Taren JA, Beierwaltes WH, Wahl RL, Liebert M, Nguyen PK. Products of cells cultured from gliomas: V. Cytology and morphometry of two cell types cultured from gliomas. *J Nat Canc Inst*. 1987; 78(1):75-84
36. Wahl RL, Khazaeli MB, LoBuglio AF, Patillo RA, Tuscan MJ, Beierwaltes WH. Radioimmunoscintigraphic detection of occult gestational choriocarcinoma. *Am J Obstet Gynecol*. 1987; 156:108-111
37. Wahl RL, Kimmel KA, Beierwaltes WH, Carey TE. Radioimmunodiagnosis of human-derived squamous cell carcinoma. *Hybridoma*. 1987; 6(2):111-119
38. Wallis JW, Gubin B, Andrews JC, Wahl RL. Gall bladder visualization on hepatic artery perfusion scintigraphy. *Clin Nucl Med*. 1987; 12(5):405-406
39. Stya M, Wahl RL, Natale R, Beierwaltes WH. Radioimmunoimaging of human small cell lung carcinoma xenografts in nude mice receiving several monoclonal antibodies. *NCI Monogr*. 1987; 3:19-23
40. McKeever PE, Smith BH, Taren JA, Wahl RL, Kornblith PL, Chronwall BM. Products of cells cultured from gliomas: VI. Immunofluorescent, morphometric and ultrastructural characterization of two different cell types growing from explants of human gliomas. *Am J Pathol*. 1987; 127(2):358-372
41. Wallis JW, Fisher S, Wahl RL. ^{99m}Tc uptake by lymph nodes following tracer infiltration: Clinical and laboratory evaluation. *Nucl Med Comm*. 1987; 8:357-363
42. Wahl RL, Wilson BS, Liebert M, Beierwaltes WH. High-dose, unlabeled, non-specific antibody pre-treatment: Influence on specific antibody localization to human melanoma xenografts. *Cancer Immunol Immunother*. 1987; 24(3):221-224
43. Wahl RL, McMeekin JD, LeGrand V, Wathen BD. Potentiation of right ventricular function at a reduced workload: A potential pitfall in assessing right ventricular function by exercise radionuclide ventriculography. *Am J Physiol Imaging*. 1987; 2:61-66
44. Liebert M, Laino L, Wahl RL. A semi-automated fluorescent (SAF) assay using viable, whole cells for screening hybridomas supernatants. *J Immunol Methods*. 1987; 101:85-90
45. Eberbach MA, Wahl RL, Argenta LC, Froelich J, Niederhuber JE. Utility of lymphoscintigraphy in directing surgical therapy of head, neck and upper thorax melanomas. *Surgery*. 1987; 102(3):433-442
46. Rodrigues L, Liebert M, Natale R, Wahl RL. Monoclonal antibody (5G6.4) against ovarian carcinoma shows inhibition of in vitro colony formation. *Gynecol Oncol*. 1987; 27(3):382-388
47. Wahl RL, Fisher S. Intraperitoneal delivery of monoclonal antibodies: Enhanced regional delivery advantage using intravenous unlabeled anti-mouse antibody. *Nucl Med Biol*. 1987; 14(6):611-615

48. Wahl RL, Geatti O, Liebert M, Wilson B, Shreve P, Beers BA. Kinetics of interstitially administered monoclonal antibodies for purposes of Lymphoscintigraphy. *J Nucl Med.* 1987; 28(11):1736-1744
49. Shulkin BL, Wahl RL. SPECT imaging of myocarditis. *Clin Nucl Med.* 1987; 12(11):841-842
50. Wahl RL, Laino L, Fisher S, Schteingart M, Beierwaltes WH. Improved radioimmunolocalization of human tumor xenografts following subcutaneous delivery of monoclonal antibodies. *Eur J Nucl Med.* 1988; 13:530-536
51. Wahl RL, Liebert M, Wilson BS, Petry NA. Radiolabeled antibodies, albumin and antimony sulfide colloid: A Comparison of lymphoscintigraphic agents. *Nucl Med Biol.* 1988; 15(3):243-250
52. Wahl RL, Waldmann S, Shapiro B. Dual-photon bone mineral density in the proximal femur: Correlation by site. *Nucl Med Comm.* 1988; 9:53-58
53. Wahl RL, Geatti O, Liebert M, Wilson B, Shreve P, Beers B. Response to Letter to the Editor. *J Nucl Med.* 1988; 29(7):1304
54. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, Wagner JG. The intraperitoneal delivery of radiolabeled monoclonal antibodies: Studies on the regional delivery advantage. *Cancer Immunol Immunother.* 1988; 26(3):187-201
55. Wahl RL, Piko CR, Beers BA, Geatti O, Johnson J, Sherman P. Systemic perfusion: a method of enhancing relative tumor uptake of radiolabeled monoclonal antibodies. *Nucl Med Biol.* 1988; 15(6):611-616
56. Eberbach MA, Wahl RL. Lymphatic anatomy: Functional nodal basins. *Ann Plas Surg.* 1989; 22(1):25-31
57. Wahl RL, Liebert M. Improved radiolabeled monoclonal antibody uptake by lavage of intraperitoneal carcinomatosis in mice. *J Nucl Med.* 1989; 30(1):60-65
58. Wahl RL, Wissing JR, Kaminski MS. Isotype switch variant anti-idiotypic monoclonal antibodies: Comparative radiolabeling and in vitro binding. *J Nucl Med.* 1989; 30(2):227-232
59. Wahl RL, Gyves J, Gross BH, Cochran M, Juni JE, Arnstein NB, Lahti D, Ackermann RJ. SPECT of the peritoneal cavity: Method for delineating intraperitoneal fluid distribution. *Am J Roent.* 1989; 152:1205-1210
60. Wahl RL. Radiolabeled monoclonal antibody imaging. *Rad Rep* 1989; 1(3):347-361
61. Del Rosario RB, Wahl RL. Site-specific radiolabeling of monoclonal antibodies with biotin/avidin. *Nucl Med Biol.* 1989; 16(5):525-529
62. Andrews JC, Williams DM, Cho KJ, Knol JA, Wahl RL, Ensminger WD. Unsatisfactory hepatic perfusion after placement of an implanted pump and catheter system: Angiographic correlation. *Radiology.* 1989; 173:779-781
63. Wahl RL, Wissing J, del Rosario RB, Zasadny KR. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. *J Nucl Med.* 1990; 31:84-89
64. Himmelsbach M, Wahl RL. Studies on the metabolic fate of [¹¹¹In] labeled antibodies. *Nucl Med Biol.* 1989; 16(8):839-845
65. Wahl RL, Wissing JR, Kaminski MS. Isotype switch variant anti-idiotypic monoclonal antibodies: Comparative radiolabeling and in vitro binding. *J Nucl Med.* 1989; 30:227-232
66. Wahl RL, Liebert M, Headington J, Wilson B, Shulkin B, Johnson J, Mallette S, Natale RB, Coon W, East M, Davenport R, Brown MB, Niederhuber JT, Swanson NA. Lymphoscintigraphy in melanoma: Initial evaluation of a low protein dose monoclonal antibody cocktail. *Cancer Res. (Suppl)* 1990; 50:941s-948s
67. Del Rosario RB, Wahl RL. Disulfide bond-targeted radiolabeling: Tumor specificity of a streptavidinbiotinylated monoclonal antibody complex¹. *Cancer Res. (Suppl)* 1990; 50:804s-808s
68. Del Rosario RB, Wahl RL, Brocchini SJ, Lawton RG, Smith RH. Sulfhydryl site-specific labeling and cross-linking of monoclonal antibodies using a fluorescent equilibrium transfer alkylation cross-link reagent. *Bioconjugate Chem* 1990; 1:51-59
69. Stewart RE, Deeb GM, Kalus ME Jr, Wahl RL. Double right atrium demonstrated by radionuclide ventriculography in cardiac transplantation. *Clin Nucl Med.* 1990; 15(2):122-123
70. Fig LM, Wahl RL, Stewart RE, Shapiro B. Morphine-augmented hepatobiliary scintigraphy in the severely ill: Caution is in order. *Radiology.* 1990; 75:467-473
71. McKeever PE, Wahl RL, Shakui P, Jackson GA, Leticia LH, Liebert M, Taren JA, Beierwaltes WH, Hoff JT. Products of cells from gliomas: VIII. Multiple-well immunoperoxidase assay of immunoreactivity of primary hybridoma supernatants with human glioma and brain tissue and cultured glioma cells. *J Histochem Cytochem.* 1990; 38(6):815-822

72. Barrett JS, Wahl RL, Wagner JG, Brown RS, Fisher S. Investigations into the route of uptake and pharmacokinetics of intraperitoneally administered monoclonal antibodies: 1. Transdiaphragmatic blockade of the terminal lymphatics in the rat. *Cancer Immuno Immunother.* 1990; 31(6):365-372
73. Sisson JC, Hutchinson RJ, Shapiro B, Zasadny KR, Normolle D, Wieland DM, Wahl RL, Singer DA, Mallette SA, Mudgett EE. 125-I MIBG to treat neuroblastoma: Preliminary report. *J Nucl Med.* 1990; 31:1479-1485
74. Wahl RL, Kaminski MS, Hutchins G. The potential of 18F-fluoro-2 deoxy-d-glucose for the detection of tumor involvement in lymph nodes. *J Nucl Med.* 1990; 31:1831-1835
75. Liebert M, Wahl RL, Lawless G, McKeever PE, Taren JA, Beierwaltes WH, Brasswell R. Direct stereotactic intracerebral injection of monoclonal antibodies and their fragments: A potential approach to brain tumor immunotherapy. *Am J Physiol Imaging.* 1990; 5:55-59
76. Wahl RL, Cody R, Hutchins G, Mudgett EE. Positron Emission Tomographic (PET) scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose. Letter to the editor. *N Engl J Med.* 1991; 324(3):200
77. Hamey JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G, Grossman HB. Uptake of 2-deoxy, 2-(18F)fluoro-d-glucose in bladder cancer: Animal localization and initial patient positron emission tomography. *J Urol.* 1991; 145:279-283
78. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S. 18F-2-deoxy-2-fluoro-d-glucose (FDG) uptake into human tumor xenografts: Feasibility studies for cancer imaging with PET. *Cancer.* 1991; 67:1544-1550
79. Wahl RL, Cody R, Hutchins GD, Mudgett E. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analog 2-[F-18]-fluoro-deoxy-2-D-glucose (FDG). *Radiology.* 1991; 179:765-770
80. Henry CA, Clavo AC, Wahl RL. Improved monoclonal antibody tumor/background ratios with exchange transfusions. *Nucl Med Biol.* 1991; 18(5):565-567
81. Wahl RL, Zasadny KR, Kaminski MS. Importance of the terminal portion of tumor time-activity curve in determining tumor dosimetry in radioimmunotherapy. Letter to the Editor. *J Nucl Med.* 1991; 32(6):1314-1315
82. Barrett JS, Wagner JG, Fisher SJ, Wahl RL. Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2ak murine monoclonal antibody in the rat. *Cancer Res.* 1991;51:3434-3444
83. Liebert M, Wedemeyer G, Chang JHC, Stein JA, McKeever PE, Carey TE, Flint A, Steplewski Z, Buchsbaum DJ, Wahl RL, Grossman HB. Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. *J Urol.* 1990; 144(5):1288-1292
84. Koral KF, Zasadny KR, Swailem FM, Buchbinder SF, Francis IR, Kaminski MS, Wahl RL. Importance of intra-therapy single-photon emission tomographic imaging in calculating tumor dosimetry for a lymphoma patient. *Eur J Nucl Med.* 1991; 18:432-435
85. Sisson JC, Hutchins RJ, Shapiro B, Wahl RL, Wieland DM. Iodine-125-meta-iodobenzylguanidine therapy for neuroblastoma - reply. *J Nucl Med.* 1991; 32(2):362
86. Wahl RL, Harney J, Hutchins G, Grossman HB. Imaging of renal cancer using FDG PET: pilot animal and human studies. *J Urol.* 1991; 146:1470-1474
87. Arcomano MA, Shulkin BL, Petry NA, Wahl RL. Metastatic angiosarcoma with thrombocytopenia and intratumoral Indium-111 platelet deposition. *J Nucl Med.* 1991; 32:2278-2280
88. Del Rosario RB, Baron LE, Lawton RG, Wahl RL. Streptavidin-biotinylated IgG conjugates: A simple procedure for reducing polymer formation. Technical Note. *Nucl Med Biol.* 1992; 19(3):417-421
89. Sisson JC, Brown RS, Zasadny KR, Normolle DP, Fisher S, Moon S, Gutowski T Wahl, RL. Biodistribution and therapeutic effects of radiolabeled metaiodobenzylguanidine in a human neuroblastoma xenograft. *Antibody, Immunology, Radiopharmaceuticals* 1992; 5(1):23-26
90. Wahl RL, Henry CA, Ethier SP. Serum glucose effects on tumor and normal tissue accumulation of 18F-Fluoro-2-deoxy-D-glucose (FDG) in rodents with mammary carcinoma. *Radiology.* 1992; 183:643-647
91. Buchsbaum DJ, Kaminski MS, Glenn SD, Normolle DP, Wahl RL. Improved delivery of radiolabeled anti-B1 MoAb to Raji lymphoma xenografts by pre-dosing with unlabeled anti-B1 MoAb. *Cancer Res.* 1992; 52(3):637-642

92. Plotzke KP, Haradahira T, Stancato L, Olken NM, Skinner S, Gross MD, Wahl RL, Counsell RE. Selective localization of radioiodinated alkylphosphocholine derivatives in tumors. *Nucl Med Biol.* 1992; 19(7):765-773
93. Elta GH, Barrett JL, Ellis JH, Ackermann R, Wahl RL. Delayed biliary drainage is common in asymptomatic post-cholecystectomy volunteers. *Gastrointest Endosc.* 1992; 38(4):435-439
94. Yang FE, Brown RA, Koral KF, Clavo AC, Jackson GA, Wahl RL. Quantitative autoradiographic evaluation of the influence of protein dose in monoclonal antibody distribution in human ovarian adenocarcinoma xenografts. *Cancer Immuno Immunother.* 1992; 35:365-372
95. Kaminski MS, Fig L, Zasadny KR, Koral KF, del Rosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP, Moon S, Scott P, Miller RA, hl RL. Imaging, dosimetry, and radiology with iodine-131-labeled anti-CD37 (MB-1) antibody in B-cell lymphoma. *J Clin Oncol.* 1992; 10(11):1696-1711
96. Wahl RL, Swanson NA, Johnson JW, Natale RB, Petry NA, Mallette S, Kasina S, Reno J, Sullivan K, Abrams P. Clinical experience with Tc-99m labeled (N2S2) anti-melanoma antibody fragments and single photon emission computed tomography. *Am J Physiol Imagaging.* 1992; 7(2):48-48
97. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131-I-labeled Pan B-cell monoclonal antibodies in nude mice bearing Raji Burkitt lymphoma xenografts. *Cancer Res.* 1992; 52:6476-648
98. Brown RS, Fisher SJ, Wahl RL. Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. *J Nucl Med.* 1993; 34(1):75-82
99. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure the proliferative activity of human cancer cells? In vitro Comparison with DNA flow cytometry and 3H-thymidine uptake. *JNucl Med.* 1993; 34(3):414-9
100. Plotzke KP, Rampy, MA, Meyer K, Ruyan M, Fisher SJ, Wahl RL, Scott Skinner, Gross MD, Counsell RE. Biodistribution, excretion, and metabolism of radioiodinated phospholipid ether analogs in tumor-bearing rats. *J Nucl Med.* 1993; 34:787-792
101. Gritters LS, Wahl RL. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) in cancer imaging, a brief review. *Oncology.* 1993; 7(7):59-66
102. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-Deoxy-D-glucose (FDG), L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. *J Nucl Med* 1993; 34:773-779
103. Neagos GR, Martinez FJ, Deeb GM, Wahl RL, Orringer MB, Lynch, III JP. Diagnosis of unilateral mainstem bronchial obstruction following single-lung transplantation with routine spirometry. *Chest* 1993; 103:1255-1258
104. Del Rosario RB, Wahl RL. Biotinylated iodo-polylysine ("BIP") for pre-targeted radiation delivery. *J Nucl Med.* 1993; 34:1147-1151
105. Dayanikli BF, Weissman AF, Wahl RL. Successful Gallium-67 imaging of North American pulmonary blastomycosis. *J Nucl Med.* 1993; 34(6):958-60
106. Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR. "Anatometabolic" tumor imaging: Fusion of FDG PET with CT or MRI to localize foci of increased activity. *J Nucl Med.* 1993; 34(7):1190-1197
107. Gritters, LS, Lelle R, Morley GW, Wahl RL. Unintentional intraluminal small bowel catheter placement detected by Tc-99m sulfur colloid scan obtained prior to planned intraperitoneal P-32 therapy. *Clin Nucl Med.* 1993; 18(3):249-50
108. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon S, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL. Radioimmunotherapy of B-cell lymphoma with [¹³¹I]anti-B1 (anti-CD20) antibody. *N Engl J Med.* 1993; 329(7):459-465
109. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2[F-18]-fluoro-2-deoxy-D-glucose (FDG) in the imaging of malignant melanoma. *J Nucl Med.* 1993; 34:1420-1427
110. Koral KF, Kwok CS, Yang FE, Brown RS, Sisson JC, Wahl RL. Autoradiography-based, three-dimensional calculation of dose rate for murine, human-tumor xenografts. *Nucl Med Biol* 1993; 20(8):901-909
111. Wahl RL, Zasadny KR, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography (PET): Initial evaluation. *J Clin Oncol.* 1993; 11(11):2101-2111

112. Sisson JC, Ackerman RJ, Meyer MA, Wahl RL. Uptake of 18-Fluoro-2-Deoxy-D-Glucose by Thyroid Cancer: Implications for Diagnosis and Therapy. *J Clin Endocrinol Metab.* 1993; 77:1090-1094
113. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues in FDG/PET: Variations with body weight and a method for correction: "SUV-lean". *Radiology.* 1993; 189:847-850
114. Brown RS, Wahl RL. Over expression of Glut-1 glucose transporter in human breast cancer: An immunohistochemical study. *Cancer.* 1993; 72(10):2979-2985
115. Weissman AF, Dayanikli BF, Wahl RL, Schlesinger AE. Indium-111 leukocyte in a patient with osseous metastatic Ewing's sarcoma. *Clin Nucl Med.* 1993; 18(12):1063-1066
116. Newman JS, Francis IR, Kaminski MS, Wahl RL. "FDG-PET Imaging in Lymphoma: Correlation with CT". *Radiology.* 1994; 190:111-116
117. Raylman R, Wahl RL. Magnetically enhanced radionuclide therapy (MERIT.) *J Nucl Med.* 1994; 34:157-163
118. Wahl RL, Experimental radioimmunotherapy: A Brief Overview. *Cancer.* 1994; 73(3):989
119. Wahl RL, Helvie MA, Chang AE, Anderson I. Detection of breast cancer in women after augmentation mammoplasty using positron emission tomography: Initial clinical evaluation. *J Nucl Med.* 1994; 35:872-875
120. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of Mediastinal Non-Small Cell Lung Cancer with FDG PET, CT, and Fusion Images: Preliminary Prospective Evaluation. *Radiology.* 1994; 191:371-377
121. Raylman R, Wahl RL. A Fiber Optically Coupled Positron-sensitive Surgical Probe. *J Nucl Med.* 1994; 35:909-91
122. Alderson PO, Bland WH, Coleman RE, Conway JJ, Fletcher JW, Goldsmith SJ, Kirchner, PT, Kraft RA, Powsner ER, Ross JF, Schelbert HR, Strauss HW, Wahl RL, Woolfended JM. Components of Professional Competence of Nuclear Medicine Physicians American Board of Nuclear Medicine. *J Nucl Med.* 1994 (Position Statement); 35(7):1234-1235
123. Sisson JC, Thompson NW, Ackermann RJ, Wahl RL. Use of FDG to Locate Parathyroid Adenomas in Primary Hyperparathyroidism [Letter to the Editor]. *Radiology.* 1994; 192(1):280
124. Wahl RL, Hawkins R, Larson SM, Hendee W, Coleman RE, Holden RW, Frick M, Gatsonis C, Brown GS, Shtern F. Proceedings of a National Cancer Institute Workshop: PET as a clinical tool in oncology - a research agenda. *Radiology.* 1994; 193:604-606
125. Koral KF, Zasadny KR, Kessler ML, Luo JQ, Buchbinder SF, Kaminski MS, Francis I, Wahl, RL. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. *J Nucl Med.* 1994; 35(10):1714-20
126. Adler D, Wahl R. New Methods for Imaging the Breast: techniques, findings, and potential. *AJR Am J Roentgenol.* 1995; 164:19-30
127. Macfarlane DJ, Cotton L, Ackermann RJ, Minn H, Ficaro EP, Shreve PD, Wahl RL. Triple-head 2-[18F]-2-deoxy-D-glucose SPECT: initial evaluation in oncology and Comparison to 18FDG PET. *Radiology.* 1995; 194:425-429
128. Minn H, Clavo AC, Grénman R, Wahl RL. In vitro Comparison of cell proliferation kinetics and uptake of tritiated 2-fluoro-2-deoxy-D-glucose and L-methionine in squamous cell carcinoma of the head and neck. *J Nucl Med.* 1995; 36(2):252-8
129. Meyer CR, Leichtman GS, Brunberg JA, Wahl RL, Quint LE. Simultaneous usage of homologous points, lines and planes for optimal, 3D, linear registration of multimodality imaging data. *IEEE Trans Med Imag* 1995; 14(1):1-11
130. Quint LE, Francis, IR, Wahl RL, Gross BH, Glazer GM. Preoperative Staging of Non-Small-Cell Carcinoma of the Lung: Imaging Methods. *AJR Am J Roentgenol.* 1995; 164:1349-1359
131. Minn HR, Zasadny KR, Quint LE, Wahl RL. Lung Cancer: Reproducibility of Quantitative Measurements for Evaluating 2-[F-18]-Fluoro-2-deoxy-D-glucose Uptake at PET. *Radiology.* 1995; 196:167-173
132. Rampy MA, Chou TS, Pinchuk AN, Skinner RWS, Gross MD, Fisher S, Wahl RL, Counsell RE. Synthesis and biological evaluation of radioiodinated phospholipid ether analogs. *J Nucl Med Biol.* 1995; 22(4):502-512
133. Wahl RL, The Harrison/Tempero article reviewed. *Oncology.* 1995; 9(7):636-641
134. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. *J Nucl Med.* 1995; 36(9):1625-32
135. Raylman RR, Wahl RL. Magnetically-enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides: Theory of application. *Medical Phys.* 1995; 22:1285-1292

136. Rampy MA, Pinchuk AN, Weichert JP, Skinner RWS, Fisher SJ, Wahl RL, Gross MD, Counsell RE. Synthesis and biological evaluation of radioiodinated phospholipid ether stereoisomers. *J Med Chem.* 1995; 38 (16):3156-62
137. Piert M, Lin H, Clavo AC, Wahl RL. Biodistribution of radiolabeled anti-Interleukin-2 and anti-Interleukin-6 receptor monoclonal antibodies in a vascular and non-vascular transplant model. *Langenbeck's Archive for Chirurgie* 1995:211-215
138. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of FDG in breast carcinoma. Are Inflammatory Cells Important? *J Nucl Med.* 1995; 36(10):1854-61
139. Raylman RR, Fisher S, Brown RS, Ethier SP, Wahl RL. Fluorine-18-fluorodeoxyglucose-guided breast cancer surgery with a positron-sensitive probe: Validation in preclinical studies. *J Nucl Med.* 1995; 36(10):1869-74
140. Wahl RL, Emission Tomography Imaging. *Acad Radiol.* 1995; 2: S122-S123
141. Brown RS, Leung JY, Fisher S, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between glut-1 expression and FDG uptake. *J Nucl Med.* 1996; 37(6):1042-1047
142. Zasadny KR, Wahl RL. Enhanced FDG-PET imaging of cancer by generation of correlation-coefficient filtered ("Tumor Tailored") influx-constant images. *J Nucl Med.* 1996; 37:371-374
143. Budo RO, Platt JF, Wahl RL, Ellis JH, Rubin JM. Suspected obstructive pyelocaliectasis: Doppler ultrasonography compared with diuretic renal scintigraphy in proven cases. *Can Assoc Radiol J.* 1996; 47:101-106
144. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of Tritiated Thymidine, L-Leucine, L-Methionine and FDG in cultured cancer cells. *J Nucl Med,* 1996; 37:502-506
145. Shreve PD, Grossman BH, Gross MD, Wahl RL. Metastatic Prostate Cancer: Initial Findings of PET with 2-Deoxy-2-[F-18]fluoro-D-glucose. *Radiology.* 1996; 199:751-756
146. Miyachi T, Wahl RL. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung. *J Nucl Med.* 1996; 23(5):517-523
147. Wahl RL, Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. *J Nucl Med.* 1996; 37(6):1038-1041
148. Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, Wahl RL. Recurrence of head and neck cancer after surgery of irradiation: Prospective Comparison of 2-deoxy-2-[F-18] fluoro-D-glucose PET and MR imaging diagnoses. *Radiology.* 1996; 200:135-41
149. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine- 131-Anti-B1 radioimmunotherapy for B-Cell lymphoma. *J Clin. Oncol.* 1996; 14(7):1974-1981
150. Rampy MA, Brown RS, Pinchuk AN, Weichert JP, Skinner RWS, Fisher SJ, Wahl RL, Gross MD, Ethier SP, Counsell RE. Biological Disposition and Imaging of a Radioiodinated Alkylphosphocholine in two rodent models of breast cancer. *J Nucl Med.* 1996; 37(9):1540-1545
151. Raylman RR, Ficaro EP, Wahl RL. Stereotactic Coordinates from ECT Sinograms for Radionuclide-Guided Breast Biopsy. *J Nucl Med.* 1996; 37(9):1562-1567
152. Wahl RL, Nuclear Medicine Techniques in Breast Imaging. *Semin Ultrasound, CT and MRI.* 1996; 17(5):494-505
153. Raylman RR, Clavo AC, Wahl RL. Exposure to strong static magnetic field slows the growth of human cancer cells In Vitro. *Bioelectromagnetics.* 1996; 17(5):358-363
154. Zasadny KR, Kison PV, Quint LE, Wahl RL. Untreated Lung Cancer: Quantification of systematic distortion in non-attenuation corrected FDG-PET images in patients with untreated lung cancers. *Radiology.* 1996; 201:873-876
155. Raylman RR, Wahl RL. Evaluation of ion-implanted-silicon detectors for use in intraoperative positron-sensitive probes. *Med Phys.* 1996; 23(11):1889-1895
156. Raylman RR, Clavo AC, Crawford SM, Recker BS, Wahl RL. Don't Forget Magnetically Enhanced Radionuclide Therapy (MERiT): In Vitro evaluation. *J Nucl Med.* 1996; 37(11):1914-1915
157. Minn H, Clavo AC, Wahl RL. Influence of Hypoxia on Tracer Accumulation in Squamous-Cell Carcinoma: In Vitro Evaluation for PET Imaging. *Nucl Med Biol.* 1996; (23):941-946
158. Torizuka T, Fisher S, Wahl RL. Insulin-induced hypoglycemia: effects on F18-FDG uptake into experimental mammary carcinoma. *Radiology.* 1997; 203:169-172
159. Torizuka T, Clavo AC, Wahl RL. Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. *J Nucl Med.* 1997; 38:382-386

160. Meyer CR, Boes JL, Kim B, Bland P, Koral K, Zasadny K, Kison P, Frey KA,, Wahl RL. Demonstration of Accuracy and Clinical Versatility of Mutual Information for Automatic Multimodality Image Fusion Using Affine and Thin-Plate Spline Warped Geometric Deformations. *Medical Images Analysis* 1997; 1(3):195-206
161. Barrett JS, Fisher SJ, Wahl RL. Postural effects of peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies. *Cancer Immunol Immunother.* 1997; 44(3):173-178
162. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary Assessment of FDG-PET in Patients with Bladder Cancer. *Eur J Nuc Med.* 1997; 24:615-620
163. Raylman RR, Clavo AC, Crawford SC, Recker B,, Wahl R. Magnetically Enhanced Radionuclide Therapy (MERiT): In Vitro Evaluation. *Int J Radiat Oncol Biol Phys.* 1997; 37(5):1201-1206
164. Kosuda S, Wahl RL. Demonstration of Recurrent Dedifferentiated Liposarcoma of the Spermatic Cord by FDG-PET. *Ann Nucl Med.* 1997; 11(3):263-266
165. Kosuda S, Fisher S,, Wahl RL. Animal Studies on the Reduction and/or Dilution of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) Activity in the Urinary System. *Ann Nucl Med.* 1997; 11(3):213-218
166. Kosuda S, Fisher S, Kison P,, Wahl RL. Uptake of 2-deoxy-2-[18 F]fluoro-D-glucose in the normal testis: Retrospective PET study and animal experiment. *Ann Nucl Med.* 1997; 11(3):195-199
167. Brown RS, Kaminski MS, Wahl RL. Intra-tumoral Micro-distribution of 131I-labelled in patients with B-cell lymphoma following radioimmunotherapy. *Nuc Med Biol.* 1997; 24:657-663
168. Koral KF, Lin S, Fessler JA, Kaminski MS, Wahl RL. Preliminary results from Intensity-Based CT-SPECT Fusion in I-131 Anti-B1 Monoclonal-Antibody Therapy of Lymphoma. *Cancer.* 1997; 80:2538-44
169. Sugawara Y, Fisher S, Zasadny K, Kison P, Baker LH, Wahl RL. Pre Clinical and Clinical Studies of Bone Marrow Uptake of Fluorine-18 Fluorodeoxyglucose with or without Granulocyte Colony Stimulation Factor During Chemotherapy. *J Clin Oncol* 1998; 16:(1):173-80
170. Fig L, Brown RS, Von Moll L, Fisher SJ, Zasadny, Lichter AS, Wicha M, Sondak V, August D, Schlom J, Colcher D, Wahl RL. Immunolymphoscintigraphy in Breast Cancer: Evaluation using 131-I labeled monoclonal antibody B72.3. *Nuc Med Biol.* 1998; 25:251-260
171. Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL. Oncologic Diagnosis with 2-[f-18]Fluoro-2-deoxy-D-glucose Imaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner. *Radiology.* 1998; 431-437
172. Macfarlane DJ, Sondak VK, Johnson TM, Wahl RL. Prospective Evaluation of FDG-PET in Staging of Regional Lymph Nodes in Patients with Cutaneous Malignant Melanoma. *J Clin Oncol.* 1998;16:1770-1776
173. Torizuka, Wahl RL. Untreated Lung and Breast Cancers Correlation with FDG Kinetic Rate Constants and Findings of in vitro Studies. *Radiology.* 1998;207(3)767-774
174. Wahl RL, B1 Therapy in Non-Hodgkin's Lymphoma: Dosimetry and Clinical Implications. *J Nucl Med. (Suppl)* 1998;39(7)1S-10S
175. Wahl RL, Zasadny KR, McFarlane D, Francis IR, Ross CW, Estes J, Fisher S, Regan D, Kroll S,, Kaminski MS. Iodine-131 Anti-B1 Antibody for B-Cell Lymphoma: An Update on the Michigan Phase I Experience. *J. Nucl Med. (Suppl)* 1998;39(7)21S-27S
176. Wahl RL, Kroll S, Zasadny KR. Patient-Specific Whole-Body Dosimetry: Principles and a Simplified Method for Clinical Implementation. *J. Nucl Med. (Suppl)* 1998;39(7)14S-20S
177. Wahl RL, Overview of the current status of PET in breast cancer imaging. *J Nucl Med.* 1998;42:1-7
178. Gates VL, Carey JE, Siegel JA, Kaminski MS,, Wahl RL. Non-Myeloablative I-131 Anti-B1 RIT is Feasible as an Outpatient Treatment. *J Nucl Med.* 1998;39:1230-1236
179. Torizuka T, Fisher SJ, Brown RS, Wahl RL. Effect of insulin on uptake of FDG into experimental mammary carcinoma in diabetic rats. *Radiology.* 1998;208:499-504
180. Sugawara T, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL. Rapid Detection of Human Infections with Fluorine-18-fluorodeoxyglucose and Positron Emission Tomography: Preliminary Results. *Eur J Nucl Med.* 1998;25:1238-1243
181. Sparks RB, Siegel JA, Wahl RL. The Need for Better Methods to Determine Release Criteria for Patients Administered Radioactive Material. *Health Phys.* 1998;Oct.75(4):385-388
182. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, Wahl RL. Procedure guideline for tumor imaging using fluorine-18-FDG. *J Nucl Med.* 1998;39(7):1302-1305
183. Schmaier AH, Wahl RL, Fisher SJ, Brenner D. The Pharmacokinetics of the Kininogens. *Thromb Res.* 1998;(92):293-297

184. A. John CS, Bowen WD, Fisher SJ, Lim BB, Vilner BJ, ahl RL. Synthesis, in-vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1'-piperidinyl)ethyl]-3-[125-I]iodo-4-methoxy benzamide, P[125-I]MBA for imaging breast cancer. *Nuc Med Biol.* 1998; 26(4):377-382
185. Shreve PD, Anzai Y, hl RL. Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants. *RadioGraphics RSNA* 1999;19(1)61-77
186. Raylman RR, Kison PV, Wahl RL. Capabilities of Two and Three-Dimensional FDG-PET for Detecting Small Lesions and Lymph Nodes in the Upper Torso: A Dynamic Phantom Study. *Eur J Nucl Med.* 1999;26(1)39-45
187. Zasadny KR, Kison PV, Francis IR, Wahl RL. FDG-PET Determination of Metabolically Active Tumor Volume and Comparison with CT. *Clin Positron Imaging.* 1998;(2):123-29
188. Raylman RR, Wahl RL. Beta-Sensitive Intraoperative Probes Utilizing Dual, Stacked Ion-Implanted-Silicon Detectors: Proof of Principle. *I.E.E.E. Trans Nucl Sci* 1998;(45):1730-6
189. Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with F-18-fluorodeoxyglucose positron emission tomography and kinetic modeling. *Radiology.* 1999;(211):249-256
190. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters to FDG uptake in untreated primary human non-small Cell Lung Cancer as assessed by PET. *J Nucl Med.* 1999;(40):556-565
191. Sugawara Y, Gutowski TD, Fisher SJ, Brown RS, Wahl RL. Uptake of PET tracers in experimental bacterial infections: A comparative biodistribution study with FDG, thymidine, Lmethionine, Ga67 and HSA125. *Eur J Nucl Med.* 1999,(26):333-341
192. Kirkwood I, Quint DI, Haig A, Wahl RL. Painful Schmorl's node: another cause of vertebral photopenia on Indium-111 labeled leukocyte scintigraphy. *Clin Nucl Med.* 1999, 24(3)206-208
193. Dehdashti F, Wahl RL. New Scintigraphic Methods for Imaging Breast Cancer: Techniques, Potential Applications, and Limitations. *Breast Imaging* 1999, 105-113
194. Anzai Y, Wahl RL. New Scintigraphic Methods for Imaging Breast Cancer: Techniques, Potential Applications, and Limitations. *Breast Imaging* 1999, 105-113
195. Sugawara Y, Quint LE, Russo JE, Recker BE, Saran PA, Iannetoni MD, Orringer MB, Wahl RL. Does the FDG uptake of primary non-small Cell Lung Cancer predict prognosis? A work in progress. *Clin Positron Imaging.* 1999, 2(2): 111-118
196. Sugawara Y, Eisbruch A, Recker BE, Kison PV, Wahl RL. Evaluation of 18F FDG Positron Emission Tomography in Patients with Cervical Cancer. *J Nucl Med.* 1999 Jul; 40(7): 1125-31
197. Wahl RL, Positron Emission Tomography in Cancer Patient Management. [Commentary] *Cancer J Sci Am.* 1999 Jul-Aug; 5(4): 205-7
198. Jamadar DA, Kazerooni EA, Martinez FJ, Whyte RI, Wahl RL. Semi-Quantitative Ventilation/Perfusion Scintigraphy and SPECT Imaging in the Evaluation of Lung Volume Reduction Surgery Candidates: Description and Prediction of Clinical Outcome. *Eur J Nucl Med.* 1999 Jul; 26(7): 734-42
199. Sugawara Y, Zasadny KR, Kison PV, Baker LH, Wahl RL. Splenic FDG Uptake is increased by Granulocyte Colony-Stimulating Factor Therapy: PET Imaging Results. *J Nucl Med.* 1999 Sep; 40(9): 1456-62
200. Sugawara, Zasadny KR, Neuhoff AW, Wahl RL. Re-evaluation of Standardized Uptake Value of FDG: Variations with Body Weight and Methods for Correction. *Radiology.* 1999 Nov; 213(2): 521-5
201. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases Staging of non-small Cell Lung Cancer in the 1990's: A meta-analytic Comparison of PET and x-ray computed tomography. *Radiology.* 1999 Nov; 213(2): 530-6
202. Tonakie A, Sondak V, Yahanda, Wahl RL. Reproducibility of Lymphoscintigraphic Drainage Patterns in Sequential Tc-99m HSA and Tc-99m sulfur colloid studies: Implications for Sentinel Node Identification in Melanoma. *Surgery.* 1999 Nov; 126(5): 955-62
203. Torizuka T, Zasadny KR, Wahl RL. Diabetes Decreases FDG Accumulation in Primary Lung Cancer. *Clin Pos Imaging.* 1999; 2(5): 281-287
204. Wahl RL. "To AC or not to AC: That is the Question?" *J Nucl Med.* 1999 Dec; 40(12): 2025-8
205. Cui J, Wahl RL, Shen T, Fisher SJ, Recker E, Ginsburg D, Long MW. Bone Marrow Cell Trafficking Following Intravenous Administration. *Br J Haematol.* 1999 Dec; 107(4): 895-902
206. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS. Multicenter Phase II Study of Iodine I131 Tositumomab for Chemotherapy-

- Relapsed/Refractory Low-Grade and Transformed Low-Grade B-cell Non-Hodgkin's Lymphoma. *J Clin Oncol.* 2000 Mar; 18(6): 1316-23
207. Minn H, Wahl RL. Effect of Nitroimidazole Sensitizers on in vitro Glycolytic Metabolism of Hypoxic Squamous Cell Carcinoma. *Acta Oncol.* 2000; 39(2): 199-205
 208. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL. Radioimmunotherapy with iodine I-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. *Blood.* 2000 Aug 15; 96(4): 1259-66
 209. Torizuka T, Wahl R. Metabolic Response to Non-Hodgkin's Lymphoma to Iodine-131-Anti-B1 Radioimmunotherapy: Evaluation with FDG PET. *J Nucl Med.* 2000 Jun; 41(6): 999-1005
 210. Lederman RJ, Raylman RR, Fisher SJ, Kison PV, San H, Nabel EG, Wahl RL: Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). *Nucl Med Commun.* 2001 Jul; 22(7): 747-53
 211. Wahl RL, Current status of PET in breast cancer imaging, staging, and therapy. *Semin Roentgenol.* 2001 Jul; 36(3): 250-60
 212. Taylor RJ, Wahl RL, Sharma PK, Bradford CR, Terrell JE, Teknos TN, Heard EM, Wolf GT, Chepeha DB: Sentinel node localization in oral cavity and oropharynx squamous cell cancer. *Arch Otolaryngol Head Neck Surg.* 2001 Aug; 127(8): 970-4
 213. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. *J Clin Oncol.* 2001 Oct 1; 19(19): 3918-28
 214. Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, Colcher D: Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. *Clin Lymphoma.* 2001 Dec; 2(3): 164-72
 215. Nakamoto Y, Eisbruch A, Achtyes ED, Sugawara Y, Reynolds KR, Johnston CM, Wahl RL: Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. *Gynecol Oncol.* 2002 Feb; 84(2): 289-95
 216. Siegel BA, Adler LP, Wahl RL. FDG positron emission tomography detection of pelvic nodal metastases in gynecologic cancer. *AJR Am J Roentgenol.* 2002 Mar; 178(3): 762-4
 217. Koral KF, Francis IR, Kroll S, Zasadny KR, Kaminski MS, Wahl RL: Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method. *Cancer.* 2002 Feb 15; 94(4 Suppl): 1258-63
 218. DeNardo SJ, Williams LE, Leigh BR, Wahl RL: Choosing an optimal radioimmunotherapy dose for clinical response. *Cancer.* 2002 Feb 15; 94(4 Suppl): 1275-86
 219. Siegel BA, Kroll S, Regan D, Kaminski MS, Wahl RL: A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy. *J Nucl Med.* 2002 Mar; 43(3): 354-63
 220. Higashi T, Fisher SJ, Nakada K, Romain DJ, Wahl RL: Is enteral administration of fluorine-18-fluorodeoxyglucose (F-18 FDG) a palatable alternative to IV injection? Pre-clinical evaluation in normal rodents. *Nucl Med Biol.* 2002 Apr; 29(3): 363-73.
 221. Pijl MEJ, Chaoui AS, Wahl RL, Van Oostayen. *Radiology of Colorectal Cancer.* *Eur J Cancer.* 2002 May; 38(7): 887-98
 222. Cohade, Wahl RL: PET scanning and measuring the impact of treatment. *Cancer J.* 2002 Mar-Apr; 8(2): 119-34
 223. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL: Expression of hexokinase II and Glut-1 in untreated human breast cancer. *Nucl Med Biol.* 2002 May; 29(4): 443-53
 224. Nakamoto Y, Chang AE, Zasadny KR, Wahl RL: Comparison Of Attenuation-Corrected And Non-Corrected FDG-PET Images For Axillary Nodal Staging In Newly Diagnosed Breast Cancer. *Mol Imaging Biol.* 2002 Mar; 4(2): 161-9
 225. Nakamoto Y, Zasadny KR, Minn H, Wahl RL: Reproducibility Of Common Semi-Quantitative Parameters For Evaluating Lung Cancer Glucose Metabolism With Positron Emission Tomography Using 2-Deoxy-2-[18F]Fluoro-D-Glucose. *Mol Imaging Biol.* 2002 Mar; 4(2): 171-8
 226. Nakamoto Y, Osman M, Cohade C, Marshal LT, Links, JM, Kohlmyer S, Wahl RL. PET/CT: Comparison of quantitative Tracer Uptake Between Germanium and CT Transmission Attenuation-Corrected Images. *J Nucl Med.* 2002 Sep; 43(9): 1137-43

227. Kaminski M, Tuck M, Regan D, Kison P, Wahl R. High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab(Bexxar). *Blood* 2002; 100 (Suppl): abstract 1381
228. Skalski J, Wahl R, Meyer C. Comparison of Mutual Information – Based Warping Accuracy for Fusing Body CT and PET by 2 Methods: CT Mapped onto PET Emission Scan Versus CT Mapped onto PET Transmission Scan. *J Nucl Med.* 2002 Sep; 43(9): 1184-7
229. Nakamoto Y, Osman M, Cohade C et al. PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. *J Nucl Med.* 2002; 43(9): 1137-1143
230. Siegel BA, Adler LP, Wahl RL. FDG positron emission tomography detection of pelvic nodal metastases in gynecologic cancer. *AJR Am J Roentgenol.* 2002; 178(3): 762-764
231. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. *Eur J Nucl Med Mol Imaging.* 2003; 30(2):274-80
232. Nakamoto Y, Tatsumi M, Cohade C, Osman M, Marshall LT, Wahl RL. “Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT. *Eur J Nucl Med Mol Imaging.* 2003; 30(4): 597-602
233. Osman MM, Cohade C, Nakamoto Y, Wahl RL. Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. *Eur J Nucl Med Mol Imaging.* 2003 Apr; 30(4): 603-6
234. Tatsumi M, Clark PA, Nakamoto Y, Wahl RL. Impact of body habitus on quantitative and qualitative image quality in whole-body FDG-PET. *Eur J Nucl Med Mol Imaging.* 2003; 30(1): 40-5
235. Skalski J, Wahl RL, Meyer CR, Comparison of mutual information-based warping accuracy for fusing body CT and PET by 2 methods: CT mapped onto PET emission scan versus CT mapped onto PET transmission scan. *J Nucl Med.* 2002; 43(9): 1184-7
236. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in Supraclavicular Area Fat ("USA-Fat"): Description on 18F-FDG PET/CT. *J Nucl Med.* 2003 Feb; 44(2): 170-6
237. Osman M, Cohade C, Nakamoto Y, Marshal LT, Leal JP, Wahl RL. Clinically Significant Inaccurate Localization of Lesions with PET/CT: Frequency in 300 Patients. *J Nucl Med.* 2003 Feb; 44(2): 240-3
238. Thomas CT, Meyer CR, Koeppe RA, Kalemkerian GP, Fisher SJ, Dull TL, Zasadny KR, Wahl RL. A Positron-Emitting Internal Marker For Identification Of Normal Tissues By Pet: Phantom Studies And Validation In Patients. *Mol Imaging Biol.* 2003 Mar; 5(2): 79-85
239. Nakamoto Y, Osman, M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. *Clin Nucl Med.* 2003 Apr; 28(4): 302-7
240. Koral KF, Dewaraja Y, Li J, Lin Q, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl, RL. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. *J Nucl Med.* 2003 Mar; 44(3): 457-64
241. Cohade C, Osman M, Nakamoto Y, Marshal LT, Links JM, Fishman EK, Wahl RL. Initial experience with oral contrast in PET/CT: phantom and clinical studies. *J Nucl Med.* 2003 Mar; 44(3): 412-6
242. Osman M, Cohade Christian C, Nakamoto Y, Wahl RL. Respiratory Motion Artifacts on PET Emission Images Obtained Using CT Attenuation Correction on PET-CT. *Eur J Nucl Med Mol Imaging.* 2003 Apr; 30(4): 603-6
243. Cohade C, Osman M, Marshall L, Wahl RL. PET-CT: Accuracy of PET and CT Spatial Registration of Lung Lesions. *Eur J Nucl Med Mol Imaging.* 2003 May; 30(5): 721-6
244. Nakamoto Y, Tatsumi M, Cohade C, Osman, Marshall L, Wahl RL. Accuracy of Image Fusion of Normal Upper Abdominal Organs Visualized with PET/CT. *Eur J Nucl Med Mol Imaging.* 2003 Apr; 30(4): 597-602
245. Nakamoto Y, Kaminski M, Wahl R. Letter to the editor “Correlation of Tumor Radiation Absorbed dose with Response is Easier to Find in Previously-Untreated Patients”. *J Nucl Med.* 2003 Sep; 44(9): 1541-3
246. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with Tositumomab and iodine I 131 tositumomab. *Semin Oncol.* 2003 Apr; 30(2 Suppl 4): 31-8
247. Thomas CT, Bradshasw mPT, Pollock BH, Montie JE, Taylor JM, Thames HD, McLaughlin PW, Deboise DA, Hussey DH, Wahl RL. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. *J Clin Oncol.* 2003 May 1; 21(9): 1715-21

248. Chin BB, Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. *J Clin Oncol.* 2003 May 1; 21(9): 1715-21
249. Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. *Radiology.* 2003 Jun; 227(3): 817-24
250. Cohade C, Wahl RL, Applications of Positron Emission Tomography/Computed Tomography Image Fusion in Clinical Positron Emission Tomography – Clinical Use, Interpretation Methods, Diagnostic Improvements. *Semin Nucl Med.* 2003 Jul; 33(3): 228-37
251. Cohade C, Mourtzikos KA, Wahl RL. “USA-Fat”: Prevalence is Related to Ambient Outdoor Temperature – Evaluation with 18F-FDG PET/CT. *J Nucl Med.* 2003 Aug; 44(8): 1267-70
252. Wahl RL. Anatomical Imaging with 2-Deoxy-2-[18F]Fluoro-D-Glucose. *Mol Imaging Biol.* 2003 Mar-Apr; 5(2): 456
253. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, Wahl RL, Montz FJ. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. *Gynecol Oncol.* 2003 Sep; 90(3): 519-28
254. Chin BB, Nakamoto Y, Bulte JWM, Pittenger MF, Wahl RL, Kraitchman DL. 111In Oxine Labeled Mesenchymal Stem Cell SPECT After Intravenous Administration in Myocardial Infarction. *Nucl Med Commun.* 2003 Nov; 24(11): 1149-1154
255. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. *J Nucl Med.* 2003 Nov; 44(11): 1797-803
256. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose Uptake in the Aortic Wall at PET/CT: Possible Finding for Active Atherosclerosis. *Radiology.* 2003 Dec; 229(3): 831-7
257. Fayad LM, Cohade C, Wahl RL, Fishman EK. Sacral fractures: a potential pitfall of FDG positron emission tomography. *AJR Am J Roentgenol.* 2003. Nov; 181(5):1239-43
258. Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF, Wahl RL. Initial Experience in Small Animal Tumor Imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18] fluoro-2-deoxy-D-glucose. *Cancer Res.* 2003 Oct 1; 63(19): 6252-7
259. Chin BB, Patel PV, Nakamoto Y, Cohade C, Osman M, Marshall LT, Wahl RL. Quantitative evaluation of 2-deoxy-2-[18F] fluoro-D-glucose uptake in hepatic metastases with combined PET-CT: iterative reconstruction with CT attenuation correction versus filtered back projection with 68Germanium attenuation correction. *Mol Imaging Biol.* 2002 Nov;4(6): 399-409
260. Chin BB, Patel P, Cohade C, Ewertz, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* 2004 Jan;89(1):91-5
261. Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. *Radiographics.* 2004 Jan-Feb; 24(1): 209-23
262. Wahl RL, Seigel BA, Coleman RE, Gatsonis CG. Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group. *J Clin Oncol.* 2004 Jan 15; 22(2): 277-85
263. Wahl RL, Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. *J Nucl Med.* 2004 Jan;45 Suppl 1:82S-95S
264. Nakamoto Y, Chin BB, Cohade C, Osman M, Tatsumi M, Wahl RL. PET/CT: artifacts caused by bowel motion. *Nucl Med Commun.* 2004 Mar;25(3):221-5
265. Kasamon YL, Wahl RL, Swinnen LJ. FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy. *Curr Opin Oncol.* 2004 Mar;16(2):100-5
266. Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. *Abdom Imaging.* 2004 Mar 18 [Epub ahead of print]
267. Kamel I, Cohade C, Neyman E, Fishman E, Wahl RL. Incremental Value of CT in Combined PET/CT Scanning of Patients with Colorectal Carcinoma. *Abdominal Imaging* 2004 May 27 [Epub ahead of print]
268. Kumbasar B, Kamel Irk, Tekes A, Eng J, Fishman EK, Wahl RL. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. *Abdom Imaging.* 2004 May 27 [Epub ahead of print]
269. Tatsumi M, Engels JM, Ishimori T, Nicely O, Cohade C, Wahl RL. Intense (18)F-FDG Uptake in Brown Fat Can Be Reduced Pharmacologically. *J Nucl Med.* 2004 Jul;45(7):1189-93

270. Koral KF, Zasadny K, Wahl RL. Bias reduction in correlation of radiation-absorbed dose with response. *J Nucl Med.* 2004 Jul;45(7):1271-2
271. Friedman KP, Wahl RL. Clinical Use Of Positron Emission Tomography In The Management Of Cutaneous Melanoma. *Semin Nucl Med.* 2004 Oct;34(4):242-53
272. Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss Elm Tatsumi M, Dang LH, Diaz LA Jr, Pomper M, Abusedera M, Wahl RL, Kinzler KW, Zhou S, Huso DL, Vogelstein B. Bacteriolytic Therapy Can Generate A Potent Immune Response Against Experimental Tumors. *Proc Natl Acad Sci USA.* 2004 Oct 19;101(42):15172-7
273. Jacene HA, Cohade C, Wahl RL. F-18 FDG PET/CT in Acute Respiratory Distress Syndrome: A Case Report. *Clin Nucl Med.* 2004 Dec; 29(12):786-788
274. Fukuchi K, Tatsumi M, Ishida Y, Oku N, Hatazawa J, Wahl RL. Radionuclide imaging metabolic activity of brown adipose tissue in a patient with pheochromocytoma. *Exp Clin Endocrinol Diabetes.* 2004 Nov;112(10):601-3
275. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ. The radioisotope contributes significantly to the activity of radioimmunotherapy. *Clin Cancer Res.* 2004 Dec 1;10(23):7792-8
276. Wahl RL, Tositumomab and ¹³¹I Therapy in Non-Hodgkin's Lymphoma. *J Nucl Med.* 2005 Jan;46(1 Suppl):128S-40S
277. Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG Distribution Patterns in the Head and Neck: PET/CT evaluation. *Radiology.* 2005 Mar; 234(3):879-85
278. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL. ¹³¹I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma. *N Engl J Med.* 2005 Feb 3;352(5):441-9
279. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL. Normal FDG Distribution Patterns In The Head And Neck: PET/CT Evaluation. *Radiology.* 2005 Mar;234(3):879-85
280. Ishimori T, Patel PV, Wahl RL. Detection of Unexpected Additional Primary Malignancies with PET/CT. *J Nucl Med.* 2005 May;46(5):752-7
281. Ishimori T, Tatsumi M, Wahl RL. Tumor Response Assessment Is More Robust With Sequential CT Scanning Than External Caliper Measurements (1). *Acad Radiol.* 2005 Jun; 12(6):776-81
282. Mathews WB, Nakamoto Y, Abraham EH, Scheffel U, Hilton J, Ravert HT, Tatsumi M, Rauseo PA, Traughber BJ, Salikhova AY, Dannals RF, Wahl RL. Synthesis and Biodistribution of [¹¹C]Adenosine 5'-monophosphate ([¹¹C]AMP). *Mol Imaging Biol.* 2005 May-Jun; 7(3):203-8
283. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of Pelvic Malignancies with In-Line FDG PET-CT: Case Examples and Common Pitfalls of FDG PET. *Radiographics.* 2005 Jul-Aug;25(4):1031-43
284. Diaz-Montes TP, Jacene HA, Wahl RL, Bristow RE. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. *Gynecol Oncol.* 2005 Sep;98(3):510-2
285. Kraitchman DL, Tatsumi M, Gilson WD, Ishimori T, Kedziorek D, Walczak P, Segars WP, Chen HH, Fritzes D, Izbudak I, Young RG, Marcelino M, Pittenger MF, Solaiyappan M, Boston RC, Tsui BM, Wahl RL, Bulte JW. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. *Circulation.* 2005 Sep 6; 112(10):1451-61. Epub 2005 Aug 29
286. Khandani AH, Wahl RL. Applications of PET in liver imaging. *Radiol Clin North Am.* 2005 Sep; 43(5):849-60
287. Osman NM, Cohade C, Fishman EK, Wahl RL. Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients. *J Nucl Med.* 2005 Aug;46(8):1352-5
288. Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT Appearance of Bone Metastases Detected with FDG PET as Part of the Same PET/CT Examination. *Radiology* 2005 Nov; 237(2) 627-634
289. Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL. Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab. *J Clin Oncol.* 2005 Nov 1; 23(31):7985-93
290. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M. Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions

- in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas. *J Clin Oncol.* 2005 Oct 20;23(30):7565-73
291. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. "Direct Comparison of FDG-PET and CT Findings in Patients With Lymphoma: Initial Experience. *Radiology.* 2005 Dec; 237(3):1038-45
 292. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccareli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. *J Clin Endocrinol Metab.* 2005 Dec 29; Epub, ahead of print
 293. Tatsumi M, Cohade C, Mourtizokos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. *Eur J Nucl Med Mol Imaging.* 2005 Oct 29
 294. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl RL, Weaver DL, Wolff AC, Winer EP; American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. *J Clin Oncol.* 2005 Oct 20;23(30):7703-20
 295. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. *Radiology.* 2005 Dec; 237(3):1038-45
 296. Bristow RE, Giuntoli RL 2nd, Panny HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. *Gynecol Oncol.* 2005 Nov;99(2):294-300
 297. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, Wahl R, Tufano RP. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. *Laryngoscope.* 2005 Feb; 115(2):237-43
 298. Wahl RL. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. *J Nucl Med.* 2005 Jan;46 Suppl 1:128S-40S. Review
 299. Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. *Ann Surg Oncol.* 2006 Mar;13(3):397-404
 300. Ha PK, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, Califano J, Cummings CW, Flint PW, Wahl RL, Tufano RP. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg.* 2006 Jan;132(1):12-6
 301. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. *J Nucl Med.* 2006 Apr;47(4):603-8
 302. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. *J Nucl Med.* 2006 Apr;47(4):648-54
 303. Cho SY, Polster J, Engles JM, Hilton J, Abraham EH, Wahl RL. In vitro evaluation of adenosine 5'-monophosphate as an imaging agent of tumor metabolism. *J Nucl Med.* 2006 May;47(5):837-45
 304. Jacene HA, Stearns V, Wahl RL. Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT. *Clin Nucl Med.* 2006 Jul; 31(7):379-381
 305. Jacene HA, Ishimori T, Engles JM, Leboulleux S, Stearns V, Wahl RL. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. *J Nucl Med.* 2006 Jun; 47(6):950-6
 306. Goetze S, Pannu HK, Wahl RL. Clinically Significant Abnormal Findings on the "Nondiagnostic" CT Portion of Low-Amperage-CT Attenuation-Corrected Myocardial Perfusion SPECT/CT Studies. *J Nucl Med.* 2006 Aug; 47(8):1312-8
 307. Rosen RS, Fayad L, Wahl RL. Increased 18F-FDG Uptake in Degenerative Disease of the Spine: Characterization with 18F-FDG PET/CT. *J Nucl Med.* 2006 Aug; 47(8):1274-1280
 308. Song H, He B, Prideaux A, Du Y, Frey E, Kasecamp W, Ladenson PW, Wahl RL, Sgouros G. Lung Dosimetry for Radioiodine Treatment Planning in the Case of Diffuse Lung Metastases. *J Nucl Med.* 2006 Dec; 47(12):1985-1994

310. Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases.
311. Arch Surg. 2006 Dec; 141(12):1220-6; discussion 1227
312. Sgouros G, Song H, Ladenson PW, Wahl RL. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med. 2006 Dec; 47(12):1977-84
313. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007 Jan; 48 Suppl 1:19S-27S
314. Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med. 2007 Jan;48(1):150-7
315. Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Homing SJ, Weber W, Sargent DJ, Dodd L, Kom E, Armitage J, Schilsky R, Christian M, Oconor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, Degennaro LJ, Sigal E, Barker A, Woodcock J. FDG-PET Lymphoma Demonstration Project Invitational Workshop. Acad Radiol. 2007 Mar;14(3):330-9
316. Goetze S, Wahl RL. Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT
317. Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, Guidos AM, Wahl RL, Hendrix CW. Hyperosmolar Sexual Lubricant Causes Epithelial Damage in the Distal Colon: Potential Implication for HIV Transmission. J Infect Dis. 2007 Mar 1;195(5):703-10
318. Legarde C, Bledsoe JL, Wahl RL. Business models for academic medical center cyclotron operations. J Am Coll Radiol. 2005 Jun; 2 (6):526-33
319. Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, Wahl RL, Sgouros G. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007 Jun; 48 (6):1008-16
320. Melton GB, Lavelly WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, Gearhart SL. Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy. J Gastrointest Surg. 2007 Jun 1
321. Baba S, Tatsumi M, Ishimori T, Lilien DL, Engles JM, Wahl RL. Effect of nicotine and ephedrine on the accumulation of 18F-FDG in brown adipose tissue. J Nucl Med. 2007 Jun; 48 (6):981-6
322. Baba S, Engles JM, Huso DL, Ishimori T, Wahl RL. Comparison of Uptake of Multiple Clinical Radiotracers into Brown Adipose Tissue Under Cold-Stimulated and Nonstimulated Conditions. J Nucl Med. 2007
323. Melton GB, Lavelly WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, Gearhart SL. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg. 2007 Aug; 11 (8):961-9; discussion 969
324. Baba S, Cho SY, Ye Z, Cheng L, Engles JM, Wahl RL. How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. Mol Imaging. 2007 Sep-Oct;6(5):315-22
325. Baba S, Engles JM, Huso DL, Ishimori T, Wahl RL. Comparison of uptake of multiple clinical radiotracers into brown adipose tissue under cold stimulated and non-stimulated conditions. J Nucl Med. 2007 Oct;48(10): 1715-23
326. Jacene HA, Goudarzi B, Wahl RL. Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging. 2008 Jan; 35(1):89-94. Epub 2007 Oct 2
327. Mosely C, Jacene HA, Holz A, Grand DJ, Wahl RL. Extramedullary hematopoiesis on F-18 FDG PET/CT in a patient with metastatic colon carcinoma. Clin Nucl Med. 2007 Nov; 32(11):878-80
328. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov;48(11) 1767-76
329. Tatsumi M, Miller JH, Wahl RL. 18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies. J Nucl Med. 2007 Dec;48(12):1923-31
330. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF.

- Recommendations on the use of 18F-FDG PET in oncology. *J Nucl Med.* 2008 Mar;49(3):480-508. Doi: 10.2967/jnumed.107.047787. Epub 2008 Feb 20
331. Kasamon YL, Wahl RL, FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. *Curr Opin Oncol.* 2008 Mar; 20(2):206-19
 332. Kapadia NS, Engles JM, Wahl RL. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. *J Nucl Med.* 2008 Apr;49(4):674-8. Epub 2008 Mar14
 333. He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I, Frey EC. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-monte carlo simulation studies. *IEEE Trans Med Imaging.* 2008 Apr;27(4):521-30
 334. Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. *Med Phys.* 2008 Mar; 35(3):1123-34
 335. Goetze S, Lavelly WC, Ziessman HA, Wahl RL. Visualization of brown adipose tissue with 99mTc-methoxyisobutylisonitrile on SPECT/CT. *J Nucl Med.* 2008 May; 49(5):752-6
 336. Wahl RL. Individualizing cancer therapies using "anatomolecular" imaging. *J Nucl Med.* 2008 Jun;49(6):65N-68N
 337. Ford EC, Lavelly WC, Frassica DA, Myers LT, Asrari F, Wahl RL, Zellars RC. Comparison of FDG-PET/CT for Delineation of Lumpectomy Cavity for Partial Breast Irradiation. *Int J Radiat Oncol Biol Phys.* 2008 Jun 1; 71(2):595-602
 338. Goudarzi B, Jacene HA, Wahl RL. Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. *J Nucl Med.* 2008 Oct;49(10):1585-92. Epub 2008 Sep 15
 339. Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based radiobiological dosimetry. *Semin Nucl Med.* 2008 Sep;38(5):321-34. Doi: 10.1053/j.semnuclmed.2008.05.008
 340. Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Ventura VP, Khwaja A, Acha-Ngwodo O, Shanmugasundaram G, Syed L, Wahl RL, Geschwind JF. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. *J Pharmacol Exp Ther.* 2008 Oct;327(1):32-7
 341. Lodge MA, Jacene HA, Pili R, Wahl RL. Reproducibility of tumor blood flow quantification with 15O-water PET. *J Nucl Med.* 2008 Oct;49(10):1620-7
 342. Goudarzi B, Jacene HA, Wahl RL. Diagnosis and Differentiation of Bronchioloalveolar Carcinoma from Adenocarcinoma with Bronchioloalveolar Components with Metabolic and Anatomic Characteristics Using PET/CT. *J Nucl Med.* 2008 Oct;49(10):1585-92
 343. Terrovitis J, Kwok KF, Lautamäki R, Engles JM, Barth AS, Kizana E, Miake J, Leppo MK, Fox J, Seidel J, Pomper M, Wahl RL, Tsui B, Bengel F, Marbán E, Abraham MR. Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography. *J Am Coll Cardiol.* 2008 Nov 11;52(20):1652-60
 344. Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy. *J Nucl Med.* 2008 Dec 17. [Epub ahead of print]
 345. Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. *J Nucl Med.* 2009 Jan;50(1):8-17
 346. Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. *J Nucl Med.* 2009 Jan;50(1):8-7. Epub 2008 Dec 17
 347. He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, Frey EC. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. *Med Phys.* 2009 Feb;36(2):612-9
 348. Kasamon YL, Wahl RL, Ziessman HA, Blackford AL, Goodman SN, Fidyk CA, Rogers KM, Bolaños-Meade J, Borowitz MJ, Ambinder RF, Jones RJ, Swinnen LJ. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. *Biol Blood Marrow Transplant.* 2009 Feb;15(2):242-8
 349. Leboulleux S, Schroder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. *J Clin Endocrinol Metab.* 2009 Apr; 94(4):1310-6

350. Buijs M, Vossen JA, Geschwind JF, Ishimori T, Engles JM, Acha-Ngwodo O, Wahl RL, Vali M. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. *Invest New Drugs*. 2009 Apr;27(2):120-3
351. Wahl RL, Reif JS. Temporal trends in bull semen quality: a comparative model for human health? *Environ Res*. 2009 Apr;109(3):273-80. Epub 2009 Jan 31
352. He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, Flinn I, Hammes RJ, Bianco J, Kahl B, Frey EC. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. *Med Phys*. 2009 May;36(5):1595-601
353. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. *J Nucl Med*. 2009 May;50 Suppl 1:122S-50S
354. Ziessman HA, Chander A, Clarke JO, Ramos A, Wahl RL. The added diagnostic value of liquid gastric emptying compared with solid emptying alone. *J Nucl Med*. 2009 May;50(5):726-31
355. Kelloff GJ, Choyke P, Coffey DS, Prostate Cancer Imaging Working Group. Challenges in clinical prostate cancer: role of imaging. *AJR Am J Roentgenol*. 2009 Jun;192(6):1455-70
356. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. *J Clin Oncol*. 2009 Jun 1;27(16):2697-704. Doi: 10.1200/JCO.2008.18.8383. Epub 2009 Apr 20
357. Hou P, Liu D, Ji M, Liu Z, Engles JM, Wahl RL, Xing M. Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. *PLoS One*, 2009 Jul 10;4(7):e6200
358. Lodge MA, Rahmim A, Wahl RL. A Practical, Automated Quality Assurance Method for Measuring Spatial Resolution in PET. *J Nucl Med*. 2009 Aug;50(8):1307-14 Epub 2009 Jul 17
359. Jacene HA, Wahl RL. The importance of brown adipose tissue. *N Engl J Med*. 2009 Jul 23;361(4):417-8; author reply 419-20
360. Tatsumi M, Cohade C, Bristow RE, Wahl RL. Imaging uterine cervical cancer with FDG-PET/CT: direct comparison with PET. *Mol Imaging Biol*. 2009 Jul-Aug;11(4):229-35
361. Heston TF, Wahl RL. Clinical significance of iodine-123 metaiodobenzylguanidine cardiac imaging. *J Am Coll Cardiol*. 2009 Aug 4;54(6):575-6; author reply 576
362. Delbeke D, Schoder H, Martin WH, Wahl RL. Hybrid imaging (SPECT/CT): improving therapeutic decisions. *Semin Nucl Med*. 2009 Sep;39(5):308-40
363. Ford EC, Herman J, Yorke E, Wahl RL. 18F-FDG PET/CT for image-guided an intensity-modulated radiotherapy. *J Nucl Med*. 2009 Oct;50(10):1655-65. Epub 2009 Sept 16
364. Terrovitis J, Lautamaki R, Bonios M, Fox J, Engles JM, Yu J, Leppo MK, Pomper MG, Wahl RL, Seidel J, Tsui BM, Bengel FM, Abraham MR, Marban E. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. *J Am Coll Cardiol*. 2009 Oct 20;54(17):1619-26
365. Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, Horton KM, Kamel I, Macura KJ, Tsai HL, Kowalski J, Wahl RL. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. *J Nucl Med*. 2009 Nov;50(11):1760-9. Epub 2009 Oct 16
366. Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, Wahl RL. Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. *J Nucl Med*. 2009 Nov;50(11):1751-9. Epub 2009 Oct 16
367. Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, Ewertz ME, Esaias CE, Ladenson PW, Sgouros G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. *J Nucl Med*. 2009 Nov;50(11):1844-7. Epub 2009 Oct 16
368. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster m, Lassman M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. *J Clin Endocrinol Metab*. 2009 Nov;94(11):4171-9. Epub 2009 Oct 22
369. Lodge MA, Rahmim A, Wahl RL. Simultaneous measurement of noise and spatial resolution in PET phantom images. *Phys Med Biol*. 2010 Feb 21;55(4):1069-81. Epub 2010 Jan 28

370. Baba S, Jacene HA, Engles JM, Honda H, Wahl RL. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. *J Nucl Med.* 2010 Feb;51(2):246-50
371. Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene H, Sgouros G. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. *J Nucl Med.* 2010 Mar;51(3):368-75. Epub 2010 Feb 11
372. Heston TF, Wahl RL. Molecular imaging in thyroid cancer. *Cancer imaging.* 2010 Jan 20;10(1):1-7
373. Liapi E, Geschwind, J. F., Vali, M., Khwaja, A. A., Prieto-Ventura, V., Buijs, M., Vossen, J. A., Ganapathy, S., and Wahl, R. L. (2011) Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor, *J Nucl Med* 52, 225-230
374. Bonta DV, Wahl RL. Overcorrection of iodinated contrast attenuation in SPECT-CT: phantom studies. *Med Phys.* 2010 Sep;37(9):4897-901
375. Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias C, Jacene HA, Sgouros G. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherap. *J nucl Med.* 2010 Mar;51(3):368-75.
376. Lodge MA, Rahmim A, Wahl RL. Simultaneous measurement of noise spatial resolution in PET phantom images. *Phys Med Biol.* 2010 Feb 21;55(4):1069-81
377. Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL. Radioimmunotherapy in non-Hodgkins lymphoma: opinions of U.S. medical oncologies and hematologists. *J Nucl Med.* 2011 May;52(5):830-8
378. Gourdarzi B, Jacene HA, Wahl RL. Measuring the “unmeasurable”:assessment of bone marrow response to therapy using FDG-PET in patient with lymphoma. *Acad Radiol.* 2010 Sep;17(9):1175-85
379. Heston TF, Wahl RL. Molecular imaging in thyroid cancer. *Cancer Imaging.* 20120 Aug;103(8):723-4
380. Hobbs RF, McNutt T, Baechler S, He B, Esaias CE, Frey EC, Loeb DM, Wahl RL, Shokek O, Sgouros G. A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. *Int j Radiat Oncol Biol Phys.* 2011 Jul 15;80(4):1256-62
381. Jacene HA, Cohade CC, Zhang Z, Wahl RL. The Relationship between Patients’ Serum Glucose Levels and Metabolically Active Brown Adipose Tissue Detected by PET/CT. *Mol Imaging Biol.* 2011 Dec;13(6):1278-83
382. Lodge MD, Chaudhry MA, Udall DN, Wahl RL. Characterization of a perirectal artifact in 18F-FDG PET/CT. *J Nucl Med.* 2010 Oct ;51(10):1501-6
383. Lodge MA, Mhlanga JC, Cho SY, Wahl RL. Effect of Patient Arm Motion in Whole-Body PET/CT. *J Nucl Med.* 2011 Dec;52(12):1891-7
384. Song N, He B, Wahl RL, Frey EC. EQPlanar: a maximum-likelihood method for accurate organ activity estimation from whole body planar projections. *Phys Med Biol.* 2011 Sep 7;56(17):5503-24
385. Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer. *Eur J Nucl Med Mol Imaging.* 2011 May;38 Suppl 1:S41-7
386. Bonios M, Terrovitis J, Chang CY, Engles JM, Higuchi T, Lautamäki R, Yu J, Fox J, Pomper M, Wahl RL, Tsui BM, O'Rourke B, Bengel FM, Marbán E, Abraham MR. Myocardial substrate and route of administration determine acute cardiac retention and lung bio-distribution of cardiosphere-derived cells. *JNucl Cardiol.* 2011 May;18(3):443-5
387. Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC. A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. *Radiology.* 2011 Mar;258(3):906-14
388. Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at US academic medical centers: an imaging response assessment team survey. *J Nucl Med* 2011 Feb;52(2):311-7
389. Liapi E, Geshwind JF, Vali M, Khwaja AA, Prieto-Ventura V, Buijus M, Vossen JA, Ganapathy S, Wahl RL. Assessment of tumoricidal efficacy and response to treatment with 18F-FDG Pet/CT after intra-arterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor. *J Nucl Med.* 2011 Feb;52(2):225-30
390. Buckler AJ, Bresolin L, Dunnick NRL, Sullivan DC, Aerts HJ, BEndriem B, Bendtsen C, Boellaard R, Boone JM, Cole PE, Conklin JJ, Dorfman GS, Douglas PS, Eidsaunet W, Elsinger C, Frank RA, Gatsonis C, Giger ML, Gupta SN, Gustafson D, Hoekstra OS, Jackson EF, Karam L, Kelloff GJ, Kinahan PE, McLennan G, Miller CG, Mozler PD, Muller KE, Patt R, Raunig D, Rosen M, Rupani H, Schwartz LH, Siegel BA, Sporensen AG, Wahl RL, Waterton J, Wolf W, Zahlmann G, Zimmerman B.

- Quantitative imaging test approval and biomarker qualification: Interrelated but distinct activities. *Radiology*. 2011 June;259(3):875-84
391. Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC, Group. A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. *Radiology*. 2011 Mar;258(3):906-14
 392. Wahl RL, Herman JM, Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. *Semin Radiat Oncol*. 2011 Apr;21(2):88-100
 393. Potter R, Horti AG, Ravert HT, Holt DP, Finley P, Scheffel U, Dannals RF, Wahl RL. Synthesis and in vivo evaluation of (S)-6-(4-fluorophenoxy)-3-((1-[11C]methylpiperidin-3-yl)methyl)-2-*o*-tolylquinazolin-4(3H)-one, a potential PET tracer for growth hormone secretagogue receptor (GHSR). *Bioorg Med Chem*. 2011 Apr;19(7):2368-72
 394. Bonios M, Terrovitis J, Chang CY, Engles JM, Higuchi T, Lautamaki R, Yu J, Fox J, Pomper M, Wahl RL, Tsui BM, O'Rourke B, Bengel FM, Marban E, Abraham MR. Myocardial substrate and route of administration to determine acute cardiac retention and lung bio-distribution of cardiosphere-derived cells. *J Nucl Cardiol*. 2011 May;18(3):443-50
 395. Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S, Bluemke DA, Wahl R, Stearns V. Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. *Breast Cancer Res Treat*. 2011 Jul;128(1):119-26
 396. Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (3D-Rd) with 124I PET 131I therapy of thyroid cancer. *Eur J Nucl Med mol Imaging*. 2011 May;38 Suppl 1:S41-7
 397. Madar I, Isoda T, Finley P, Angle J, Wahl R. 18F-fluorobenzyl triphenyl phosphonium: a noninvasive sensor of brown adipose tissue thermogenesis. *J Nucl Med*. 2011 May;52(5):808-14
 398. Schaefer NG, Huang P, Buchanan JW, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. *J Nucl Med*. 2011 May;52(5):830-8
 399. Schaefer NG, James E, Wahl RL. Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma. *Nucl Med Commun*. 2011 Nov;32(11):1046-51
 400. Schaefer NG, Geschwind JF, Engles J, Buchanan JW, Wahl RL. Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. *Transl Res*. 2012 Jan;159:51-7
 401. Senthamizhelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, Wahl RL, Loeb DM, Sgouros G. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. *J Nucl Med*. 2012 Feb;53(2):215-24
 402. Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Wahl R, Forastiere A, Gillison M. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (MO) squamous cell carcinoma of the head and neck. *Clin Cancer Res*. 2012 Mar 15;18(6):1735-42
 403. Louissaint NA, Fuchs EJ, Bakshi RP, Nimmagadda S, Du Y, Macura KJ, King KE, Wahl RL, Goldsmith AJ, Caffo B, Cao YJ, Anderson J, Hendrix CW. Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse. *J Infect Dis*. 2012 Mar 1;205(5):725-32
 404. Bravo PE, Pinheiro A, Higuchi T, Rischpler C, Merrill J, Santaularia-Tomas M, Abraham MR, Wahl RL, Abraham TP, Bengel FM. PET/CT Assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. *J Nucl Med*. 2012 Mar;53(3):407-14
 405. Cao YJ, Caffo BS, Fuchs EJ, Lee LA, Du Y, Li L, Bakshi RP, Macura K, Khan WA, Wahl RL, Grohskopf LA, Hendrix CW. Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and Magnetic Resonance Imaging. *Br J Clin Pharmacol*. 2012 Mar 9. Doi:10.1111/j1365-2125.2012.04267.x.
 406. Frohlich E, Maier E, Wahl RL. Interspecies differences in membrane-associated protease activities of thyrocytes and their relevance for thyroid cancer studies. *J Exp Clin Cancer Res*. 2012 May 16;31(1):45
 407. Lodge MA, Chaudhry MA, Wahl RL. Noise consideration for PET quantification using maximum and peak standardized uptake value. *J Nucl Med*. 2012 Jul;53(7):1041-7
 408. Bravo PE, Pozios I, Pinheiro A, Merrill J, Tsui BM, Wahl RL, Bengel FM, Abraham MR, Abraham TP. Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic

- changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy. *Am J Cardiol.* 2012 Oct 1;110(7):1033-9.
409. Chang CY, Chan AT, Armstrong PA, Luo HC, Higuchi T, Strehin IA, Vakrou S, Lin X, Brown SN, O'Rourke B, Abraham TP, Wahl RL, Steenbergen CJ, Elisseeff JH, Abraham MR. Hyaluronic acid-human blood hydrogel for stem cell transplantation. *Biomaterials.* 2012 Nov;33(32):8026-33
 410. Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS. Promise and pitfalls of quantitative imaging in oncology clinical trials. *Magn Reson Imaging.* 2012 Aug 13
 411. Rajaram M, Tahari AK, Lee AH, Lodge MA, Tsui B, Nekolla S, Wahl RL, Bengel FM, Bravo PE. Cardiac PET/CT misregistration causes significant changes in estimated myocardial blood flow. *J Nucl Med.* 2013 Jan;54(1):50-4.
 412. Gok B, Jallo G, Hayeri R, Wahl R, Aygun N. The evaluation of FDG-PET imaging for epileptogenic focus localization in patients with MRI positive and MRI negative temporal lobe epilepsy. *Neuroradiology.* 2013 May;55(5):541-50.
 413. Dieudonne A, Hobbs RF, Lebtahi R, Maurel F, Baechler S, Wahl RL, Boubaker A, Le Guludec D, Sgouros G, Gardin I. Study of the impact of tissue density heterogeneities on 3-dimensional abdominal deosimetry; comparison between dose kernel convolution and direct Monte Carlo methods. *J Nucl Med.* 2013 Feb;54(2):236-43.
 414. Chang C, Chan A, Lin X, Higuchi T, Terrovitis J, Afzal JM, Rittenbach A, Sun D, Vakrou S, Woldemichael K, O'Rourke B, Wahl R, Pomper M, Tsui B, Abraham MR. Cellular bioenergetics is an important determinant of the molecular imaging signal derived from luciferase and the sodium-iodide symporter. *Circ Res.* 2013 Feb 1;112(3):441-50.
 415. Bravo PE, Zimmerman SL, Luo HC, Pozios I, Rajaram M, Pinheiro A, Steenbergen C, Kamel IR, Wahl RL, Bluemke DA, Bengel FM, Abraham MR, Abraham TP. Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging.* 2013 Mar 1;6(2):210-7.
 416. Rischpler C, Fukushima K, Isoda T, Javadi MS, Dannals RF, Abraham R, Wahl R, Bengel FM, Higuchi T. Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. *Eur J Nucl Med Mol Imaging.* 2013 Jul;40(7):1077-83.
 417. Bravo PE, Goudarzi B, Rana U, Filho PT, Castillo R, Rababy C, Ewertz M, Ziessman HA, Cooper DS, Ladenson PW, Wahl RL. Clinical significance of discordant findings between pre-therapy (123I) and post-therapy (131I) whole body scan in patients with thyroid cancer. *Int J Clin Exp Med.* 2013 May 22;6(5):320-33.
 418. Weber WA, Wahl RL. Surveillance of cancer patients with imaging: self-evident or evident-based? *J Nucl Med.* 2013 Sep;54(9): 1513-5.
 419. Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ, Sgouros G. Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-hodgkin lymphoma. *J Nucl Med* 2013 Sep;54(9):1535-42.
 420. Tahari AK, Lee A, Rajaram, Fukushima K, Lodge MA, Lee BC, Ficaro EP, Nekolla S, Klein R, Dekemp RA, Wahl RL, Bengel FM, Bravo PE. Absolute myocardial flow quantification with (82)Rb PET/CT: comparison of different software packages and methods. *Eur J Nucl Med Mol Imaging.* 2014 Jan 41(1): 126-35. Epub 2013 Aug 28.
 421. Karakatsanic NA, Lodge MA, Tahari AK, Zhou Y, Wahl RL, Rahmim A. Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application. *Phys Med Biol.* 2013 Oct 21;58(20):7391-7418 Epub 2013 Sep 30.
 422. Karakatsanic NA, Lodge MA, Zhou Y, Wahl RL, Rahmim A. Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation. *Phys Med Biol* 2013 Oct 21;58(20):7419-7445.
 423. Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials Planning Meeting. *Int J Gynecol Cancer.* 2013 Oct;23(8):1528-34.
 424. Wahl RL. 2013 SNMMI Highlights Lecture: Oncology. *J Nucl Med.* 2013 Nov;54(11):11N-22N.
 425. Frohlich E, Wahl R, Czarnocka B, Duntas L. New Diagnostic and Therapeutic Tools for Thyroid Cancer. *Int J Endocrinol.* 2013;2013:312-378.
 426. Paidpally V, Tahari AK, Lam S, Alluri K, Marur S, Koch W, Wahl RL, Subramaniam RM. *J Nucl Med.* 2013 Dec;54(12):2039-45.

427. Tahari AK, Lodge MA, Wahl RL. Respiratory-gated PET/CT versus Delayed Images for the Quantitative Evaluation of Lower Pulmonary and Hepatic Lesions. *J Med Imaging Radiat Oncol.* 2014 Jun 58(3):277-82.
428. Valenta I, Dilsizian V, Quercioli A, Jungling FD, Ambrosio G, Wahl RL, Schindler TH. Impact of Obesity and Bariatric Surgery on Metabolism and Coronary Circulatory Function. *Curr Cardiol Rep.* 2014 Jan;16(1):433.
429. Fahey F, Zukotynski K, Capala J, Knight N; Organizing Committee, Contributors, and Participants of NCI/SNMMI Joint Workshop on Targeted Radionuclide Therapy. *J Nucl Med.* 2014 Feb;55(2):337-48.
430. Tahari AK, allure KC, Quon H, Koch W, Wahl RL, Subramaniam RM. FDG PET/CT Imaging of Oropharyngeal Squamous Cell Carcinoma: Characteristics of Human Papillomavirus-positive and –negative tumors. *Clin Nucl Med.* 2014 Mar;39(3):225-31.
431. Mhlanga JC, Durand D, Tsai HL, Durand CM, Leal JP, Wang H, Moore R, Wahl RL. Differentiation of HIV-associated Lymphoma from HIV-associated Reactive Adenopathy using Quantitative FDG PET and Summetry. *Eur J Nucl Med Mol Imaging.* 2014 Apr;41(4):596-604.
432. Tahari AK, Wahl RL. Quantitative FDG PET/CT in the community: Experience from Interpretation of Outside Oncologic PET/CT Exams in Referred Cancer Patients. *J Med Imaging Radiat Oncol.* 2014 Apr;58(2):183-8. Doi:10.1111.1754-9485.12140. Epub 2013 Dec 3.
433. Antoniou AJ, Marcus C, Tahari AK, Wahl RL, Subramaniam RM. Follow-up or Surveillance 18F-FDG PET/CT and Survival Outcome in Lung Cancer Patients. *J Nucl Med.* 2014 May 19 55(7): 1128-1131, Epub 2014 Apr 28.
434. Mounts JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, Gillies RJ, Huang W, Jacobs MA, Kinahan PE, Laymon CM, Linden HM, Mankoff DA, Schwartz LH, Shim, H, Wahl RL. Letter to Cancer Center Directors: Progress in Quantitative Imaging as a means to Predict and/or Measure Tumor Response in Cancer Therapy Trials. *J Clin Oncol.* 2014 Jul 1 32(19): 2115-6. Epub 2014 May 27. Pii: JCO. 2014.55.8866
435. Chirindel A, Alluri KC, Tahari AK, Chaudhry M, Wahl RL, Lodge MA, Subramaniam RM. Liver Standardized Uptake Value Corrected for Lean Body Mass at FDG PET/CT: Effect of FDG Uptake Time. *Clin Nucl Med.* 2015 Jan 40(1): e17-22. Epub 2014 May 28.
436. Hyun O J, Lodge MA, Jagannath S, Buscaglia JM, Olagbemi Y, Wahl RL. An Exocrine Pancreatic Stress Test with 11C-Acetate PET and Secretin Stimulation. *J Nucl Med.* 2014 May 19;55(7):1128-1131.
437. Tahari AK, Chien D, Azadi JR, Wahl RL. Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging. *J Nucl Med.* 2014 Sep 55(9): 1481-4.
438. Marcus C, Ciarallo A, Tahari AK, Mena E, Koch W, Wahl RL, Kiess AP, Kang H, Subramaniam RM. Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria)-Interreader, Reliability, Accuracy, and Survival Outcomes. *J Nucl Med.* 2014 Sep 55(9): 1411-6.
439. Raunig DL, McShane LM, Pennello G, Gatsonis C, Crson PL, Voyvodic JT, Wahl RL, Kurland BF, Schwarz AJ, Gonen M, Zahlmann G, Kondratovich M, O'Donnell K, Petrick N, Cole PE, Garra B, Sullivan DC; Quantitative assessment of myocardial blood flow—clinical and research applications. QIBA Technical Performance Working Group. *Stat Methods Med Res.* 2015 Feb;24(1):27-67.
440. Wang X, Wahl R. Responses of the insulin signaling pathways in the brown adipose tissue of rats following cold exposure. *PLoS One.* 2014 Jun 10;9(6):e99772. Doi: 10.1371/journal.pone.0099772.eCollection 2014.
441. Schindler TH, Quercioli A, Valenta I, Ambrosio G, Wahl RL, Dilsizian V. Quantitative Assessment of Myocardial Blood Flow—Clinical and Research Applications. *Semin Nucl Med.* 2014 Jul;44(4):274-93. Doi: 10.1053/j.semnuclmed.2014.04.002
442. Dholakia AS, Chaudhry M, Leal JP, Chang DT, Raman SP, Hacker-Prietz A, Su Z, Pai J, Oteiza KE, Griffith ME, Wahl RL, Tryggestad E, Pawlik T, Laheru DA, Wolfgang CL, Koong AC, Herman JM. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys.* 2014 Jul 1;89(3):539-46.doi: 10.1016/j.ijro.2014.02.031\
443. Mhlanga JC, Carrino JA, Lodge M, Wang H, Wahl RL. 18F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters. *Eur J Nucl Med Mol Imaging.* 2014 Dec;41(12):2337-45. 2014 Aug 19
444. Alluri KC, Tahari AK, Wahl RL, Koch W, Chung CH, Subramaniam RM. Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal

- squamous cell carcinoma. *AJR Am J Roentgenol.* 2014 Oct;203(4):897-903. doi: 10.2214/AJR.14.12497. PubMed PMID: 25247958; PubMed Central PMCID: PMC4332840.
445. Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V. TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. *J Nucl Med.* 2015 Jan;56(1):31-7.
 446. Valenta I, Wahl RL, Schindler TH. Longitudinal myocardial blood flow gradient and CAD detection. *Curr Cardiol Rep.* 2015 Jan;17(1):550.
 447. Marcus C, Paidpally V, Antoniou A, Zaheer A, Wahl RL, Subramaniam RM. 18F-FDG PET/CT & Lung Cancer: Value of Fourth and Subsequent Post Therapy follow up scans in Patient Management. *J Nucl Med.* 2015 Feb;56(2):204-8. 2015 Jan 22. pii: jnumed.114.147884.
 448. Tahari AK, Paidpally V, Chirindel A, Wahl RL, Subramaniam RM. Two-Time-Point FDG PET/CT: Liver SULmean Repeatability. *AJR Am J Roentgenol.* 2015 Feb;204(2):402-7.
 449. Anizan N, Wang H, Zhou XC, Wahl RL, Frey EC. Factors affecting the repeatability of gamma camera calibration for quantitative imaging applications using a sealed source. *Phys Med Biol.* 2015 Feb 7;60(3):1325-37.
 450. Antoniou AJ, Raja S, El-Khouli R, Mena E, Lodge MA, Wahl RL, Clarke JO, Pasricha P, Ziessman HA. Comprehensive radionuclide esophagogastrointestinal transit study: methodology, reference values, and initial clinical experience. *J Nucl Med.* 2015 May;56(5):721-7. PMID: 25766893.
 451. Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman GS. Summary of the UPICT Protocol for FDG PET/CT Imaging in Oncology Clinical Trials. *J Nucl Med.* 2015 Jun;56(6):955-61. PMID: 25883122.
 452. Chirindel A, Alluri KC, Chaudhry MA, Wahl RL, Pawlik TM, Herman JM, Subramaniam RM. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. *AJR Am J Roentgenol.* 2015 May; 204(5):1093-9.
 453. Bravo PE, Tahari A, Pozios I, Luo HC, Bengel FM, Wahl RL, Abraham MR, Abraham TP. Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy: Clinical predictors and potential mechanisms. *J Nucl Cardiol.* 2015 May 20. [Epub ahead of print]
 454. Lodge MA, Holt DP, Kinahan PE, Wong DF, Wahl RL. Performance assessment of a NaI(Tl) gamma counter for PET applications with methods for improved quantitative accuracy and greater standardization. *EJNMMI Phys.* 2015 May;2. pii: 11. doi: 10.1186/s40658-015-0114-3.
 455. Bravo PE, Luo HC, Pozios I, Zimmerman SL, Corona-Villalobos CP, Sorensen L, Kamel IR, Bluemke DA, Wahl RL, Abraham MR, Abraham TP. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? *Eur Heart J Cardiovasc Imaging.* 2015 Jun 14. pii: jev154. [Epub ahead of print]
 456. Rowe SP, Vicente E, Anizan N, Wang H, Leal JP, Lodge MA, Frey EC, Wahl RL. Repeatability of Radiotracer Uptake in Normal Abdominal Organs with ¹¹¹In-Pentetreotide Quantitative SPECT/CT. *J Nucl Med.* 2015 Jul;56(7):985-8.
 457. Marashdeh W, Wahl RL. Case Report: Brown Fat Accumulation of Tc-99m Macroaggregated Albumin in a Lung Perfusion Study in a Patient With Multiple Lung Arteriovenous Malformations and Right-to-Left Shunting. *Medicine (Baltimore).* 2015 Oct;94(42):e1820. doi: 10.1097/MD.0000000000001820.
 458. Wahl RL, Horner TJ, Lin TS, Kaminski MS. Observational Retrospective Study of Altered Biodistribution of Tositumomab and ¹³¹I-Tositumomab. *J Nucl Med.* 2015 Nov;56(11):1800-3. doi: 10.2967/jnumed.115.156190. Epub 2015 Sep 3.
 459. Karakatsanis NA, Zhou Y, Lodge MA, Casey ME, Wahl RL, Zaidi H, Rahmim A. Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET. *Phys Med Biol.* 2015 Nov 21;60(22):8643-73.
 460. Plyku D, Loeb DM, Prideaux AR, Baechler S, Wahl RL, Sgouros G, Hobbs RF. Strengths and Weaknesses of a Planar Whole-Body Method of (¹⁵³Sm) Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. *Cancer Biother Radiopharm.* 2015 Nov;30(9):369-79.
 461. Sullivan DC, Obuchowski NA, Kessler LG, Raunig DL, Gatsonis C, Huang EP, Kondratovich M, McShane LM, Reeves AP, Barboriak DP, Guimaraes AR, Wahl RL; Metrology Standards for

- Quantitative Imaging Biomarkers. RSNA-QIBA Metrology Working Group. *Radiology*. 2015 Dec;277(3):813-25.
462. Wu I, Wang H, Huso D, Wahl RL. Optimal definition of biological tumor volume using positron emission tomography in an animal model. *EJNMMI Res*. 2015 Dec;5(1):58.
 463. Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL. Quantitative Imaging in Cancer Clinical Trials. *Clin Cancer Res*. 2016 Jan 15;22(2):284-90.
 464. Wahl RL. Breast Cancer Supplement: Quo Vadis—PET and Single Photon Breast Cancer. *J Nucl Med*. 2016 Feb;57 Suppl 1:3S-8S.
 465. O JH, Lodge MA, Wahl RL. Practical PERCIST: A simplified guide to PET Response Criteria in Solid Tumors (PERCIST) 1.0. *Radiology*. 2016 Feb 24;142043
 466. O JH, Luber BS, Leal JP, Wang H, Bolejack V, Schuetz SM, Schwartz L, Helman LJ, Reinke D, Baker LH, Wahl RL. Response to early treatment evaluated with 18F-FDG PET and PERCIST 1.0 predicts survival in patients with Ewing sarcoma family of tumors treated with a monoclonal antibody to the insulin-like growth factor 1 receptor. *J Nucl Med*. 2016 May; 57(5)735-40.
 467. Chen KY, Cypess AM, Laughlin MR, Haft CR., Hu HH, Bredella MA., Enerback S, Kinahan PE, Lichtenbelt WM, Lin FI, Sunderland JJ, Virtanen KA, Wahl RL. Brown Adipose Reporting Criteria in Imaging Studies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans. *Cell Metabolism*. 2016 August; 24 1-13.
 468. Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetz SM, Baker LH. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. *J Clin Oncol*. 2016 Aug 29.
 469. Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL. Repeatability of 18F-FLT PET in a Multi-Center Study of Patients with High Grade Glioma. *J Nucl Med*. 2017 March; 58 393-398.
 470. Yue J, Mauxion T, Reyes D, Lodge MA, Hobbs RF, Rong X, Dong Y, Herman JM, Wahl RL, Geschwind JFH, Frey EC. Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer. *Medical Physics*. 2016 October 43.10: 5779-5790.
 471. Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL. Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. *Mol Imaging Biol*. 2017 June; 19 429-436.
 472. Soltani M, Sefidgar M, Bazmara H, Casey ME, Subramaniam RM, Wahl RL, Rahmim A. Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. *Ann Nucl Med*. 2017 Feb; 31 109-124.
 473. Chu LC, Tsai HL, Wang H, Crandall J, Javadi MS, Wahl RL. Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma. *EJNMMI Res*. 2016 Dec; 6(1)42.
 474. Crandall J, Tahari AK, Juergens R, Brahmer, Rudin C, Esposito G, Subramaniam DS, Knopp MV, NC Hall, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL. A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stage IB-IIIa resectable NSCLC. *EJNMMI Research*. 2017 Dec; 7 8.
 475. Vicente EM, Lodge MA, Rowe SP, Wahl RL, Frey EC. Simplifying volumes-of-interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole-organ VOIs. *Med Phys*. 2017 May; 44(5)1707-1717.
 476. Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA, The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. *J Neurooncol*. 2017 May; 132(3)513-519.
 477. Cho SY, Lipson EJ, Im HJ, Rowe SP, Mena E, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early Time-Point FDG-PET/CT Imaging in Patients with Advanced Melanoma. *J Nucl Med*. 2017 Mar 30
 478. O JH, Jacene HA, Luber B, Wang H, Leal J, Huynh MH, Wahl RL. Quantitation of cancer treatment response by FDG PET/CT: multi-center assessment of measurement variability. *J Nucl Med*. 2017 Mar 30.
 479. Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D, Timed sequential therapy

- of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. *Neuro Oncol.* 2017 Jun 1; 19(6)845-852.
480. Duncan JR, Lieber MR, Adachi N, Wahl RL DNA Repair Following Exposure to Ionizing Radiation is Not Error-Free. *J Nucl Med.* 2017 Aug 3
481. Chondronikola M, Beeman S, Wahl RL, Non-invasive methods for the assessment of brown adipose tissue in humans. *J Physiol.* 2017 Nov 8.
482. Mhlanga JC, Chirindel A, Lodge MA, Wahl RL, Subramaniam RM Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms. *Nucl Med Commun.* 2017 Dec 8.

Non-Peer Reviewed

1. Wahl RL. "Monoclonal antibodies: 'Radioactive magic bullets' can detect and treat cancer." *Michigan Hospital*, June 1987; 33-34
2. Wahl RL. "Imaging of thyroid nodules." *Imaging Update*, Fall 1990; III (3)
3. Wahl RL. "Radiolabeled antibodies: From research to clinical tool." *Decisions in Medical Economics*, July 1992
4. Wahl RL. "Radiolabeled monoclonal antibodies." *Administrative Radiology*, October 1992
5. Alderson PO, Bland WH, Coleman RE, Conway JJ, Fletcher JW, Goldsmith SJ, Kirchner, PT, Kraft RA, Powsner ER, Ross JF, Schelbert HR, Strauss HW, Wahl RL, Woolfended JM. Components of Professional Competence of Nuclear Medicine Physicians American Board of Nuclear Medicine. *J Nucl Med* 1994 (Position Statement); 35(7):1234-1235
6. Kazerooni EA, Wahl RL, and Quint LE. "Current status of PET scanning for lung cancer staging." *Michigan Oncology Journal*, Fall 1995:11-13
7. Wahl RL. "ICP and 7th Annual PET Conference." *PET and SPECT NEWS - Tomography in Nuclear Medicine*, December 1995:3-4
8. Wahl, RL. "Clinical Application of PET in Oncology." *A Clinical Symposium on PET and SPECT*, January 1995:53-61
9. Wahl RL. "PET begins to prove itself in Cancer Care." *Diagnostic Imaging*, December 1996:67-71
10. Hawkins, RA and Wahl RL. "Image Guided Diagnosis and Treatment of Breast Cancer." *US Public Health Services on Women's Health*. Shtern F, Wood S, and Krause C. (eds) July 1999:17-18
11. Chance B, Collins JM, Eckelman WC, Wahl RL et. al. Report of the Joint Working Group on Quantitative In Vivo Functional Imaging in Oncology. Sponsored by the U.S. Public Health Service's Office on Women's Health and National Cancer Institute, held January 6-8, 1999. Shtern F and Winfield D (eds). *Acad Radiol* 1999

Additional articles available upon request.

Book Chapters

1. Abeloff M, Armitage, Kastan, Niederhuber, Wahl RL, "Clinical Oncology, 3rd Edition" Chapter 18. "Imaging" Elsevier Science Philadelphia, PA 2003
2. Abeloff's Clinical Oncology, 5th Edition. 2013. Chapter 21. "Imaging" . Elsevier Science Philadelphia, PA
3. Additional chapters available on request

Books

1. "Atlas of Clinical Positron Emission Tomography," Maisey M, Wahl RL, Barrington S. Arnold Publishers (Oxford University Press), London UK. 1999, ISBN# 0-340-740981
2. "Principles and Practice of Positron Emission Tomography" Wahl RL, Buchanan JW. (Lippincott Williams & Wilkins), Philadelphia PA. 2002, ISBN# 0-7817-2904-1
3. "Atlas of Clinical Positron Emission Tomography 2nd Edition" Barrington SF, Maisey MN, Wahl RL. Arnold Publishers (Oxford University Press, Inc), New York, NY, 2006, ISBN# 0-340-81693 7
4. "Wahl & Isreal Atlas of PET/CT With SPECT/CT" Wahl Richard L., Israel Ora. Saunders Elsevier, Philadelphia, PA, ISBN# 978-1-4160-3361-5
5. "Principles and Practice of PET/CT, 2nd edition: Wahl, Richard L. editor. Lippincott Williams & Wilkins, Philadelphia, PA. 2008. ISBN #0781779995

Abstracts

1. Lana Volokh, Richard Wahl, Eric Frey, Yong Du, Harvey Ziessman, Taek-Soo Lee, Xide Zhao, Heather Jacene, and Benjamin Tsui Study of iterative SPECT corrective reconstruction methods for lesion detection and localization in In-111 ProstaScint® imaging by means of combination of Monte-Carlo simulations and clinical evaluation techniques. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 188P.
2. William Lavelly, Heather Jacene, Jeffrey Leal, Zhe Zhang, and Richard Wahl. Comparative performance of FDG PET/CT and Tc-99m bone scintigraphy for detecting and localizing bone metastases in patients with breast cancer *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 35P.
3. Richard Wahl, Eric Frey, Brad Kahl, Jay Bianco, Richard Hammes, J Webb, L Swinnen, w Kasecamp, G Sgouros, and Ian Flinn When can hematopoietic stem cells safely be reinfused following myeloablative radioimmunotherapy? Comparison of methods and time to re-engraftment following Y 90 ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 98P.
4. E. Frey, B. He, G. Sgouros, I. Flinn, and R. Wahl. Estimation of post-therapy marrow dose rate in myeloablative Y-90 ibritumomab tiuxetan therapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 156P.
5. Ross Filice, H Jacene, W Kasecamp, and R Wahl Comparison of Bexxar® (tositumomab and iodine I-131 tositumomab) and Zevalin® (Y-90 ibritumomab tiuxetan) in a single center clinical practice setting. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 106P.
6. Yong Du, Bin He, Richard Wahl, and Eric Frey. Model-based downscatter estimation in simultaneous I-131/In-111 dual-isotope SPECT imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 196P.
7. William Lavelly, Genevieve Melton, Richard Schulick, Michael Choti, Susan Gearhart, and Richard Wahl. Serial PET/CT in the evaluation of response to neoadjuvant therapy in patients with newly diagnosed rectal carcinoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 45P.
8. Heather Jacene, P Ginsburg, J Kwon, G Nyugen, E Montgomery, T Bayless, and R Wahl. FDG PET and PET/CT in Crohn's disease. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 148P.
9. D Bonta, H Patel, and R Wahl. Phantom study of iodinated contrast in SPECT/high resolution CT imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 188P.
10. Richard Wahl, Eric Frey, B Kahl, S Piantadosi, J Bianco, R Hammes, W Kasecamp, G Sgouros, and I Flinn. Organ dosimetry dose escalation of Yttrium 90 ibritumomab tiuxetan radioimmunotherapy (90Y IT) with stem cell transplantation (ASCT) in patients with non-Hodgkin's lymphoma (NHL). *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 97P.
11. A. Prideaux, H. Song, P Ladenson, R Wahl, and G. Sgouros. 3D-Radiobiologic dosimetry (3D-RD): Patient-specific, 3-D dosimetry with radiobiologic modeling to evaluate treatment efficacy and toxicity. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 219P.
12. Heather Jacene, Ross Filice, Wayne Kasecamp, and Richard Wahl. Average versus summed SUV for assessing metabolic tumor response to therapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 145P.
13. Behnaz Goudarzi and Richard Wahl. PET/CT evaluation of bronchioloalveolar carcinoma: Correlation with CT and FDG/PET findings. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 122P.
14. Martin Lodge, Roberto Pili, Heather Jacene, and Richard Wahl. Reproducibility of tumor blood flow quantification with ¹⁵O-water PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 194P.
15. Tracy Brown, Jennifer Merrill, Frank Bengel, and Richard Wahl. Incidence and correlates of increased coronary calcium in patients with normal myocardial perfusion utilizing an integrated hybrid SPECT-CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 53P.
16. Heather Jacene, Sophie Leboulleux, Shingo Baba, Daniel Chatzifotiadit, Behnaz Goudarzi, and Richard Wahl. Inter-observer variability of quantitative FDG PET and CT measurements of tumor response to therapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 146P.
17. Shingo Baba, Andrew Horti, Leonard Wiebe, James Engles, and Richard Wahl. The FAZA/FDG uptake ratio: Potential index of tumor hypoxia? *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 74P.
18. Behnaz Goudarzi and Richard Wahl. Value of PET/CT fusion imaging versus conventional CT scans in the staging and management of patients with malignant pleural mesothelioma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 123P.

19. Steve Cho, Kelvin MacDonald, Pamela Zeitlin, and Richard Wahl. 3H-Adenosine 5'-monophosphate (3H-AMP) lung uptake as a marker of normal pulmonary function in a mouse model of LPS induced lung inflammation. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 124P.
20. Nirav Kapadia, James Engles, and Richard Wahl. In vitro evaluation of Rituxan as a radiosensitization agent for non-Hodgkin's lymphoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 24P.
21. Heather Jacene, Ross Filice, Wayne Kasecamp, and Richard Wahl. FDG PET/CT for monitoring response of non-Hodgkin's lymphoma to radioimmunotherapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 189P.
22. Jeffrey Leal, Martin Lodge, and Richard Wah. Reproducibility of SUV max for oncologic PET: Significant differences in quantification of the SAME study between PET-only and PET-CT analysis modes. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 107P.
23. D. Mollura, Y. Kasamon, R. Jones, and R. Wahl. Cost efficacy of PET/CT versus CT in relapsed diffuse large B-cell lymphoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 41P.
24. Heather Jacene, Oleg Teytelboym, Wen Wee Ma, Wells Messersmith, Antonio Jimeno, Daniel Laheru, Manuel Hidalgo, and Richard Wahl. Rapamycin induced "stunning" on FDG PET/CT in pancreatic cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 58P.
25. Behnaz Goudarzi, Heather Jacene, and Richard Wahl. Quantitative assessment of tumor response in patients with lymphoma and bone marrow involvement by PET/CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 135P.
26. Richard Wahl, Ian Flinn, Bin He, Brad Kahl, Eric Frey, K. Rogers, Miah Jung, Heather Jacene, and Lode Swinnen SPECT-CT/organ dosimetry: Phase I dose-escalation trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with stem cell transplantation (ASCT) in NHL. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 144P.
27. H. Sawamoto, S. Cho, P. Finley, J. Engles, and R. Wahl. Comparison of acetate and L-methionine as potential pancreatic imaging agents: Pre-clinical studies *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 40P. James Engles, Mustafa Vali, Jean-Francois Geschwind, and Richard Wahl. Tissue uptake and effects of the metabolic inhibitor 3-bromopyruvate on fluorodeoxyglucose in vivo. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 100P.
28. Claude Nahmias, Lindi Wahl, Misty Long, and David Townsend. Reproducibility of SUV measurements determined by FDG-PET in malignant tumors. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 107P.
29. Martin Lodge, Jeffrey Leal, and Richard Wahl. Quantifying metabolic tumor response to therapy: The influence of image noise on maximum and mean SUV. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 108P.
30. Hubert Chuang, Martin Lodge, and Richard Wahl. Initial evaluation of respiratory gated PET/CT of upper abdominal lesions. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 108P.
31. Martin Lodge, Arman Rahmim, Frank Bengel, and Richard Wahl. Examining the effect of patient body size on 2D and 3D PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 121P.
32. Martin Lodge and Richard Wahl. Fully-automated PET quality assurance using Fourier and statistical methods. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 24P.
33. Behnaz Goudarzi, Heather Jacene, and Richard Wahl. Quantitative analysis of PET/CT in bronchioloalveolar carcinoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 363P.
34. Sébastien Baechler, Robert Hobbs, Heather Jacene, Andrew Prideaux, Richard Wahl, and George Sgouros. A kinetic model of patient platelets after radioimmunotherapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 48P.
35. Hirofumi Sawamoto, Takuro Isoda, James Engles, and Richard Wahl. Time course of FDG uptake into brown adipose tissue activated by the beta3-adrenoceptor agonist CL316243. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 319.
36. Godfree Mlambo, Nirbhay Kumar, William Mathews, R Wahl, and Steve Cho. Evaluation of hypoxanthine for malaria imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 613.
37. Martin Lodge and R Wahl. Quantifying metabolic tumor response to therapy: Total lesion glycolysis and partial volume reduction. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 237.
38. NG Schaefer, GK von Schulthess, and R Wahl. Radioimmunotherapy.org: A web 2.0-based online community *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 805.

39. Thomas Heston and Richard Wahl. Exercise capacity and body mass index are more important than diabetes in the prediction of high risk markers on myocardial perfusion imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 544.
40. Robert Hobbs, Sebastien Baechler, Srinivasan Senthamizhchelvan, H Song, Bin He, Eric Frey, R Wahl, H Jacene, and George Sgouros. Aortic wall modeling/dosimetry in lymphoma patients treated with radioimmunotherapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 625.
41. H Jacene and R Wahl. Is the number of target lesions evaluated on FDG PET important in assessing treatment response? *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 626.
42. Robert Hobbs, Martin Lodge, R Wahl, Mehrbod Javadi, Steve Cho, David Chien, Marge Ewertz, Paul Ladenson, and George Sgouros. 124-I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: Real-time treatment planning. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 152.
43. Mehrbod Javadi, Aditi Shruti, Robert Bristow, and Richard Wahl. FDG-PET/CT in assessing ovarian cancer recurrence and patient outcome: Comparison to CA-125. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 174.
44. Gregory Havlena, Nirav Kapadia, Hong Song, Peng Huang, James Engles, George Sgouros, and Richard Wahl.
45. 213Bi-Anti-CD20 RIT and bioluminescent imaging of micrometastatic B-cell lymphoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 171.
46. Arman Rahmim, Martin Lodge, Jing Tang, Yun Zhou, Babar Hussain, Dean Wong, Roberto Pili, and Richard Wahl.
47. Dynamic FDG PET imaging using direct 4D parametric reconstruction in cancer patients. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 354.
48. Niklaus Schaefer, James Engles, and Richard Wahl. Use of radioimmunotherapy in the United States of America: Opinions of nuclear physicians and radiation oncologists. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 595.
49. Igal Madar, Takuro Isoda, James Engles, Paige Finley, and Richard Wahl. The inverse relationship of oxidative phosphorylation (OXPHOS) and glycolysis in rat mammary tumor (RMT) revealed by the PET biomarkers fluorobenzyl triphenyl phosphonium (FBnTP) and FDG. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 227.
50. Heather Jacene, Y. Kasamon, R. Ambinder, Wayne Kasecamp, D. Serena, and Richard Wahl. Initial experience monitoring response of Hodgkin's lymphoma to radioimmunotherapy with FDG PET/CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 348.
51. Xiaofei Wang and Richard Wahl. Molecular basis of brown adipose tissue accumulation of FDG and MIBI. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 538.
52. Paco Bravo, Raymond Castillo, Paulo Togni Filho, Paul Ladenson, and Richard Wahl. Diagnostic concordance of I-123 whole body scan for the evaluation of residual thyroid tissue and metastatic thyroid cancer compared to post-ablation I-131 scan. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 317.
53. Paco Bravo, Marge Ewertz, Richard Wahl, David Cooper, and Paul Ladenson. Comparison of a four-day recombinant thyrotropin regimen with thyroid hormone withdrawal to prepare for postoperative radioiodine ablation of thyroid remnants in patients with thyroid carcinoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 311.
54. Heather Jacene, Behnaz Goudarzi, and Richard Wahl. Initial evaluation of the applicability of PET response criteria in solid tumors (PERCIST 1.0). *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 593.
55. Yun Zhou, Arman Rahmim, Martin Lodge, Heather Jacene, Roberto Pili, Dean Wong, and Richard Wahl. Feasibility of parametric imaging in multi-bed dynamic human FDG PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 127.
56. Takuro Isoda, James Engles, and Richard Wahl. Time dependence of hypoxia-specific accumulation of pimonidazole in rodent breast cancers. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 228.
57. Igal Madar, Takuro Isoda, James Engles, Paige Finley, and Richard Wahl. The differential response of fluorobenzyl triphenyl phosphonium (FBnTP) and FDG upon activation of brown adipose tissue (BAT) thermogenesis. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 444.
58. Takuro Isoda, James Engles, and Richard Wahl. Prediction of tumor hypoxia using paired images of tumor proliferation and glucose metabolism in rodent breast cancers. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 229.

59. Niklaus Schaefer, Julia Buchanan, and Richard Wahl. Radioimmunotherapy in non-Hodgkin's lymphoma: Opinions of US medical oncologists and hematologists. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 352.
60. David Chien and Richard Wahl. Effects of serum glucose on SUL of normal liver, a dynamic glucose metabolism organ. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 218.
61. Martin Lodge, Xing Rong, Eric Frey, Jean-Francois Geschwind, and Richard Wahl. Quantitative potential of Y-90 PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 601.
62. Abdel Tahari, Muhammad Chaudhry, Martin Lodge, and Richard Wahl. Respiratory-gated PET/CT vs delayed images in the quantitative evaluation of lower pulmonary and hepatic lesions in clinical practice. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 423.
63. David Chien, Martin Lodge, and Richard Wahl. Reproducibility of liver and mediastinal blood pool F-18 activity as normal reference tissues. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 536.
64. Joyce Mhlanga, Jeffrey Leal, Muhammad Chaudhry, and Richard Wahl. Does the PERCIST 1.0 minimum glycolytic activity metric allow evaluation of primary breast cancers? *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 362.
65. David Chien, Muhammad Chaudhry, Richard Wahl, and Steve Cho. Low-dose propranolol (LDP) is effective in suppressing FDG brown adipose tissue (BAT) uptake in pediatric patients: Qualitative and quantitative analyses. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 400.
66. Abdel Tahari and Richard Wahl. CT in clinical PET/CT in the community: Evaluation of the CT component. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 532.
67. David Chien and Richard Wahl. Feasibility and potential limitations of PERCIST 1.0 criteria for comparison of sequential studies in routine clinical practice. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 588.
68. Jeffrey Leal, Muhammad Chaudhry, and Richard Wahl. Performance of a PERCIST 1.0 based CAD system in the evaluation of head and neck cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 9
69. Igal Madar, Takuro Isoda, and Richard Wahl. Functional mitochondria detected by 18F-FBnTP is a prominent trait of tumor cell proliferation in vivo. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 581.
70. Jeffrey Leal, Joyce Mhlanga, Muhammad Chaudhry, and Richard Wahl. A PERCIST 1.0 based Computer Assisted Detection (CAD) system: Performance compared to an expert reader in the evaluation of breast cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 363.
71. Igal Madar, Takuro Isoda, and Richard Wahl. The inverse spatial and quantitative relationships of the voltage sensor 14C-FBnTP (fluorobenzyltriphenylphosphonium) and spontaneous apoptotic cell death in rodent syngeneic mammary tumors. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 582.
72. David Chien and Richard Wahl. Relationship of age, gender and body morphometry to normal hepatic SUL: Paradoxically low hepatic SUL in morbidly obese women. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 535.
73. Takuro Isoda, Igal Madar, and Richard Wahl. Assessment of non-specific binding and optimization of the uptake time for 18F-FMISO hypoxia detection: Correlation with pimonidazole. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 240.
74. Martin Lodge, Abdel Tahari, and Richard Wahl. Contrast recovery in positron emission mammography. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 433.
75. Robert Hobbs, Yi Le, Elwood Armour, Jonathan Efron, Nilofer Azad, Luis Diaz, Richard Wahl, George Sgouros, Susan Gearhart, and Joseph Herman. Changes in FDG-PET SUV correlate with voxel absorbed dose in HDR brachytherapy of rectal cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 581.
76. Abdel Tahari, Mahadevan Rajaram, Kenji Fukushima, Martin Lodge, Benjamin Tsui, Stephan Nekolla, Richard Wahl, Frank Bengel, and Paco Bravo. Determination of absolute flow quantification: Comparison of different software packages and methods. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 32.
77. Joyce Mhlanga, John Carrino, and Richard Wahl. High resolution 18F-FDG small joint positron emission mammography arthroPET imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 534.
78. Robert Hobbs, Abdel Tahari, Martin Lodge, Sebastien Baechler, Eric Frey, Richard Wahl, and George Sgouros. Uncertainty method and values for whole organ and tumor absorbed doses calculated in

- 3DRD for ^{90}Y PET/CT dosimetry in selective internal radiation therapy (SIRT). *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 582.
79. Xiaofei Wang and Richard Wahl. Comparison of lung cancer genomic profiles for glycolysis versus proliferation radiotracers. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 18.
 80. Ho (Andy) Lee, Muhammad Chaudhry, and Richard Wahl. Comparison of quantitative NaF PET bone scan findings to quantitative CT density (Hounsfield units) in malignant NaF-avid bone lesions. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 166.
 81. Muhammad Chaudhry and Richard Wahl. Comparative analysis of ^{18}F -FDG and ^{18}F -NaF PET/CT in detecting osseous metastases in breast cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 337.
 82. Joyce Mhlanga and Richard Wahl. ^{18}F -FDG-PET-CT evaluation of melanoma progression versus non-progression using PERCIST 1.0. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 169.
 83. Yun Zhou, Sulei Zhang, Jianhua Zhang, Nikolaos Karakatsanis, Arman Rahmim, Martin Lodge, Richard Wahl, Dean Wong, and Rong Fu Wang. Generalized population-based input function estimation given incomplete blood sampling in quantitative dynamic FDG PET studies. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 380.
 84. Jeffrey Leal and Richard Wahl. A survey of normal reference hepatic SUL variability in whole body PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 556.
 85. Alin Chirindel, Muhammad Chaudhry, Ho (Andy) Lee, and Richard Wahl. ROC-analysis of quantitative early and delayed PET SUL in malignant peripheral nerve sheath tumors (MPNST) versus neurofibroma (BT). *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 164.
 86. Yun Zhou, Jianhua Zhang, Rong Fu Wang, Qiang Wang, Richard Wahl, Dean Wong, and Yun Zhou. Optimization of noninvasive parametric imaging in dynamic whole-body FDG PET-CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 210.
 87. Martin Lodge and Richard Wahl. Characterizing the repeatability of oncology PET standardized uptake values. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 335.
 88. Yun Zhou, Jianhua Zhang, Rong Fu Wang, Qiang Wang, Weiguo Ye, Richard Wahl, Dean Wong, and Yun Zhou. Evaluation of image derived input function methods for quantification of dynamic whole-body FDG PET-CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 211.
 89. Joo Hyun Oo, Heather Jacene, Vered Stearns, and Richard Wahl. How many lesions to measure for response assessment? Comparing SULpeak changes in a single lesion and the sum of the 5 hottest lesions in 3 types of cancer and 3 types of therapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 229.
 90. Abdel Tahari, Krishna Chaitanya Alluri, Vasavi Paidpally, Shanthi Marur, Richard Wahl, and Rathan Subramaniam. FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: Characteristics of HPV-positive and HPV-negative tumors. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 457.
 91. Joo Hyun Oo, Jeffrey Leal, Vered Stearns, and Richard Wahl. Assessing PERCIST 1.0 non-measurable (low FDG uptake) lesions in patients with breast cancer does not diminish the predictive value of FDG PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 73.
 92. Jeffrey Leal, Joo Hyun Oo, Laurence Baker, and Richard Wahl. HIPP: A heterogeneity and irregularity parameter based on PERCIST for FDG PET imaging with prognostic value. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 663.
 93. Joo Hyun Oo, Jeffrey Leal, Abdel Tahari, Laurence Baker, and Richard Wahl. Early treatment response by FDG PET in patients with the Ewing sarcoma family of tumors predicts survival. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 600.
 94. Joo Hyun Oo, Jeffrey Leal, Vered Stearns, and Richard Wahl. Change in tumor-to-liver uptake ratios is comparable to PERCIST 1.0 in predicting complete response in primary breast cancer systemic therapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 123.
 95. Jianhua Zhang, Rong Fu Wang, Qiang Wang, Yan Fan, Zhanli Fu, Xuchu Zhang, Weiguo Ye, Dean Wong, Richard Wahl, and Yun Zhou. First comparison study of dynamic whole-body versus conventional FDG PET/CT scan in oncologic imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 208.
 96. Joo Hyun Oo, Martin Lodge, Yetunde Olagbemiro, and Richard Wahl. A novel exocrine pancreas stress test with ^{11}C -acetate PET and secretin stimulation. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 592.

97. Charles Marcus, Richard Wahl, and Rathana Subramaniam. The role of FDG PET/CT in the evaluation of patients with T1 and T2 (early stage) head and neck squamous cell carcinoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 343.
98. Diane Abou, Hugo Guerrero-Cazares, Il Minn, Martin Pomper, Alfredo Quiñones-Hinojosa, Alfred Morgenstern, Tom Back, Robert Hobbs, Richard Wahl, and George Sgouros. ²²⁵Ac imaging of NK1-targeted α -particle for glioblastoma radiotherapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 393.
99. Richard Wahl, John Crandall, Prateek Gajwani, and Jeffrey Leal. Repeatability of test-retest measurements of brown adipose tissue presence, metabolic activity, and volumes in humans. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 233.
100. James Engles, Hirofumi Sawamoto, Paige Finley, and Richard Wahl. Time course of FDG uptake into brown adipose tissue following single and repeated β -3 agonist administrations - Effect of washout period. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 234.
101. Steven Rowe, Nadège Anizan, Jeffrey Leal, Hao Wang, Martin Lodge, Eric Frey, and Richard Wahl. Stability of SPECT uptake value ("SPECT-UV") in normal abdominal organs for ¹¹¹In- imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 585.
102. Alin Chirindel, Krishna Chaitanya Alluri, Muhammad Chaudhry, Richard Wahl, Timothy Pawlik, Joseph Herman, and Rathana Subramaniam. Prognostic value of FDG-PET/CT derived parameters in pancreatic adenocarcinoma at initial PET/CT staging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 75.
103. Charles Marcus, Abdel Tahari, Anthony Ciarallo, Richard Wahl, and Rathana Subramaniam. Head and neck PET/CT: Therapy response interpretation criteria ('Hopkins criteria'). *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 344.

Posters

1. Shingo Baba, Mitsuaki Tatsumi, Takayoshi Ishimori, James Engles, and Richard Wahl. Effect of nicotine and ephedrine on brown adipose fat tissue accumulation of FDG with rodent studies. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 342P.
2. Heather Jacene, L King, P Ginsburg, J Kwon, G Nguyen, T Bayless, and R Wahl. Effects of IV contrast on quantitative PET/CT parameters. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 370P.
3. Steve Cho, Edward Abraham, and Richard Wahl. In vitro characterization of nucleoside transporter mediated uptake and intracellular accumulation of [³H]AMP in tumor cells. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 422P.
4. Steve Cho, Kelvin MacDonald, Shingo Baba, Pam Zeitlin, and Richard Wahl. In vivo evaluation of [³H]adenosine 5'-monophosphate lung uptake as a marker of normal pulmonary function in a mouse model of lung inflammation. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 358P.
5. Steve Cho, William Mathews, Takayoshi Ishimori, Betty Tyler, Henry Brem, and Richard Wahl. In vivo pre-clinical PET/CT evaluation of [¹¹C]adenosine 5'-monophosphate as a novel PET radiotracer for imaging tumor nucleoside transporters. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 422P.
6. Shingo Baba, Andrew Horti, Steve Cho, James Fox, Henry Brem, Betty Tyler, James Engles, and Richard Wahl. Distribution of 2-[¹⁸F]fluoro-adenosine in normal and brain tumor bearing rats. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 288P.
7. Heather Jacene, S Baba, J Engles, and R Wahl. Effects of pegfilgrastim (Neulasta®) on FDG biodistribution in a rat tumor model. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 432P.
8. Shingo Baba, James Engles, and Richard Wahl. Uptake of various clinical tracers in the brown adipose fat tissue under stimulated and non-stimulated conditions. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 344P.
9. Shingo Baba, Steve Cho, Zhaohui Ye, Linzhao Cheng, and Richard Wahl. Mouse lymphoma model for monitoring the tumor growth and effects of immunoradiotherapy using a non-invasive in vivo optical imaging system. *J. NUCL. Med. MEETING ABSTRACTS*, May 2006; 47: 431P.
10. Steve Cho and Richard Wahl. Potential for augmentation of FDG uptake in tumor cells in-vitro with A₃ adenosine receptor stimulation. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 339P.

11. Shingo Baba, Steve Cho, Zhaohui Ye, Linzhao Cheng, and Richard Wahl. Assessing radio immunotherapy of disseminated lymphomas with non-invasive in vivo bioluminescence. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 346P.
12. Dacian Bonta and Richard Wahl. Accuracy of image fusion of normal upper abdominal organs visualized with In111 Octreotide SPECT/CT using a 16 slice CT/SPECT scanner. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 423P.
13. Martin Lodge, Ahsan Khan, Arman Rahmim, Bruce Line, Frank Bengel, and Richard Wahl. Optimizing injected activity in whole-body 3D PET: Relating NECR and singles rates. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 435P.
14. Shingo Baba, James Engles, and Richard Wahl. Choline uptake and RNA expression profile in cancerous and normal prostate cell lines: No significant role of choline transporter in PET tracer uptake. *J. NUCL. Med. MEETING ABSTRACTS*, May 2007; 48: 335P.
15. Steve Cho, Kelvin MacDonald, Pamela Zeitlin, and Richard Wahl. AMP and FDG lung uptake in a mouse model of cystic fibrosis. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 278P.
16. Sébastien Baechler, Robert Hobbs, Heather Jacene, Andrew Prideaux, Richard Wahl, and George Sgouros. Factors affecting hematotoxicity after 90Y-ibritumomab tiuxetan or 131I-tositumomab radioimmunotherapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 322P.
17. Alexander Kowal and Richard Wahl. Impact of initial FDG PET/CT on stage and radiation therapy in newly-diagnosed pediatric Hodgkin's lymphoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 275P.
18. James Engles, Bryan Traughber, Mitsuaki Tatsumi, Yuji Nakamoto, and Richard Wahl. Comparative biodistribution of 18F-fluoro-2-deoxy-D-glucose (FDG) and eight radiolabeled amino acids in a rodent model of breast cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 317P.
19. Alexander Kowal and Richard Wahl. Findings on initial staging FDG PET/CT in newly-diagnosed pediatric Hodgkin's lymphoma with comparison to physical exam and diagnostic CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 275P.
20. John Terrovitis, Riikka Lautamäki, Jianhua Yu, Andreas Barth, Martin Pomper, Richard Wahl, Benjamin Tsui, M. Roselle Abraham, Eduardo Marbán, and Frank Bengel. Genetic labeling of cardiac stem cells for in vivo monitoring of engraftment in ischemic myocardium. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 184P.
21. Jeffrey Leal, Martin Lodge, and Richard Wahl. Between application differences in the calculation of standardized uptake values (SUV) in PET-CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 325P.
22. Dacian Bonta and Richard Wahl. Is a "yes"- "no" answer adequate in reporting nuclear medicine diagnostic imaging results? *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 272P.
23. H. Sawamoto, J. Engles, and R. Wahl. Ephedrine administered directly into brown adipose tissue markedly reduces FDG accumulation. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 336P.
24. Heather Jacene, Behnaz Goudarzi, and Richard Wahl. Lymphoma response criteria should include a metabolic assessment of bone marrow disease. *J. NUCL. Med. MEETING ABSTRACTS*, May 2008; 49: 338P.
25. Thomas Heston and Richard Wahl. How often are statistically significant results clinically relevant? Not often. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1370.
26. H Jacene, Sophie Leboulleux, Shingo Baba, Daniel Chatzifotiadit, Karen Horton, Ihab Kamel, Oleg Teytelbaum, Katarzyna Macura, Jeanne Kowalski, and Richard Wahl. Assessment of reproducibility in quantitative FDG PET and CT measurements of tumor response to therapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1624.
27. M Chaudhry and Richard Wahl. PET/CT imaging in pancreatic cancer: A retrospective review. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1748.
28. Hirofumi Sawamoto, J Engles, and R Wahl. Time course of tissue uptake of L-methionine as a potential pancreatic imaging agent: Rodent studies. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1317.
29. H Jacene, Sophie Leboulleux, Shingo Baba, Daniel Chatzifotiadit, Behnaz Goudarzi, and R Wahl. Determination of metabolic tumor response by FDG PET is highly reproducible with the same or different readers pre- and post-therapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1326.
30. Xiaofei Wang and Richard Wahl. Transcriptome foundations of choline and acetate uptake in prostate cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1572.

31. Thomas Heston, Richard Wahl, and Heather Jacene. A systematic approach to PET/CT interpretation and reporting in oncology. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1089.
32. Harvey Ziessman, Ankit Chander, Alison Ramos, John Clark, and Richard Wahl. The added diagnostic value of liquid gastric emptying when solid emptying is normal – 2009 update. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1310.
33. Thomas Heston, Jennifer Merrill, Frank Bengel, and Richard Wahl. Coronary calcium scores in patients with normal myocardial perfusion. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1160.
34. Martin Lodge, Arman Rahmim, Dean Wong, and R Wahl. Measuring the effect of count rate on PET spatial resolution using a uniform cylinder phantom. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1483.
35. D Udall, R Wahl, and H Jacene. Prior rituximab exposure does not affect response to radioimmunotherapy for non-Hodgkin's lymphoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1615.
36. M Chaudhry and Richard Wahl. FDG PET/CT imaging in urinary bladder cancer: A retrospective analysis. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1810.
37. Michael Graham, Ramsey Badawi, and R Wahl. Variation in PET-CT methodology at academic centers. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1043.
38. Xiaofei Wang and R Wahl. Transcriptome foundations of low FDG uptake in prostate cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1571.
39. Amanda Eveler, Wayne Kasecamp, and R Wahl. Patient discharge instructions for I-131 Bexxar therapy vs. I-131 sodium iodide therapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 2213.
40. Xiaofei Wang and Richard Wahl. Transcriptome foundations of high FDG uptake in lung cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1608.
41. NG Schaefer, R Balasubramanian, H Song, J Engles, and R Wahl. Enhancing anti-CD20 directed radioimmunotherapy. Preliminary studies using lenalidomide-accelerated internalization. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 1609.
42. William Epley, H Jacene, Martin Lodge, and R Wahl. The impact of PET pixel size on contrast recovery for small lesions. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 2018.
43. William Epley, Bineyam Gebrewold, Thomas Heston, and Richard Wahl. Minimizing variation in uptake times in a busy multi-camera PET/CT oncology clinic. *J. NUCL. Med. MEETING ABSTRACTS*, May 2009; 50: 2029.
44. Abdel Tahari and Richard Wahl. Clinical PET/CT in the community: Experience from interpretation of outside PET/CT exams in referred patients: Methods and quantitation. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1179.
45. Ovsev Uzuner, Muhammad Chaudhry, Nedim Gulaldi, and Richard Wahl. Inter-observer agreement of functional imaging of the paranasal sinuses with FDG PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1596.
46. James Engles, Takuro Isoda, and Richard Wahl. Profound morphological changes are associated with high FDG uptake in brown adipose tissue as observed in TEM images. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1133.
47. Martin Lodge, Heather Jacene, Roberto Pili, and Richard Wahl. Measuring blood flow to renal cell carcinoma metastases with ^{15}O water PET/CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1174.
48. Niklaus Schaefer, James Engles, and Richard Wahl. PARP inhibitors in combination with external beam and radioimmunotherapy in aggressive lymphoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1135.
49. Muhammad Chaudhry, Christine Alewine, Luis Diaz, and Richard Wahl. Correlation of K-ras mutation with FDG uptake in lung cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1247.
50. Takuro Isoda, James Engles, and Richard Wahl. Tumor uptake of ^{14}C -thymidine in rodent breast cancer: Interrelationship with perfusion, hypoxia, glycolysis and glucose transporter expression. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1102.
51. Jeffrey Leal and Richard Wahl. Issues using volumetric image quantification tools across clinical workstations. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1330.

52. Takuro Isoda, James Engles, and Richard Wahl. Prediction of tumor hypoxia using paired images of tumor perfusion and glucose metabolism in rodent breast cancers. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1100.
53. Martin Lodge, Don Udall, Muhammad Chaudhry, and Richard Wahl. Identification of a characteristic perirectal artifact in FDG PET/CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1215.
54. Takuro Isoda, James Engles, and Richard Wahl. Hypoxia marker pimonidazole accumulation and glucose transporter-1 expression are strongly correlated in rodent breast cancers. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1101.
55. Muhammad Chaudhry, Christine Alewine, Luis Diaz, and Richard Wahl. Correlation of K-ras mutation with FDG uptake in colorectal cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1210.
56. Muhammad Chaudhry, Corina Voicu, Elizabeth Prusha, Lawrence Shombert, and Richard Wahl. Inguinal lymph nodes in patients undergoing clinical C-11 Acetate PET/CT for prostate cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2010; 51: 1265.
57. Takuro Isoda, Igal Madar, and Richard Wahl. Intratumoral co-distribution of 18F-FDG, hypoxia and apoptosis. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1700.
58. David Chien, Muhammad Chaudhry, and Richard Wahl. Normal hepatic SUL measured over a wide range of time points post FDG injection - Potential application in background correction in quantitative PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1776.
59. Muhammad Chaudhry, Beril Gok, and Richard Wahl. Brain 18F-FDG PET/CT findings in patients with possible paraneoplastic syndrome. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1218.
60. Muhammad Chaudhry and Richard Wahl. Semi-quantitative assessment of dual time point whole body FDG PET/CT imaging in patients with pancreatic cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1834.
61. Muhammad Chaudhry and Richard Wahl. Impact of renal function on average hepatic standardized uptake value (SUVavg). *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1774.
62. Martin Lodge, Muhammad Chaudhry, and Richard Wahl. Noise considerations for tumor response monitoring with FDG PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1784.
63. Takuro Isoda, Igal Madar, and Richard Wahl. Intratumoral distribution of GLUTs and hexokinase II in rodent breast cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1667.
64. Heather Jacene, Yvette Kasamon, Richard Ambinder, Donna Serena, Wayne Kasecamp, and Richard Wahl. Initial experience with tositumomab and iodine I 131 tositumomab for treatment of relapsed/refractory Hodgkin lymphoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1757.
65. David Chien and Richard Wahl. Reproducibility of "glucose corrected" hepatic SUL compared to uncorrected hepatic SUL in baseline and follow-up studies. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1771.
66. Behnaz Goudarzi, Paco Bravo, Marjorie Ewertz, Paul Ladenson, and Richard Wahl. Radioiodine therapy in pediatric and adolescence with well differentiated thyroid cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1403.
67. Martin Lodge, Joyce Mhlanga, and Richard Wahl. Effect of patient arm motion in whole-body PET/CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 2024.
68. Beril Gok, Nafi Aygun, and Richard Wahl. Evaluation of asymmetry index of temporal lobes on 18FDG PET/CT localizing the epileptogenic zone in drug resistant temporal lobe epilepsies. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1201.
69. Heather Jacene, Sophie Leboulleux, Shingo Baba, Daniel Chatzifotiadis, Behnaz Goudarzi, O. Teytelbaum, K. Horton, Katarzyna Macura, Ihab Kamel, and Richard Wahl. Importance of the same or different readers pre- and post-therapy for anatomic vs. metabolic response assessments. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1773.
70. Muhammad Chaudhry, Richard Wahl, and Atif Zaheer. Efficacy of FDG PET/CT in patients with recurrent pancreatic cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1836.
71. Igal Madar, Takuro Isoda, and Richard Wahl. Non-invasive PET imaging of brown adipose tissue (BAT) and quantification of the kinetics of the thermogenic function using the voltage sensor 18F-FBnTP (fluorobenzyl triphenyl phosphonium). *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1475.
72. Takuro Isoda, Igal Madar, and Richard Wahl. Time-dependent analysis of 18F-FLT distribution in rat mammary tumors. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 1683.

73. Martin Lodge, Magnus Dahlbom, and Richard Wahl. Cross-calibration of gamma counters and PET scanners using Ge-68/Ga-68. *J. NUCL. Med. MEETING ABSTRACTS*, May 2011; 52: 2065.
74. Xiaofei Wang and Richard Wahl. Comparative gene expression related to the uptake of PET radiotracers in prostate cancer cell lines. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1144.
75. Xiaofei Wang and Richard Wahl. Molecular pathway analysis of glycolysis and acetate accumulation in hepatocellular carcinoma - Rationale for PET/CT imaging tracer selection. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1147.
76. Ho (Andy) Lee, Muhammad Chaudhry, and Richard Wahl. Comparison of quantitative NaF PET bone scan findings to quantitative CT density (Hounsfield units) in degenerative NaF-avid bone lesions. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 2166.
77. Mahadevan Rajaram, Abdel Tahari, Kenji Fukushima, Martin Lodge, Benjamin Tsui, Stephan Nekolla, Richard Wahl, Frank Bengel, and Paco Bravo. Cardiac PET-CT misregistration causes significant changes in myocardial flow reserve (MFR). *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1808.
78. Ho (Andy) Lee, Alin Chirindel, Muhammad Chaudhry, and Richard Wahl. ROC-analysis of quantitative NaF PET SUL in detecting malignant vs. benign skeletal lesions. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1248.
79. Srinivasan Senthamizhchelvan, Muhammad Chaudhry, Hayden Ravert, John Crandall, Daniel Holt, Robert Dannals, Richard Wahl, George Sgouros, and Igal Madar. Human biodistribution and radiation dosimetry of 18F-fluorobenzyltriphenyl phosphonium. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1512.
80. Martin Lodge, Arman Rahmim, Nikolaos Karakatsanis, Yun Zhou, Joyce Mhlanga, Abdel Tahari, and Richard Wahl. Implementation and evaluation of a dynamic whole-body PET/CT protocol. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1237.
81. Arnaud Dieudonné, Robert Hobbs, Rachida Lebtahi, Fabien Maurel, Sebastien Baechler, Heather Jacene, Richard Wahl, Dominique Le Guludec, George Sgouros, and Isabelle Gardin. Tissue density heterogeneities influence and simple density correction method for 3D dosimetry in the abdominal region. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1093.
82. James Engles, Ingrid Wu, Paige Finley, and Richard Wahl. BAT activation in diabetic rats undergoing treatment with CL316, 243 and cold exposure. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1586.
83. Jeffrey Leal and Richard Wahl. SUL-PEAK, -MAX and -PAX in PERCIST 1.0: An ROC analysis. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1223.
84. Nikolaos Karakatsanis, Martin Lodge, Yun Zhou, Joyce Mhlanga, Muhammad Chaudhry, Abdel Tahari, Richard Wahl, and Arman Rahmim. Towards parametric whole-body FDG PET/CT imaging: Potentials for enhanced tumor detectability. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1236.
85. Angel Chan, Connie Chang, Takahiro Higuchi, Jianhua Yu, Dongdong Sun, Richard Wahl, Martin Pomper, Benjamin Tsui, and Maria Roselle Abraham. Cellular metabolism is an important determinant of 99mTc uptake by the sodium-iodide symporter. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1774.
86. Ho (Andy) Lee, Paco Bravo, and Richard Wahl. Clinical utility of whole body scan in addition to cardiac FDG PET in the evaluation of active cardiac sarcoidosis. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1852.
87. Martin Lodge and Richard Wahl. Gamma camera count rate performance assessment without specialized equipment. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 2406.
88. Srinivasan Senthamizhchelvan, George Sgouros, and Richard Wahl. Tracer kinetic model and dosimetry for orally administered 18F-FDG. *J. NUCL. Med. MEETING ABSTRACTS*, May 2012; 53: 1505.
89. Uzma Rana, Alin Chirindel, Alison Ramos, Harvey Ziessman, and Richard Wahl. Pediatric radiopharmaceutical dose reduction in nuclear medicine imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 2006.
90. Joyce Mhlanga, Alin Chirindel, Martin Lodge, Richard Wahl, and Rathana Subramaniam. Assessing the agreement of PET/CT metrics obtained using different software platforms. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 2048.

91. Martin Lodge, Katarzyna Macura, Michael Jacobs, Martin Pomper, Richard Wahl, and Steve Cho. Combined PET/CT/MRI of the pelvis using software registration. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 2089.
92. Anthony Fotenos and Richard Wahl. Evaluating quality in practice: A primer on peer review for nuclear medicine physicians. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1257.
93. Xiaofei Wang, Joo Hyun Oo, and Richard Wahl. Molecular comparison of glycolytic and DNA synthesis pathways in human breast cancer before and after treatment with an aromatase inhibitor: Implications for FDG and FLT PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1360..
94. Alin Chirindel, John Crandall, and Richard Wahl. Diagnostic value of FDG PET/CT imaging in monitoring patients with endometrial carcinoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1510.
95. Jianhua Zhang, Rong Fu Wang, Yan Fan, Zhanli Fu, Xuchu Zhang, Xuhe Liao, Yun Zhou, and Richard Wahl. Metabolic activity measured by 18F-FDG PET/CT in newly diagnosed patients with lymphoma: Correlation with immunophenotype. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1563.
96. Joo Hyun Oo, Jeffrey Leal, Laurence Baker, and Richard Wahl. ROC analysis of varying PET metrics to predict survival in patients with Ewing sarcoma family of tumor. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 2085.
97. Nikolaos Karakatsanis, Martin Lodge, Richard Wahl, and Arman Rahmim. Direct 4D whole-body PET/CT parametric image reconstruction: Concept and comparison vs. indirect parametric imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 2133.
98. MTA I: EDUCATIONAL EXHIBITS - ONCOLOGY: Joo Hyun Oo and Richard Wahl. Practical PERCIST 1.0 *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1305.
99. Alin Chirindel, Muhammad Chaudhry, Jaishri Blakeley, and Richard Wahl. Correlation of metabolic activity on FDG PET/CT to the size of benign and malignant lesions in patients with neurofibromatosis type 1 (NF1). *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1618.
100. Bineyam Gebrewold, Alin Chirindel, and Richard Wahl. Trends of quality control practices in multicenter PET/CT facilities. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 2526.
101. Abdel Tahari, Javad Azadi, and Richard Wahl. Relationship of age, FDG dose, body morphology, and dimensional scanner acquisition mode to image noise as measured by the coefficient of variation of normal hepatic SUL. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1427.
102. Joo Hyun Oo, Nikolaos Karakatsanis, Arman Rahmim, Martin Lodge, and Richard Wahl. A novel imaging method for assessing vessel wall inflammation: Dynamic multi-bed PET parametric imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1670.
103. Richard Wahl, John Crandall, Daniel Holt, Hayden Ravert, Robert Dannals, and Igal Madar. Unraveling brown adipose tissue (BAT) thermogenic makeup using 18F-fluorobenzyl triphenyl phosphonium (FBnTP) and FDG PET in humans. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1868.
104. Nadège Anizan, Eric Frey, and Richard Wahl. Factors affecting repeatability of activity quantification in SPECT/CT *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 2061.
105. Vasavi Paidpally, Alin Chirindel, Shanthi Marur, Richard Wahl, and Rathan Subramaniam. FDG volumetric parameters and patient outcome in recurrent head and neck squamous cell cancer patients after definitive chemoradiotherapy. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1538.
106. Joo Hyun Oo, Laurence Baker, and Richard Wahl. Not all progressive metabolic diseases on PET are equal in patients with relapsed or refractory sarcoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1617.
107. Joo Hyun Oo, Heather Jacene, Wayne Kasecamp, and Richard Wahl. Change in hottest tumor location on FDG PET in non-CMR patients with NHL: A marker of good prognosis? *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1553.
108. Joo Hyun Oo, Heather Jacene, Jeffrey Leal, Wayne Kasecamp, and Richard Wahl. Treatment response by FDG PET/CT in patients with non-Hodgkin's lymphoma treated with radioimmunotherapy: Link to survival. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1568.
109. Joo Hyun Oo, Jeffrey Leal, Laurence Baker, and Richard Wahl. Change in hottest tumor location following treatment on FDG PET in patients with Ewing sarcoma: A marker of poor prognosis. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1607.

110. Alin Chirindel, Brandon Lubner, Hao Wang, Andy Lee, Richard Wahl, and Steve Cho. Assessment of quantitative FDG PET parameters for prognosis in pediatric Hodgkin lymphoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1999.
111. Ingrid Wu and Richard Wahl. Delineation of viable tumor volume using FDG-PET validated with macroscopic sectioning of pathological specimens. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1313.
112. Abdel Tahari, Javad Azadi, and Richard Wahl. Development of a new correction to SUV in PET based on measurement of adipose/lean tissue content in a single CT slice. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1410.
113. Abdel Tahari, Javad Azadi, and Richard Wahl. Gender-specific effect of different lean body mass formulations on hepatic SUV: Paradoxical low values in morbidly obese women. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1435.
114. Alin Chirindel, Krishna Chaitanya Alluri, Abdel Tahari, Stella Lam, Richard Wahl, and Rathan Subramaniam. Inter-reader variability of PET parameters in pancreatic adenocarcinoma: Impact of early and delayed images. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1501.
115. Uzma Rana, Srinivasan Senthambichelvan, Richard Wahl, and Rathan Subramaniam. Inter-reader reliability and variability of ¹⁸F-FDG PET volumetric tumor parameters in sarcoma. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1614.
116. Aileen Green, David Chien, Brandon Lubner, Hao Wang, Richard Wahl, and Steve Cho. Low-dose propranolol is safe for use in pediatric patients to decrease FDG brown adipose tissue uptake. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 2009.
117. Jeffrey Leal and Richard Wahl. Auto-PERCIST™: A semi-automated system for the quantitative assessment of FDG PET images by PERCIST 1.0. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1301.
118. Robert Hobbs, Richard Wahl, Eric Frey, Hong Song, Yvette Kasamon, Peng Huang, Richard Jones, and George Sgouros. Methodology for radiobiological optimization of combination radiopharmaceutical therapy (RPT). *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1401.
119. John Crandall, Alin Chirindel, and Richard Wahl. Diagnostic performance of FDG PET/CT in patients with endometrial cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1517.
120. John Crandall, Alin Chirindel, and Richard Wahl. Performance of FDG PET/CT in the initial staging of endometrial cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1518.
121. Alin Chirindel, Vasavi Paidpally, Abdel Tahari, Richard Wahl, and Rathan Subramaniam. Reproducibility of liver SULmean on two different FDG PET/CT scans. *J. NUCL. Med. MEETING ABSTRACTS*, May 2013; 54: 1949.
122. John Crandall, Prateek Gajwani, Daniel Mawhinney, Fred Sterzer, and Richard Wahl. Passive microwave radiometry for the non-invasive detection of human brown fat: First human studies with direct correlation to FDG/PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1648.
123. Xiaofei Wang and Richard Wahl. Abundance of message levels for pyruvate kinase (PKM2) and thymidylate synthase (TYMS) in CNS cancer cell lines appears better correlated with their doubling times than do Ki67 or PCNA message levels. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1424.
124. Charles Marcus, Richard Wahl, and Rathan Subramaniam. Single photon emission computed tomography/computed tomography (SPECT/CT) in sentinel lymph node imaging in head and neck cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1363.
125. John Crandall, Lalitha Shankar, and Richard Wahl. Phase II single-arm trial comparing the use of FLT PET/CT to standard computed tomography to assess the treatment response of neoadjuvant docetaxel and cisplatin in stage IB-IIIA resectable non-small cell lung cancer. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1609.
126. James Engles, Xiaofei Wang, Paige Finley, and Richard Wahl. Brown adipose tissue (BAT) lipid content, a dynamic parameter potentially confounding measurements of BAT radiotracer targeting. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1644.
127. Xiaofei Wang and Richard Wahl. Abundance of hexokinase 1 (HK1) mRNA in hematological cancer cell lines appears better correlated with their doubling times than Ki67 and PCNA. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1389.
128. Jeffrey Leal and Richard Wahl. Auto-PERCIST™: A semi-automated system for response assessment based on the PERCIST 1.0 criteria for quantitative analysis of FDG PET. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1368.

129. Xiaofei Wang and Richard Wahl. Thymidine kinase 1 (TK1) message levels in colon cancer cell lines are better correlated with cancer cell doubling times than PCNA or transporter message levels. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1413.
130. Xiaofei Wang and Richard Wahl. Abundance of thymidine kinase 1 (TK1) message in breast cancer cell lines is better correlated with their doubling times than Ki67 or PCNA message levels. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1425.
131. John Crandall, Prateek Gajwani, Keya Joshi, Muhammad Chaudhry, and Richard Wahl. Diagnostic performance of F18-FDG PET/CT in patients with suspected paraneoplastic syndrome. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1892.
132. Alexander Antoniou, Matthew Kruse, Richard Wahl, and Harvey Ziessman. Comparison of two methods for measuring liquid gastric emptying. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1963.
133. Paul Kinahan, Richard Wahl, Lingxiong Shao, Richard Frank, and Eric Perlman. The QIBA profile for quantitative FDG-PET/CT oncology imaging. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1520.
134. Xiaofei Wang and Richard Wahl. Different transcriptome responses in brown fat following exposure to a β_3 agonist or cold temperature. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1647
135. Jeffrey Leal, Steven Rowe, and Richard Wahl. Performance comparison of Auto-PERCIST (a semi-automated PERCIST-based CAD system) and a clinician in the measurement of PERCIST 1.0 metrics for response assessment. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 2073.
136. Xiaofei Wang and Richard Wahl. Abundance of thymidine kinase 1 (TK1) message in melanoma cell lines appears better correlated with their doubling times than Ki67 and PCNA message levels. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1423.
137. Alexander Antoniou, Matthew Kruse, Richard Wahl, and Harvey Ziessman. Comprehensive esophago-gastro-intestinal transit study: Methodology and normal values. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1964.
138. Martin Lodge, Paul Kinahan, and Richard Wahl. Moving NaI(Tl) gamma counters towards improved quantitative accuracy for PET applications using traceable calibration sources. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 2053.
139. Joo Hyun Oo, Jeffrey Leal, Jun Zhang, Sally Barrington, Ronald Boellaard, Edward Eikman, and Richard Wahl. Multicenter quantitative assessment of treatment response by FDG PET/CT. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 2061.
140. Srinivasan Senthamizchelvan, Abdel Tahari, Prateek Gajwani, John Crandall, Martin Lodge, George Sgouros, and Richard Wahl. Orally administered 18F-FDG: Human biodistribution and dosimetry. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1133.
141. Charles Marcus, Rathan Subramaniam, and Richard Wahl. 223Ra- Dichloride therapy for castrate-resistant prostate cancer osseous metastases. *J. NUCL. Med. MEETING ABSTRACTS*, May 2014; 55: 1345.
142. Baum RP, Wahl RL. Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts. *J Nucl Med.* 2015 May;56 (Supplement 2):2A-30. PubMed PMID: 25934686.